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ABSTRACT 
 
Molecular dynamics (MD) simulation has been widely used in understanding the physical 
basis of the structure and function of biological macromolecules. However, its 
application in pharmaceutical research is still at an early stage. This dissertation attempts 
to establish the use of MD simulation in studying several important pharmaceutical mass 
transfer processes. The three-series study included (1) the understanding of drug crystal 
dissolution at molecular level, (2) the elucidation of an unique mechanism for facile 
polymorphic transformation of crystalline drugs in solutions, and (3) the determination of 
drug–polymer interactions at water–crystal interface and the implications to 
crystallization inhibition. 
A drug crystal dissolution into aqueous solution was simulated successfully for 
the first time on acetaminophen crystal Form I. The results revealed distinct corner & 
edge effect and differentiated dissolution rate among the three crystal surfaces of (001), 
(101) and (100), which correlated strongly with total interaction energies among the drug 
molecules and between the drug and water molecules.  This study helped us gain 
additional fundamental understanding in the relationship between dissolution rate and 
particle size and morphology. 
A series of MD simulations and experimental methods were utilized to evaluate 
the thermodynamic and kinetic forces that control the polymorphic transformation in 
solutions. Acetaminophen Form II, a metastable crystalline form which readily converts
 xx 
to the themodymically stable Form I when in contact with solution was studied. It was 
found that the facile polymorphic transformation is not attributed to the solubility 
differences; rather it is caused by a unique mechanism of surface facilitated phase 
transformation (SurFPT). This new mechanism is able to promote faster polymorphic 
transformation than the well-known mechanism of solution-mediated phase 
transformation (SMPT), thus it is more detrimental. 
In the third study, the molecular mechanism of crystal surface specific drug–
polymer interaction was investigated by simulating tolazamide crystals in the presence of 
hydrated PEG-b-PLA, a diblock copolymer. The results from the simulations 
demonstrated the polymer’s strong interaction with the (001) face, weaker interaction 
with the (010) face and minimal to no interaction with the (100) face, which matched 
remarkably well with the reported crystal habit alteration by the preferential interaction of 
PEG-b-PLA primarily with the (001) and partially with (010).  Interestingly, van der 
Waals interactions were identified as the dominant forces (accounts for 77–93% of total 
interaction energies) that enabled such strong drug–polymer interactions. These findings 
suggest that polymers capable of forming strong hydrophobic interactions are more 
effective in inhibiting crystallization of poorly-water soluble and hydrophobic drugs in 
aqueous media than those with hydrogen bonding capacities.  Such in-depth analysis and 
understanding facilitate the rational selection of polymers in designing supersaturation-
based enabling formulations. 
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CHAPTER ONE 
BACKGROUND 
This dissertation is concerned with three important pharmaceutical mass transfer 
phenomena taking place in aqueous solutions: (1) the dissolution of drug crystals, (2) the 
polymorphic transition, and (3) the inhibition of crystal growth through drug–polymer 
interactions. These three topics will be briefly reviewed in this section. The main focus of 
this dissertation is to apply new methodologies, especially molecular dynamics (MD) 
simulation to gain a better mechanistic understanding of these phenomena. Thus, the 
background of MD simulations will also be briefly reviewed in the context of drug 
dissolution and drug–polymer interactions. 
Drug Dissolution 
Dissolution is defined as the process by which a solute forms a solution in a solvent. It is 
a kinetic process quantified by rate and driven by equilibrium solubility. In the 
dissolution of crystalline solids, the crystal structure of the solute disintegrates as separate 
ions, atoms, or molecules. How the solute and solvent interact with one another 
determines the thermodynamic energies involved, such as the heat and entropy of 
dissolution. In order for dissolution to occur, the overall Gibbs free energy must be 
negative. Dissolution will continue until the Gibbs free energy becomes zero at which the 
equilibrium solubility is established.
2 
 
 
Dissolution and Drug Development 
The basic theories and laws of dissolution have been established in chemistry since 
the late 19th century.1 In the pharmaceutical field, the dissolution process is of 
fundamental importance to the design, development, manufacture and quality control of 
drug products for the following reasons: (1) the large majority of active pharmaceutical 
ingredients (API) and inactive ingredients (or excipients) are solids; (2) these solids often 
undergo dissolution and precipitation processes during the manufacturing process of the 
API’s and drug products and (3) most importantly, before the therapeutic effect of a drug 
can be realized, the drug must go into solution at the site of absorption in order to cross 
the biological membrane into the systemic circulation (Figure 1). Since the rate at which 
a drug dissolves from a dosage form often affects its rate and/or extent of absorption (also 
referred to as bioavailability), dissolution is considered one of the most critical steps in 
oral drug absorption. This is particularly the case for sparingly soluble drugs. 
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Figure 1. Drug dissolution and absorption of orally administered solid tablet dosage forms in the gastrointestinal (GI) tract.  
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In general, the rate of drug dissolution is influenced by the physicochemical 
properties of the drug substance, formulation and manufacturing process of the dosage 
form. Over the past decades, extensive studies have been conducted to evaluate 
thermodynamic and kinetic factors affecting dissolution of drug substances. The 
thermodynamic factors relate to the intrinsic solid-state properties such as solubility 
which changes with different solid forms (polymorphs and amorphous forms) and with 
other conditions (dissolution media, temperature, pH, buffer type, and ionic strength). 
The extrinsic factors that drive the kinetic process include particle surface area, 
hydrodynamics (stirring rate), and fluid viscosity. Besides the solid form and surface area 
which may change during dissolution, other aforementioned variables can be controlled 
in dissolution testing. Polymorphism is very common among drug substances, and 
different crystal forms have been shown to exhibit different dissolution and in vivo 
performance in both animal models and human subjects.2,3 As a result, many approaches 
have been investigated for enhancing the solubility and dissolution properties such as the 
use of salts and amorphous solid dispersions. These formulation approaches are 
collectively called enabling technologies. Enabling formulations have a tendency to 
crystallize back to the parent form crystals after forming supersaturated solutions during 
dissolution. Therefore, thorough characterization of the supersaturation maintenance and 
understanding of the likely consequences of crystallization during dissolution are 
recognized as an essential part of rational drug development. 
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Methods of Assessing Dissolution 
of Pharmaceutical Solids 
Models that are widely used to describe dissolution process are the Noyes-Whitney 
equation4 and the Nernst-Brunner diffusion layer model,5 as shown schematically in 
Figure 2. 
 
Figure 2. Schematic illustration of diffusion layer dissolution model from a planar 
surface. 
 
Noyes-Whitney equation: )Ck(C
dt
dQ
bS   
Nernst-Brunner equation: )C(C
h
DA
dt
dQ
bS   
Where dQ/dt = dissolution rate; k = dissolution rate constant; CS = solubility; Cb = bulk 
solution concentration; D = diffusion coefficient of the solute; A = surface area; and h = 
diffusion layer thickness. They were derived by applying Fick’s first law for mass flux 
under the assumption of (1) presence of a stagnant layer between solid and the bulk 
solution, (2) constant diffusion layer thickness under fixed hydrodynamics, (3) constant 
concentration gradient (steady-state), and (4) diffusion-controlled transport. 
6 
 
 
For particulate dissolution, three diffusion-controlled models have been reported6 
for spherical particles. It is assumed that dissolution rate is proportional to surface area of 
the sphere, as illustrated in Figure 3. 
 
Figure 3. Concentration gradient from the diffusion layer to the bulk in dissolution of a 
spherical particle,6 where h is the diffusion layer thickness, Cs is the equilibrium 
solubility and Cb is the drug concentration in the bulk at any given time, and r is the 
radius of the spherical particle.  
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One of the spherical dissolution models is the cube-root law by Hixson and 
Crowell.6 
Hixson and Crowell equation: ܹଵ ଷൗ ൌ ଴ܹ
ଵ ଷൗ െ ݇ݐ 
In the equation, W is the particle weight, W0 is the initial particle weight, t is time 
and k is the dissolute rate constant. During the dissolution of spherical particles, the cubic 
root of the total weight at a given time, t, is decreasing from the cubic root of the original 
weight at a rate of kt. The rate constant, k, is expressed as ݇ ൌ ቀସగఘேଷ ቁ
ଵ ଷൗ ஽஼ೞ
ఘ௛ , where ρ is 
particle density, N is number of particles, D is diffusion coefficient, Cs is equilibrium 
solubility and h is diffusion layer thickness. The particles by the definition of the model 
should be monosized. Particles with different particle size distributions and different 
shapes are too complex to model.  
Dissolution rate generally is expressed as the mass of solute appearing in the 
dissolution medium per unit time (e.g., mass×sec–1), but dissolution flux is expressed as 
the rate per unit area (e.g., mass×cm–2 sec–1). Depending on the study objectives, different 
dissolution test methods are utilized for assessing the drug substance and factors affecting 
dissolution.  
 Intrinsic Dissolution  
The intrinsic dissolution rate (IDR) refers to the rate of mass transfer per area of 
dissolving surface under sink conditions (Cb ≤ 0.1 × Cs). Essentially, it is the initial 
dissolution rate long before the saturation solubility is reached. Since Cb << Cs, the 
8 
 
 
Nernst-Brunner equation can be simplified to SbS Ch
DA)C(C
h
DA
dt
dQ  . This 
simplified equation means that the dissolution rate measured under sink conditions is 
directly correlated to how fast the compound is released from the crystal lattice into 
solution which is solely determined by intrinsic solid state properties of the drug. 
According to the United States Pharmacopeia (USP), IDR is the dissolution rate of pure 
substances under the condition of constant surface area. This allows different solid forms 
to be compared in dissolution rate by holding the testing conditions constant (surface 
area, dissolution medium, stirring rate, temperature, pH, ionic strength, etc.). Thus IDR is 
considered a tool in the functionality and characterization of bulk drug substances.  
Two types of apparatus are described in Pharmacopeias for the intrinsic dissolution 
test: a stationary disk system, listed only in the USP, and a rotating disk system, known 
as “Wood’s apparatus,” listed in the USP, the European pharmacopeias (EP) and the 
British pharmacopeias (BP).7 These apparatus measure the release from a compact 
consisting of pure API with a flat and well-defined surface area into a test medium 
(Figure 4). A difference between the two procedures is the source of fluid flow over the 
dissolving surface. In the rotating disk procedure, fluid flow is generated by the rotation 
of the die, but for the stationary disk procedure, the fluid flow is generated by a paddle or 
other stirring device. 
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(a)  
 
(b) 
 
 
 
Figure 4. IDR test system. Schematic diagram of (A) the rotating disk apparatus (Wood 
Apparatus) and (B) the stationary disk apparatus (Source: USP37).  
10 
 
 
Powder Dissolution  
Solid drug substances are, in most cases, harvested through crystallization or 
precipitation in the manufacturing process. The resultant final APIs are composed of fine 
particles with a wide range of shapes, sizes and surface properties. For spherical particles, 
diffusion-controlled dissolution rate can be calculated once IDR of the drug is 
determined.8,9 However, the real world drug particles are almost never spherical. It is 
nearly impossible to accurately and reliably estimate the size, size distribution and 
surface areas of particles having various irregular shapes. Hence, the dissolution rate of 
powders needs to be measured experimentally. 
To determine the dissolution rate of powders in an aqueous medium, USP 
Apparatus 1 and Apparatus 2 shown in Figure 5 are usually used. They are also known as 
basket and paddle dissolution methods, respectively, and are typically used for 
dissolution testing of tablet and capsule dosage forms as well. The test procedures 
involve introduction of small and known quantity of sample powders into an appropriate 
dissolution medium, followed by analysis of solution concentration at predetermined time 
intervals. The concentration–time curves (dissolution profiles) obtained from the powder 
dissolution tests can be used for assessing how API variables may affect dissolution rate, 
assuring consistent quality of the API, comparing drug substance of different solid state 
properties, helping guide product and process development, and ultimately ensure 
consistent drug absorption following administration of solid dosage forms. 
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(a)  
 
(b) 
 
 
Figure 5. Powder dissolution system. Schematic diagram of (A) USP Apparatus 1 where 
the dosage form is placed inside the basket and the basket rotates during dissolution to 
provide mixing, and (B) USP Apparatus 2 where the dosage form is place on the bottom 
of the flask in a sinker and the paddle rotates to provide mixing (Source: Metrolab). 
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Despite the well-established dissolution methods to control the product quality and 
understand formulation performance, dissolution at the molecular level in large part has 
not been adequately studied.  
Polymorphism and Polymorphic Transition 
Drug Property Change due to Polymorphism 
The active pharmaceutical ingredient (API) is the drug portion in the 
pharmaceutical dosage forms. Most APIs are crystalline solids due to the ease of 
purification by crystallization processes and a better chemical stability in the solid state. 
However, a crystalline solid may not be physically stable because it can rearrange into 
different internal crystalline structures by varying molecular packing, conformation, 
hydrogen bonding pattern, chirality and tautomerization. This physical instability gives 
rise to polymorphism, the ability of a substance to exist as two or more crystalline phases 
that have different arrangements and/or conformations of the molecules in the crystalline 
lattice.10  
Polymorphism induces a long list of solid state property changes.10,11 The different 
molecular packing affords changes in molar volume and density, refractive index, 
electrical and thermal conductivity, and hygroscopicity. The thermodynamic properties 
are altered, resulting in differences in melting and sublimation temperatures, internal 
energy, enthalpy, entropy, heat capacity, free energy and chemical potential, 
thermodynamic activity, vapor pressure, and solubility. Spectroscopic properties are also 
different, such as electronic (UV), vibrational (IR), rotational (far-IR or microwave), 
nuclear interactions. The kinetic properties that are modified include dissolution rate and 
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rates of solid state reactions. In the surface property arena, the changes are in surface free 
energy, interfacial tensions, and crystal habit. Finally, mechanical properties are also 
different including hardness, tensile strength, compatibility, tableting, powder handling, 
flow, and blending.  
These changes formed the basis for analytical methods to detect and analyze 
polymorphism. The commonly used characterization techniques include optical 
microscopy (based on reflective index change), thermal analysis such as differential 
scanning calorimetry (DSC), based on the thermodynamic property, heat capacity and 
melting point changes), single crystal or powder X-ray diffraction (PXRD, based on 
different packing distance), Infrared and Raman spectroscopy (based on vibrational 
property changes), solid-state nuclear magnetic resonance spectroscopy (SSNMR, based 
the chemical shift anisotropy and the internuclear dipolar coupling), and so forth.  
A lot of these changes have a profound impact to pharmaceutical formulation 
development. For example, mechanical property changes lead to a difference in powder 
flow, blending and tableting. Different reaction rates cause the chemical stability 
differences among the polymorphic APIs. However, the most substantial impact is the 
change in solubility and dissolution rate. When a solid form converts to the 
thermodynamically more stable form, its solubility decreases, and so does its dissolution 
rate, resulting in significantly altered pharmacokinetic factors such as rates of absorption 
and drug bioavailability. This problem became significantly worse for poorly water-
soluble drugs for which the solubility and dissolution rate are already undesirable. If the 
thermodynamically stable form is not discovered during the earlier stages of development 
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and a metastable form is used in the formulation, there is a risk that the metastable form 
will recrystallize into the stable form during product manufacturing and storage resulting 
in reduced product performance in vivo. For this reason, rigorous polymorph screening 
and characterization to discover the most stable form and to understand the complex 
polymorphism of each drug candidate have been implemented in the early stages of drug 
development in every pharmaceutical company. 
Polymorphic Transformation 
Polymorphic transformation from the metastable polymorph to the stable 
polymorph is dictated by thermodynamics. In a pair of polymorphs, Polymorph I and 
Polymorph II, the stability relationship between the two polymorphs is determined 
entirely by their free energy differences at different temperatures.12 The free energy of a 
particular solid is expressed by the following equation: 
  STHG   
where G is the Gibbs free energy, H is the enthalpy, T is temperature, and S is the 
entropy. Thus, the free energy for the transition from Polymorph I to Polymorph II: 
  IIIIIIIIIIIIIIIIII )()(   STHTSHTSHGGG  
where IIIIII HHH    and IIIIII SSS   . At any given temperature, three 
possibilities exist: 
1. 0III  G : Polymorph II has lower free energy, is therefore more stable than 
Polymorph I. The transition from Polymorph I to Polymorph II occurs spontaneously. 
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2. 0III  G : Polymorph I has lower free energy, therefore, the transition from 
Polymorph II to Polymorph I is a spontaneous process. 
3. 0III  G : Polymorph I and Polymorph II has the same free energy. Therefore, 
both polymorphs have equal stability. There will be no overall transition between the two 
polymorphs.  
The temperature at which 0III  G  is defined as the transition temperature (Tt). If 
Tt is located below the melting points of both polymorphs, the two polymorphs are 
enantiotropically related, the representative phase diagram of which is shown in Figure 
6a. Therefore below Tt, Polymorph I is more stable. Above Tt, Polymorph II is more 
stable.  
If Tt is located above the melting points of both polymorphs, the two polymorphs 
are monotropically related, the representative phase diagram of which is shown in Figure 
6b. In this system, Polymorph I is more stable throughout the temperature range. 
In either monotropic or enantiotropic systems, polymorphic transition can occur. In 
the monotropic system (Figure 6b), Polymorph II has a higher free energy than 
Polymorph I until it melts. Therefore, below the melting point, Polymorph II will sooner 
or later convert to Polymorph I. The rate of conversion depends on the experimental 
conditions. The enantiotropic system (Figure 6a) is a little more complicated. The free 
energy relationship reverses when Tt is reached. Below Tt, Polymorph 2 will eventually 
converts to Polymorph 1. However, above Tt, Polymorph 2 will never convert to 
Polymorph 1. For polymorphic forms exhibiting an enantiotropic relationship, 
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determination of the Tt, is essential to control polymorphism. For example, if the Tt is 
55 °C and the temperature used in API manufacturing ranges from 45 to 65°C, then the 
drug could crystallize out as Polymorph I in one batch and as Polymorph II in another. In 
order to consistently manufacture Polymorph I, the crystallization temperature needs to 
be maintained significantly below 55 °C. 
 
(a) (b) 
 
Figure 6. Thermodynamic phase diagrams of polymorphs. (a) Enantiotropy; (b) 
Monotropy. The stable phases are indicated using solid lines and dotted lines for the 
meta-stable phases. L is for liquid which is the melt of the solid. Tm is the melting point.12 
 
Transformation from the metastable polymorph to the stable polymorph is mainly 
via four routes: vapor, melt (liquid state), solid state, and solution state. Pharmaceutical 
solids usually have a low vapor pressure and transition vial sublimation at ambient 
temperature is not very common. When the crystal is heated to the melting point, 
crystallization to another form can happen during the cooling of the melt. Conversion in 
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the solid state usually occurs in response to an energy input. For examples, mechanic 
milling induces crystal defects or an amorphous phase which are higher energy spots that 
can promote nucleation to the more stable form. Compaction force during tableting 
process can also cause polymorphic conversion. Heating the metastable form greatly 
increases the molecular mobility to trigger recrystallization which can be determined by 
DSC. The thermal events prior to the melting in a DSC thermogram are indicative of the 
nature of polymorphic transformation.12-14 The conversion can also take place when the 
metastable form is in contact with solution15 or moisture16 due to the solubility difference 
between the two solid forms. The metastable form dissolves into the solution to reach the 
solubility, which would be supersaturated with respect to the stable configuration. When 
the supersaturation level is high enough, nucleation of the stable form commences. This 
solution induced transition is referred to as solution-mediated phase transformation 
(SMPT).17,18 The presence of the solvent does not change the thermodynamics and 
stability relationship unless a solvate/hydrate forms with the solvent. However, owing to 
the much higher mobility in the solution state than in the solid, the transformation to the 
stable phases is much faster.  
SMPT is the most relevant solid form conversion mechanism when considering the 
drug dissolution into the aqueous medium in vivo. It not only describes the phase 
transformation from a metastable form to the stable form, but also that from an 
amorphous solid to a crystalline solid19 and from a salt to its parent20 or from co-crystal to 
another co-crystal.21 For poorly water-soluble compounds for which the absorption in 
vivo is highly dependent on drug concentration (dissolution rate or solubility-limited 
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absorption), conversion to a thermodynamically more stable form is detrimental to 
bioavailability and performance of the final drug product. 
Crystallization Inhibition by Polymers 
As stated previously, APIs are predominantly crystalline solids manufactured through 
crystallization from solutions. Crystallization in solution occurs under conditions of 
supersaturation with the first step being nucleation followed by crystal growth. As shown 
in Figure 7, crystallization includes two processes: nucleation, and crystal growth after 
nucleation. The mechanism of nucleation is divided into primary and secondary (induced 
by crystals only) nucleation with the primary route further categorized into homogenous 
and heterogeneous nucleation. Homogeneous nucleation is driven by concentration 
fluctuations in a multicomponent fluid systems at the limit of Gibbs free energy stability 
(spinodal decomposition), which is not a common event.22 Heterogeneous nucleation is 
induced by foreign surfaces such as impurity particles or even glass walls which are 
ubiquitous. The large sale crystallization of APIs is often done by secondary nucleation 
where seed API crystals are added deliberately to induce faster crystallization and to 
control the polymorphism. 
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Figure 7. Crystallization from solution. Reproduced based on reference.22 
However, the situation changes when the API enters the formulation development 
phase, where particle size control and crystallization inhibition become the central focus. 
Poorly soluble compounds often require an enabling technology to deliver, including salt 
formation, lipid based formulation delivery systems, amorphous solid dispersions and 
nanotechnology. Without exception, these formulations are metastable when 
administered orally or by injection. Salt in water could disproportionate into the parent 
drug plus the counter ion depending on the pH, and the drug molecule could crystallize 
into less soluble parent crystals. Lipid based formulations as well as amorphous solid 
dispersions upon dilution or dissolving could quickly reach high supersaturation 
concentration, a driving force for crystallization. Nanoparticles can also be unstable in 
aqueous solutions due to particle aggregation and size growth which threaten the 
formulation performance. Even for less insoluble compounds, particle size growth is a 
problem in formulating a pharmaceutical suspension common for ophthalmic or pediatric 
Crystallization
Nucleation Crystal Growth
PrimarySecondary
(induced by crystals)
Homogeneous
(spontaneous)
Heterogeneous
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use. APIs used in suspension formulations are milled by crushing and grinding 
operations, yielding particle surfaces with higher free surface energy. These particles 
have a tendency of growing or knitting together to form a hard cake, causing difficulties 
in re-suspending and producing a gritty texture unsuitable for topical, especially 
ophthalmic, applications.23 Thus, inhibiting crystallization is an important task in 
pharmaceutical formulation development.  
Nucleation Theory 
Before going into crystallization inhibition, it is necessary to understand the basics 
of nucleation and crystal growth. Although crystals are ubiquitous, they have an 
accidental nature to them.24 The molecules located in the internal lattice have a lower 
chemical potential (µ) and are more stable, while those on the surface are coordinated 
with fewer neighbors and thus they have a higher chemical potential (µ) and are less 
stable. Assuming a tiny crystal with a radius, r, which is comprised of N interior 
molecules (Nint) contributing to the stabilization of the tiny crystal, the stabilizing free 
energies equal to െ ௜ܰ௡௧ߤ௜௡௧. The volume of the interior crystal is ܸ ൌ ସଷ ߨݎଷ by assuming 
spherical nuclei. Correspondingly, the N surface molecules with the surface area of 
ܣ ൌ 4ߨݎଶ will contribute to the destabilizing free energy by ൅ ௦ܰ௨௙ߤ௘௫௧. The tiny crystal 
can only survive if the free energy of the interior molecules exceeds that of surface 
molecules. Let G stand for the total free energy for a growing approximately spherical 
tiny crystal, then we have: 
ܩ ൌ െ43ߨݎ
ଶ ௜ܰ௡௧ߤ௜௡௧	݌݁ݎ	ݑ݊݅ݐ	ݒ݋݈ݑ݉݁ ൅ 4ߨݎଶ ௦ܰ௨௥ߤ௦௨௥	݌݁ݎ	ݑ݊݅ݐ	ܽݎ݁ܽ 
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The minimal requirement for radius, r, is when G is minimized. The derivative of G gives 
the following,24 
݀ܩ
݀ݎ ൌ 0 ൌ െ4ߨݎ
ଶ ௜ܰ௡௧ߤ௜௡௧	݌݁ݎ	ݑ݊݅ݐ	ݒ݋݈ݑ݉݁ ൅ 8ߨݎ ௦ܰ௨௥ߤ௦௨௥	݌݁ݎ	ݑ݊݅ݐ	ܽݎ݁ܽ 
ݎ ൌ 2 ൈ ௦ܰ௨௥ߤ௦௨௥	݌݁ݎ	ݑ݊݅ݐ	ܽݎ݁ܽ
௜ܰ௡௧ߤ௜௡௧	݌݁ݎ	ݑ݊݅ݐ	ݒ݋݈ݑ݉݁  
Above equation indicates that the nucleus radius has to exceed two times the ratio 
of the surface free energy over the interior free energy in order to be stable. 
At this critical radius, the rate of nucleation, J, e.g. the number of nuclei formed per 
unit time per unit volume, can be derived based on the Arrhenius reaction velocity 
equation and the basic Gibbs–Thomson equation, as shown below.22 
J	ൌAe‐
∆G
kbTൌAe‐
16πγ3v2
3kb3T3ሺlnSሻ2 
 
Where A is the pre-exponential factor (the total number of collisions), ݁ି
∆ಸ
಼್೅ is the 
probability of any collisions that lead to the reaction, ݇௕ is the Boltzmann constant, T is 
the absolute temperature, ߛ	is interfacial tension, ݒ is the molar volume and S is the 
supersaturation defined as the ratio of drug concentration over the crystalline solid 
solubility. It is evident that the nucleation rate is a complex process affected by many 
factors. At a given T, increasing S will increase the nucleation rate. A plot of J vs S at 
natural log scale will indicate an initial linear increase but J becomes extremely fast when 
some critical level of S is exceeded.22 Higher temperature increases the nucleation rate as 
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well. J is also affected by A, the total number of collisions, which is expected to increase 
with higher temperature and drug concentration. Therefore, an increase in both S and T 
will increase the nucleation rate. Nucleation is the rate limiting step in crystallization. 
Following the birth of nuclei, crystal growth may proceed rapidly. 
Crystal Growth 
Crystal growth has been described by several theories.25 The surface energy 
theories, which have been almost entirely abandoned, are based on the assumption that 
the total free energy of a crystal would be a minimum. The diffusion theories assume that 
solute molecules are deposited continuously on a crystal surface at a rate proportional to 
the concentration gradient between the bulk solution and the crystal surface. It is thus 
considered a reverse process of crystal dissolution. The mathematical treatment is 
therefore very similar to other mass transfer processes: 
݀݉
݀ݐ ൌ ܭீܣሺܥ௕ െ ܥ௜ሻ
௚ 
The crystal growth rate, ௗ௠ௗ௧ , is proportional to the overall crystal growth coefficient, 
KG, the crystal surface area, A, and the driving force for diffusion, ሺܥ௕ െ ܥ௜ሻ where Cb is 
the bulk concentration and Ci is the concentration at the crystal surface. The exponent g is 
the overall process order. When g = 1 (first order), KG will be defined by 
ଵ
௄ಸ ൌ
ଵ
௞೏ ൅
ଵ
௞ೝ 
where kd is the diffusion coefficient of mass transfer and kr is the rate constant for surface 
integration. This indicates that crystal growth is a two-step process, the first being the 
diffusion of the molecules to the crystal surface and the second being the integration of 
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the molecules into the crystal layer. If integration is fast, then the crystallization is rate-
limited by diffusion. If the diffusion is fast, then integration becomes the rate limiting 
step. 
Adsorption-layer theories, on the other hand, assume that crystal growth is not a 
continuous process; rather it is taking place by adsorption, growing layer by layer. There 
will be a loosely absorbed layer of molecuels on the crystal surface, which will link into 
the lattice in positions where the attractive forces are the greatest. Before the next layer 
commences, a monolayer island nucleus is created. This is called two-dimensional 
nucleation. The mathematical equation for the velocity of the two-dimensional nucleation 
is ܬ	 ൌ ܣ݁ି∆ಸೖ೅ ൌ ܣ݁ି
ഏ೓ംమೡ
ೖమ್೅మ೗೙ೄ	which was developed similarly as the classical nucleation 
theory described above with the letters having the same meanings. Similar to nucleation 
rate, the crystal growth rate is faster when increasing temperature and supersaturation 
levels. 
Crystallization Inhibition by Polymers 
It has been known as early as 1958 that polymers can be added to pharmaceutical 
suspensions to increase viscosity and thus, to retard the overall crystal nucleation and 
growth process.23 More recent pharmaceutical research in crystallization inhibition by 
polymers has done mainly to meet the need to deliver poorly water-soluble compounds 
by enabling technologies, particularly amorphous solid dispersions. A large number of 
publications have been focused on how to screen polymers for making amorphous solid 
dispersions of selected model compounds. As a comparison, studies with an objective to 
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elucidate polymer–drug interaction mechanism are fewer. Simonelli et al., in 1970 first 
described the underlying principles of using polymers to inhibit crystallization of drug 
molecules.26 By studying sulfathiazole crystal growth at different concentrations and 
different molecular weights of polyvinylpyrrolidone (PVP), Simonelli et al. established a 
kinetic model to describe the dependence of crystal growth rate on the diffusion rate of 
the polymer relative to that of the drug. The model entails that the polymer in solution 
needs to reach the crystal surface from the bulk solution ahead of the drug molecules, and 
the polymer concentration needs to be high enough to sufficiently cover the crystal 
surface to cause inhibition of crystal growth. Their data also indicate that the polymer 
must be tightly bound to the surface in order to be effective at low concentrations. 
Therefore, the adsorption of the polymer to the crystal surface is of great interest. Many 
models have been developed ever since27-31 for modeling polymer adsorption to a surface 
using the Langmuir adsorption equation addressing polymer chain flexibility, molecular 
weight, pH, rate of adsorption, etc. Recently, Alonzo et al.32 studied HPMC 
(hydroxypropyl methylcellulose) for inhibiting nucleation and crystal growth of 
felodipine. In the presence of HPMC, the crystal growth of felodipine shifted toward an 
integration-controlled mechanism from a diffusion-controlled mechanism. 
Based on these mechanistic studies, it was believed that the adsorption of a large 
linear polymer molecule is due to the binding of particular sites; the remainder of the 
chain projects into the aqueous phase as tails (the ends of the polymer) or loops (the 
middle of the chain), as envisioned in Figure 8. The strong adsorption is due to the 
collective energies of many binding sites on the polymer.28 Clearly, more studies are 
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beneficial to understand exactly how the long polymer chain interacts with a crystal 
surface and which energy forces are involved in the adsorption. This will also help to 
understand the selectivity of the polymer adsorption to drug molecules which may lead to 
better ways to design the most efficient formulations. 
 
Figure 8. Schematic of the configurationally change of adsorbed polymers with 
increasing surface concentration.27  
 
Molecular Dynamics Simulation 
The first molecular dynamics (MD) simulation of a macromolecule of biological interest 
was published in 1977,33 which changed the early view of proteins as relatively rigid 
structures to a dynamic model. Since then, computational biology, particularly MD 
simulations, have advanced rapidly in methodology and applications in parallel with 
advances in computing power and simulation programs.34-36 
Molecular modeling takes its roots from quantum mechanics (QM) which is based 
on the solution of the Schrödinger wave equation.37 The wave equation describes the 
motions of the electrons and nuclei in molecular systems. The 3D molecular structure, 
molecular energies and many associated properties can be calculated by this equation. 
However, the level of complexity to solve the Schrödinger equation is prohibitive in 
26 
 
 
calculating a large system. To simply the calculation, Born and Oppenheimer made an 
approximation by assuming the nuclei, which are much heavier than the electrons, are 
fixed on the time scale of electronic vibration.37 There are primarily two QM methods 
derived from the Born-Oppenheimer approximation: ab initio QM and semi-empirical 
QM. The former is more rigorous than the latter; therefore it requires more computational 
time. DFT (density function theory) is a variation of ab initio QM which improved the 
calculation efficiency. Nevertheless, all of the QM methods are still very demanding in 
terms of computational expenses and time, therefore they are not practical in calculating 
larger systems, such as proteins. This led to the development of an alternative approach – 
the molecular mechanics (MM). 
The MM model treats all of the atoms as spheres connected by springs representing 
bonds. Internal forces experienced in the model structure are described using simple 
mathematical functions38 forming the potential energy function. MD simulation uses  
molecular mechanics (MM) models to numerically solve Newton’s equations of motion, 
thus allowing atomic or molecular motions to be observed with respect to time,38 and 
providing the ultimate details of motional phenomena.  
Potential Energy Function 
The success of a MD simulation is highly dependent upon a suitable potential 
energy function which is called a force field. The current study uses the CHARMM 
(Chemistry at HARvard Molecular Mechanics) force field39 which has been separately 
parameterized for proteins, nucleic acids, lipids, and carbohydrates, making it highly 
versatile and widely used. The potential function, ܸሺ ሬܴԦ), is a sum over individual terms 
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representing the internal and nonbonded contributions as a function of the atomic 
coordinates, as described in the following equation.38  
 
 
Equation 1. Potential energy function of CHARMM27.38  
As summarized in Table 1, each term in Figure 1 represents a simple functional 
form and describes an intermolecular or intramolecular force within the system. These 
terms are additive in nature, resulting in the potential-energy function to describe the 
energy landscape of the system from a single set of atomic coordinates. The force 
constants for bonds (Kd), angles (Kθ and KUB), dihedrals (Kχ) and improper dihedrals (Kφ) 
are empirically determined. The reference (or equilibrium or ideal) values for bonds (d0), 
angles (θ0 and S0) and dihedrals (φ0) were determined by both experimental techniques 
and quantum mechanical calculations which are included in the force field in the MD 
simulation programs. Besides the CHARMM force field, there are others available, such 
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as AMBER (preferred by nucleic acid modelers), ECEPP (dihedral angle program for 
proteins), and GROMOS, OPLS, CFF, and SIGMA.37 
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Table 1. Individual Terms in CHARMM27 Potential Function. 
Term Function 
 
Bond stretching.  
Kd: bond length force constant.  
d: bond length. 
d0: reference value of bond length. 
 
Angle bending using 1,3-nonbonded 
interactions.  
KUB: Urey-Bradley force constant.  
S: Urey-Bradley. 
S0: reference value of Urey-Bradley. 
 
Angle bending.  
Kθ: bond angle force constant.  
θ: bond angle. 
θ0: reference value of bond angle. 
 
Dihedral (torsion angle) motion.  
Kχ: dihedral angle force constant.  
χ: dihedral angle. 
n: periodicity of the dihedral angle 
δ: phase shift 
 
Improper dihedral motion (out of plane 
bending).  
Kφ: improper angle force constant.  
φ: improper dihedral angle. 
φ0: reference value of improper dihedral 
angle. 
Nonbonded interactions. Coulombic 
equation for the electrostatic energy and 
Lennard-Jones potential for van der 
Waals (VDW) energy. 
ϵij: Lennard-Jones well depth. 
ܴ௜௝௠௜௡:	distance at which the Lennard-
Jones potential is zero. 
rij: distance between atoms i and j. 
qi: partial atomic charge of atom i. 
qj: partial atomic charge of atom j. 
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Newtonian Molecular Dynamics 
Under the influence of the force, particles in a system move according to Newton’s 
equation of motion, 
ܨ ൌ ݉ܽ ൌ ݉݀ݒ݀ݐ ൌ ݉
݀ଶݔ
݀ݐଶ ൌ െ׏ܸ 
where F is the force exerted on the particle, m is mass of the particle, a is its acceleration, 
v is the velocity, t is the time, x is the distance the particle moves and ׏ܸ is the gradient 
of the potential function. The force, F, is the negative gradient (first partial derivative) of 
the potential energy. The velocity of the particle can be obtained by integrating ܽ ൌ ௗ௩ௗ௧ to 
give the following equation. 
ݒ ൌ ܽݐ ൅ ݒ଴ 
Similarly, integration of the velocity (ݒ ൌ ௗ௫ௗ௧ ) give the following equation. 
ݔ ൌ ݒݐ ൅ ݔ଴ 
Combining of above two equations leads to the following expression, 
ݔ ൌ ܽݐଶ ൅ ݒ଴ݐ ൅ ݔ଴ 
which correlates the position of the particle to the acceleration a, the initial velocity ݒ଴, 
and the initial position ݔ଴ at time t. This means that if the initial position and the initial 
velocity of the particle are defined, the position at a given time can be calculated because 
the acceleration can be obtained from the derivative of the potential energy function with 
respect to the particle position (ܽ ൌ െ ଵ௠
ௗ௏
ௗ௫). 
The initial positions are determined by the starting coordinates (e.g. crystal 
structure). The initial velocities are typically set pseudorandomly from a Maxwell-
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Boltzmann or Gaussian distribution at a given temperature, which is accomplished by 
many software packages.40 
In simulation of a large system, the potential energy is a function of the atomic 
positions of all the atoms in the system. Due to the complicated nature of this function, a 
numerical integrator is needed. Among the numerous numerical algorithms available, the 
Leapfrog/Verlet Algorithm is the most commonly used. The Verlet algorithm is based on 
a Taylor series expansion. It uses the positions at time t and the velocities at time 
ݐ െ ቀ∆௧ଶ ቁ	for updating both positions and velocities via the acceleration a. The equation to 
update velocity is ݒ ቀݐ ൅ ∆௧ଶ ቁ ൌ ݒ ቀݐ െ
∆௧
ଶ ቁ ൅ ܽሺݐሻ∆ݐ. The equation to update the 
coordinates is ݎሺݐ ൅ ∆ݐሻ ൌ ݎሺݐሻ ൅ ݒሺݐ ൅ ∆௧ଶ ሻ∆ݐ.38 
In practice, a successful MD simulation requires implementing many details, such 
as obtaining appropriate parameters, coordinates and topology files, setting initial 
conditions, selecting a program, acquiring high speed computers, and visualizing and 
analyzing the large size data set, and so forth. 
Applications of MD Simulations to Pharmaceutical Research 
MD Simulation to Study Drug Dissolution 
MD simulation of drug crystal dissolution into anaqueous medium has not been 
reported prior to 2013.41 However, there have been several dissolution simulations of 
non-drug crystals in the literature. The earlier work was on inorganic salt crystals (i.e. 
NaCl) by Ohtaki and his co-authors in the late 1980’s.42-44 The motivation to study NaCl 
was that sea salt (i.e. NaCl) crystal dissolution is one of most crucial dissolution process 
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in atmospheric chemistry. Due to the limitation of computational resources, these earlier 
studies simulated very small crystals in a small water box. The first study43 reported in 
1988 was a 7 ps long MD simulation of a 32 NaCl molecule crystal in 216 water 
molecules to calculate ion–ion, ion–water and water–water interactions. Based on their 
results, chloride ions from the five corners dissolved but the sodium ions did not. A year 
later, a follow-on study42 simulated the dissolution of the NaCl (111) face which was 
covered with chloride ions only and the (–1–1–1) faces which was with the sodium ions 
only. Similarly, 28 NaCl molecules were put into the water box containing 189 waters 
which was simulated for 7 ps. This second simulation repeated the previous results in that 
only the chloride ions dissolved and sodium ions remained on the crystals. It was 
hypothesized that the repulsive forces arising between the chloride ions and the water 
molecules push the chloride ion out from the crystal surface as they possess a smaller 
hydration energy than the sodium ions. These authors reported another study44 in 1993 
that expanded the salt list to include many alkali halide crystals (LiCl, NaCl, CsF, KCl, 
NaF, and KF). Within 12 to 20 ps, the anions in the LiCl, NaCl and CsF crystals have 
dissolved but none of the cations have. Interestingly, for crystals of KCl, NaF and KF 
having similar size of cations and anions, no ions have dissolved within 20 ps. Using 
anion solution X-ray diffraction, NaCl and KCl were found to form 1:1 ion pairs in 
solution. On the other hand, KF and CsF solutions formed ion clusters larger than 1:1 ion 
pairs. It appears no conclusion could be made based on these results. In 2011 (eight years 
later), Liu eta al. did a simulation on NaCl dissolution in water45 using the state-of-the-art 
ab initio molecular dynamics and free energy sampling techniques. Their results shed 
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some light on the anions preferential initial dissolution. The crystal was comprised of 3 
layers of NaCl covered with a 15 Å thick water layer. The simulation was performed for 
a total of 1 µs with classical force fields [molecular mechanics (MM)] and a separate 0.6 
ns of ab initio QM (quantum mechanics simulation). In the force-field MM description, 
the Born–Mayer–Huggins potential was used for NaCl and the TIP3P model was for 
water. For the QM description, density-functional theory (DFT) with the PBE27 
exchange–correlation function was used. They showed that NaCl dissolution is a complex 
multi-step process triggered by the initial departure of Cl ions from the lattice followed 
by the departure of Na ions. A well-defined intermediate state was identified in which the 
departing Cl ion is partially solvated and still retains contact with the crystal. Based on 
the calculated QM free energy barriers, the initial rate of Cl ions dissolution will be about 
1000 times larger than that of Na ions. The departure of Cl ions disrupts the surface and 
leaves a Na ion in an almost fully solvent-exposed location, primed for subsequent 
dissolution. The better results from the 2011 study seem related to the use of more 
advanced simulation methods including a different force field, ab initio MD, and a longer 
run time. Nevertheless, the very early studies by Ohtaki and his co-authors did indicate 
that Cl ions should departure first in NaCl crystal dissolution. This reminds us of the 
remark Martin Karplus made in his review article in 2002, “The conceptual changes 
resulting from the early studies make one marvel at how much of great interest could be 
learned with so little—such poor potentials, such small systems, so little computer 
time.”46 
34 
 
 
The simulation of salt crystal continued in 2012 with KCl dissolution. The study 
employed density-functional theory (DFT) calculations and molecular dynamics studies 
using the GROMACS force field.47 In the MD simulation, three crystal surfaces each 
with 105–120 KCl molecules were simulated in about 3000 waters for 2.5 ns. The 
observations were similar to the NaCl study in 2011. The DFT calculation indicated the 
departure of Cl ions was before the Na ions and has been found to be more significant 
from the edge of the KCl crystal. At least four water molecules were found to be 
necessary to initiate the separation of the ions from KCl crystal. The observation from 
MD simulation indicated different ion departure profiles with the three different KCl 
faces. 
Simulations were also done on poorly water-soluble salts. In 1999, Parker and 
coworkers48 modeled different stepped surfaces of a calcium carbonate crystal with a 
small amount of water using a molecular dynamic simulation. This process represents the 
aqueous corrosion which is of importance in geological science. By simulating a 
monolayer of water on the calcium carbonate surface, they found that water has a 
stabilizing effect causing slower dissolution than that in vacuo. The same authors 
conducted another MD simulation study49 in 2006 on the interaction of two solid 
surfaces, namely the (001) hematite (α-Fe2O3) and (104) calcite (CaCO3) surfaces in 
contact with aqueous electrolyte solutions containing different concentrations of NaCl. A 
few layers of water were added and the simulation lasted for 1 ns. They observed a 
characteristic double layer of water at neutral surfaces and that the charge distribution 
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oscillates into the bulk. The presence of dissolved ions was found to make a small but 
significant reduction to the dissolution free energies. 
MD simulation on organic molecule dissolution has been rare before 2013 and only 
two papers were found. In the study reported in 2005, a flat crystal surface of urea (001) 
was built and simulated using the GROMACS force field in the presence of water to 
monitor the dissolution and subsequent recrystallization.50 They observed that at 298 K 
the dissolution proceeded until two layers of urea were completely dissolved. At this 
point, the surface layer concentration was calculated as 2–7 M which is still below the 
saturation solubility of 11 M, but it is probably high enough to slow down the dissolution 
rate to the point that it is no longer measurable by MD simulation. They then decreased 
the temperature to 260 K and simulated a further 38 ns. After a short induction period, 
formation of a nucleus on the crystal face was observed which continued to grow until a 
new layer was formed on the crystal surface. The supersaturation on the surface for 
nucleation was assumed due to the solubility difference between 298 and 260 K. The 
paper did not discuss what the solubility of urea is at 260 K which may not be measurable 
in frozen water (ice). 
The second organic molecule dissolution was published in 2011 by Hayakawa and 
co-authors.51 The dissolution process of cellulose triacetate (CTA) II crystal was studied 
in dimethyl sulfonamide (DMSO). The nanocrystal consisting of 18 CTA chains in an 
8 × 8 × 8 nm box with DMSO molecules was simulated for 9 ns using the CHARMM 
program and carbohydrate force field. As illustrated in Figure 7, one CTA chain detached 
from the crystal surface and entered the DMSO solution at 9 ns. The three types of H-
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bonds with varying degrees of bond strength responsible for forming the crystal all 
disappeared during the dissolution. The two stronger H-bonds provide the major 
resistance to solvation with DMSO based on the energetic calculation.  
 
 
Figure 9. MD Simulation of dissolution of cellulose triacetate II nanocrystal into DMSO 
at time 0 (a) and 9 ns (b) (from Figure 2 of reference 51).51  
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Several papers emerged in 2014. Toroz et al.52 reported MD simulations of two 
polymorphs of para-aminobenzoic acid (which is not a drug per se but structurally similar 
to some drugs) at temperatures of 0, 50 and 100 °C for 5 ns. The crystals were solvated 
using TIP3P model but the water box size was not described. The two polymorphs, α 
form and β form are enantiotropically related, with the transition temperature (Tt) at 13.8–
16 °C. Below the Tt the β form is more stable, and above the Tt the α form is more stable. 
Thus, simulation at 0 °C should identify β form as the stable form, while at 50 °C or 
100 °C should identify the α form. Their results showed that at 0 °C both forms remained 
as ordered crystal, but at 50 °C the two forms became partially disordered and 100 °C 
both lost long range order. The stability of the nanocrystals appeared to be an issue, and 
will need more investigations in the future. 
In summary, the practice of using MD simulation to study crystal dissolution has 
been demonstrated in the literature; and the methodology has gradually improved over 
the last two decades. There have been very few reported studies limited to small salt 
crystals and two organic molecules (urea and cellulose). There have been no reported 
studies on drug crystal dissolution. Hence, it is necessary to establish MS simulation of 
drug crystal dissolution as a special focus in pharmaceutical research considering that (1) 
the small salt crystals or large molecular weight cellulose crystals are structurally 
different from the majority of organic drug crystals, and (2) the purpose of drug 
dissolution is to understand the effect of surface area, polymorphism, polymorphic 
transition, supersaturation level, dissolution media, etc. which are very different from the 
dissolution studies done in the above surveyed disciplines.  
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MD Simulation to Study  
Polymer Interaction with Drug Crystals 
There are quite a few papers in recent years reporting the simulations of the 
interaction of polymers with drug or drug like molecules in solution. The purpose of 
these studies was to understand or identify polymer systems for polymer based drug 
delivery (i.e. polymeric nanoparticles), therefore, single or multiple drug molecules rather 
than a drug crystal was simulated with the polymers.53-57 For example, in 2011, Subashini 
et al.57 conducted MD simulations to model drug uptake by polymers. The structures of 
three drugs and six polymers at decamer or hexamer length were built with 
HYPERCHEM® software. MD Simulations were performed in 11,300 water molecules 
using the GROMACS forcefield for 300 ps at 300 K, and the interaction energy between 
various drugs and polymers was calculated. They found the interaction energies were 
correlated with the experimentally observed drug uptake values. In another example, 
Kasimova et al.55 in 2012 studied how four different lipophilic drugs (cyclosporine A, 
griseofulvin, ketoconazole, and quercetin dihydrate) were loaded into a polymeric micelle 
consisting of six chains of amphiphilic copolymer PEG−hexPLA (built at molecular 
weight of 5000 g/mol). The four drugs and monomers were parameterized using the 
general AMBER force field (GAFF), and simulated in TIP3P explicit water for 10 ns 
after equilibration in vacuum. The interactions between the PEG−hexPLA and the drugs 
were evaluated by Flory−Huggins interaction parameters which are routinely used to 
measure the miscibility of two polymers or polymer with other materials. The 
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Flory−Huggins parameters calculated from the MD simulations were consistent with the 
experimentally measured Flory−Huggins parameters. 
MD simulations with the objective to study drug crystallization inhibition by 
polymers have also been reported. They can be divided into two main areas: (1) polymer–
drug interactions in amorphous solid dispersion systems which primarily investigated the 
solubility or miscibility of the drug and polymer(s) in the solid state,58-63 and (2) 
polymer–drug interactions in crystal systems to investigate crystal growth inhibition in 
the solution state.64-66 In the former, the rationale is that if the drug is fully dissolved in 
the polymer or miscible with the polymer, then the crystallization of the amorphous drug 
in the polymer matrix will not take place. Described here are the two representative 
papers. Gupta et al.60 performed MS simulations using the COMPASS force field to 
predict the miscibility of indomethacin with polyethylene oxide, sucrose and glucose 
through the calculated cohesive energy and the solubility parameter. An amorphous cell 
with 60 indomethacin molecules with either 72 sucrose molecules, or 144 glucose 
molecules or 14 chains of polyethylene oxide (PEO) each containing 30 monomer units 
were made into a 3 × 3 × 3 (nm) box. The system was equilibrated for 2 ns followed by a 
500 ps production simulation. The MD simulations predicted indomethacin to be miscible 
with polyethylene oxide and to be borderline miscible with sucrose and immiscible with 
glucose. The MD simulation of indomethacin with PVP by Xiang and Anderson63 was 
done differently. Five assemblies with varied indomethacin and PVP compositions with 
parameters assigned from the Amber force field were first equilibrated in their molten 
states and cooled to generate amorphous glasses. Prolonged aging dynamic runs (100 ns) 
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at 298 K were then carried out, from which the solubility parameters, the Flory–Huggins 
interaction parameters, and associated hydrogen bonding properties were obtained. It was 
found that inter-drug molecule H-bonding was decreased and replaced by drug–polymer 
intermolecular H-bonding. The calculated Flory–Huggins interaction parameter was able 
to predict the miscibility accurately when compared to experimental results.  
In the second area involving polymers to inhibit drug crystal growth in aqueous 
media, there are only three published studies. Zhu et al. simulated the interaction of 
several additives such as hydroxypropyl methylcellulose (HPMC) in water with crystal 
surface of fenofibrate66 and griseofulvin.65 A short HPMC chain (five repeating units) 
was constructed and placed into a small water box (1500 water molecules) with the 
simulation carried over a short duration (600–800 ps). The simulated binding energies 
between the additives and crystal surface were correlated with the experimental results 
when these additives were found to reduce the particle size of recrystallized griseofulvin. 
In 2012, Yani, Chow and Tan reported64 a 400 ps MD simulation of large polymers (225 
monomers for PVP and 62 for HPMC) with different crystal phases of salbutamol sulfate 
in a vacuum. Hydrogen bonding between PVP and salbutamol sulfate, which was ~40% 
of the total binding energy, was thought to dominate in prohibiting crystal growth.  
Outside of the pharmaceutical area, simulations of polymers with crystals were 
reported in recent years. The collection of literature includes the simulation in dry state of 
the (poly(octadecyl acrylate)) incorporating into the surfaces of a paraffin crystal (which 
is a kind of liquid crystal) to inhibit crystal growth,67 the simulations of 6 polymers 
(which have not been used as pharmaceutical excipients) with mineral crystal 
41 
 
 
hydroxyapatite which identified the importance of the carboxyls at the ends of the 
polymer chains,68 and a similar study of other sets of polymers with hydroxyapatite 
crystal69 and with calcite.70  
In summary, in the second area (polymers inhibiting pharmaceutical crystal growth 
in solutions), very limited MD simulations have been done under only limited conditions 
(short runs, in vacuum or in small water box with short run times). Thus, this area was 
identified as a gap to motivate future research. 
 
 
 
42 
 
CHAPTER TWO 
STATEMENT OF RESEARCH 
The literature review identified several areas in pharmaceutical field which we believe 
can benefit from the application of molecular dynamics simulation. The areas of focus for 
this dissertation include drug crystal dissolution, polymorphic transition and drug–
polymer interactions. The hypothesis is that MD simulation can potentially help 
understand these pharmaceutical mass transfer processes in aqueous media at the 
molecular level. This greater understanding could lead to better control over drug 
dissolution and polymorphic transformation. 
Drug Crystal Dissolution 
Understanding drug dissolution has been a subject of extensive pharmaceutical research 
due to its impact on drug absorption and therapeutic effect in humans. Despite the many 
mathematical models and well-established experimental methodologies, understanding of 
how a drug molecule detaches itself from solid phase (mostly crystalline) and enters into 
solution is quite poor for the most part. The purpose of our research is to: 
1. To develop and establish methodology in building crystal structure files using 
acetaminophen as the model drug. Acetaminophen was chosen because of its 
relatively simple chemical structure for obtaining the parameters, and the 
interesting polymorphism which is the second focus of this dissertation.
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2. To conduct dissolution simulation in water containing 0.15M NaCl at 37 °C, a 
condition relevant to in vivo. 
3. To analyze how each molecule dissolves into water in order to gain a 
molecular level dissolution profile and the energetics involved in the 
dissolution. 
Polymorphic Transition 
Acetaminophen Form II is well known to undergo a fast conversion to the stable Form I 
in solution. Since the conversion occurs in the presence of solution, it was assumed that 
the solution-mediated polymorphic transformation is the responsible mechanism for such 
a conversion. However, the details of the transformation have not been understood, and 
the reasons for such fast conversion are mostly unknown. The motivation is to elucidate 
the mechanism of the conversion by conducting the following studies. 
1. Determine the thermodynamic driving force for the Form II to Form I 
transformation through experimental methods and MD simulation. 
2. Identify the reason for generating the supersaturation necessary for nucleation 
using MD simulation and/or experimental methods.  
3. Explain the fast kinetics of Form II to Form I conversion  
Drug–Polymer Interaction 
The ability of polymers to inhibit crystallization of drug molecules has been the subject 
of intense research in recent years. Polymers are used to stabilize a metastable solid form 
in formulations, i.e. amorphous solid dispersions and nancrystals to deliver poorly water-
soluble small molecular drugs. Polymers also are used to maintain supersaturation during 
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dissolution of enabling formulations for maximizing formulation performance. Finally, 
polymers can play an important role in modifying the crystal habit during solution 
crystallization. In this dissertation, we selected to study a polymer drug system reported 
to have crystal surface specific interactions with the polymer. The objectives are: 
1. To build and obtain the hydrated PEG-b-PLA structure. 
2. To develop procedures to build structural files of tolazamide crystals with a large 
crystal surface area. 
3. To conduct MD simulations on the interaction of the hydrated polymer with 
several crystal surfaces in water and to compare these with experimental results. 
4. To understand the mechanism of interaction by calculating and analyzing the 
interaction energies. 
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CHAPTER THREE 
MOLECULAR DYNAMICS OF DRUG CRYSTAL DISSOLUTION:  
SIMULATION OF ACETAMINOPHEN FORM I IN WATER 
Abstract 
In order to gain a molecular level understanding of drug dissolution into aqueous media, 
we report the first molecular dynamics (MD) simulation of a drug crystal dissolving. The 
simulation was performed for acetaminophen crystal Form I dissolving in 0.15 M 
aqueous NaCl solution at 37 °C. The 10 ns simulation revealed interesting details of the 
dissolution process. Dissolution of the molecules from the crystal surface is far from a 
random process. On the contrary, the order of which molecules enter the solution depends 
on their initial positions in/on the crystal. Molecules located on the corners and edges 
dissolved first followed by those located on (100), (010) and (001) surfaces with slight 
variation. This corner and edge effect that has been observed by our real dissolution 
experiment conducted under polarized light microscope was successfully predicted at the 
molecular-scale by the MD simulation. Further analyses revealed the underlying 
mechanism: the differences in the molecular interaction energetics between the drug and 
water molecules. The molecules located on corners and edges of the parallelepiped 
crystal are not as tightly bound to their surrounding neighbors as those located in other 
positions, but they are more strongly interacting with the surrounding water molecules. 
The extent of molecular release is strongly correlated with the interplay between 
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interaction forces with solvent molecules and with other drug molecules in the crystal 
lattice. These findings, especially the significant “corner and edge effect”, will help us 
gain additional fundamental understanding in the relationship between dissolution rate 
and particle size and morphology, and thus are very relevant in the context of particle size 
reduction in delivering poorly water-soluble compounds. This study has also 
demonstrated that MD simulation is a powerful tool in studying dissolution phenomena. 
  
Key words: molecular dynamic simulation; crystal form; dissolution; corner and edge 
effect; electrostatic and van der Waals; acetaminophen 
Introduction 
The first important step in drug absorption from oral solid dosage forms is dissolution, a 
process by which the drug molecules detach from the solid particles and enter into the 
surrounding gastrointestinal (GI) milieu. Thus dissolution rate is of fundamental 
importance in pharmaceutical dosage form design. Over the years, understanding drug 
dissolution has been a subject of extensive pharmaceutical research.6,71-75 Despite the 
many mathematical models and well-established experimental methodologies, 
understanding of how a drug molecule detaches itself from the solid phase (mostly 
crystalline) and enters into solution is quite poor for the most part. One possible reason is 
that the dissolution mechanism, at a molecular level, is difficult to deduce even with 
highly sophisticated experimental approaches. In this context, computational methods, 
molecular dynamics (MD) simulation in particular, are a powerful tool that has the 
potential to help discern patterns and add insights that are otherwise difficult to gain.76 
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In biological sciences, MD simulation has contributed significantly with manifold 
applications relating to proteins,77-79 nucleic acids80-82 and lipids.83,84 For example, it 
changed the earlier view of proteins being rigid molecules and replaced those notions 
with a dynamic structural model with constant motion that is vital in their biological 
functions.85 In drug discovery, MD simulation plays an essential role in drug design and 
structural optimization.86-89 Application of MD simulation in other aspects of 
pharmaceutical sciences is also emerging although publications are limited to date. 
Recently, Xiang and Anderson90-93 applied MD simulation to the study of lipid bilayers 
and gained mechanistic understanding of solute partitioning and transport across 
biomembranes. They have also studied the mobility of a small peptide, Phe-Asn-Gly, in 
amorphous glasses of poly(vinyl pyrrolidone) (PVP) containing small amounts of water 
and ammonia using MD simulation. They were able to observe glass transition, aging 
processes, and the associated structural and dynamic properties of PVP and the embedded 
peptide.24 Li and coauthors94,95 simulated etching patterns on the acetaminophen 
monoclinic (010) crystal face by calculating the energies associated with molecular 
detachment, surface diffusion, and additive molecule adsorption using a refined Monte 
Carlo simulation model. Fuelled by the dramatic increases in computing power in recent 
years, the use of computational methods in pharmaceutical sciences has showed a 
growing trend.64,96,97 However studying dissolution of organic molecules, such as drugs, 
using this methodology has not yet been reported. Parker and coworkers48 modeled 
different stepped surfaces of calcium carbonate crystal using molecular dynamic 
simulation. By simulating a monolayer of water on the calcium carbonate surface, they 
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found that water has a stabilizing effect causing slower dissolution than that in vacuo. 
Dissolution of sea salt crystals (NaCl and KCl) into water was also simulated in the early 
1980’s by molecular dynamics simulation42-44 and more recently by quantum mechanics 
simulations.45,47 The scope and purpose of these studies are very different from the 
dissolution concept applied in pharmaceutical fields. The aim of this work is to 
investigate the dissolution behavior and energetics of key stages in drug molecule 
dissolution using MD simulations. Acetaminophen (designated as APAP hereafter), a 
widely used analgesic and fever reducing medicine, was used as a model drug. Its initial 
dissolution into biologically relevant aqueous medium was studied by MD simulation, the 
simulated data were analyzed by interaction energy calculations, and key results from the 
simulation were verified experimentally. 
Experimental 
Material 
Acetaminophen anhydrous polymorph I (Form I) with high purity was purchased 
from Sigma (SigmaUltra, lot 116K0124), and was used in solubility studies as received. 
Deionized, distilled water for preparing the dissolution medium (0.15 M sodium chloride 
in water) was purified to 18.2 mΩ/cm resistivity by passing distilled water through a 
deionizer/charcoal filter (Milli Q academic model, Millipore Corp., Bedford, MA). 
Sodium chloride used met ACS Reagent specifications. 
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Solubility Measurement 
Equilibrium solubility of acetaminophen Form I was measured in an 0.15 M 
aqueous solution of sodium chloride at 37 °C. Sufficient solid was added to 3 mL of 
medium in six replicates. The suspensions were equilibrated for >2 days at 25 rpm on an 
end-over-end tumbler, model 30-1200 (Vankel, Cary, NC), in a water bath set at 37 °C. 
After equilibration, the saturated solution was collected by filtration (13 mm Acrodisc® 
syringe filter with 0.45 µm GHP membrane, Pall Life Sciences, Ann Arbor, MI), at least 
1.5 mL of the filtrate was discarded, and the last 0.5 mL was collected. The filtrate was 
then immediately diluted into HPLC mobile phase and analyzed by HPLC using a five-
point external standard curve. The average concentration of the saturated solutions was 
reported as the solubility at 37 °C.  
Theoretical Methods 
Building the Crystal 
The single crystal structure of acetaminophen Form I, HXACAN01,98 was retrieved 
from the Cambridge Structural Database (Cambridge, UK). The unit cell comprises four 
APAP molecules. Using the Mercury software (Mercury 2.2, CCDC 2001-2008), a 
crystal lattice was built by repeating the unit cell at each of the three dimensions for four 
times. The resultant crystal, referred to as APAP1 4 x 4 x 4, consists of 64 unit cells and 
256 APAP molecules. The size of this crystal is 51.72 × 37.60 × 28.40 Å, about 4.6 nm in 
diameter. The shape of the crystal is parallelepiped in the monoclinic crystal system. 
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Preparing the Crystal for Simulation 
The 4 x 4 x 4 crystal constructed above was prepared using Visual Molecular 
Dynamics software (VMD, version 1.8.7, August 2009).99 First, the structure file of the 
crystal was built using the Automatic PSF Builder function from the input of the Mercury 
file and the APAP topology file. The topology and atom types for the CHARMM2739 
force field for APAP were obtained by comparison with similar molecules already in the 
standard topology file. Second, a water box was built to surround the crystal. The water 
box (containing 0.15 M sodium chloride to mimic the ionic strength of biological fluid) 
extends 40 Å on each side of the crystal to amount to 58622 TIP3 (water) molecules. The 
size of the water box is 131.7 × 117.6 × 108.4 Å3, which equals to 1.5 × 10-18 milliliters. 
The ratio of water molecules to the NaCl molecules in the system is 370 to 1. 
MD Simulation 
The computer code used for the MD simulations was the parallel, scalable MD 
program NAMD version 2.5.100 Periodic boundary conditions were used. The cutoffs for 
nonbonding (van der Waals and electrostatic) interactions were 12 Å. The switch distance 
was 10 Å, and a 1.0 1–4 scaling factor was used. The 4 x 4 x 4 crystal in the water box 
was first subjected to energy minimization (6000 steps) followed by slow heating from 
10 to 310 K over 30000 steps. The pressure on the system was equilibrated for 
10000 steps using a Langevin piston. The system was then allowed to equilibrate for 
30000 steps at constant temperature (310 K) and pressure (1 atm) before production data 
51 
 
 
was accumulated. Production simulations (10 ns) were performed at constant volume and 
temperature. 
Calculation of Interaction Energies 
Interaction energies were calculated using algorithms of the van der Waals and 
electrostatic energies and the NAMD program.100 These calculations were performed for 
specific APAP molecules with their surrounding APAP molecules, water molecules, and 
Na+/Cl-, for defined groups of APAP molecules with the surrounding water molecules 
within 4 Å. Because partial charges exist in any atom due to the different 
electronegativities of the atoms, the potential function used in the molecular dynamics 
simulation considers the partial charge in every atom even when the molecules are 
neutral (such as APAP). The electrostatic interactions, including ion–dipole interactions 
and H-bonding, are calculated using these partial atomic charges (CHARMM potential 
function39). The results of interaction energy calculations were analyzed using VMD. 
Visualize Dissolution of APAP Crystals under 
Polarized Light Microscope (PLM) 
The purpose of the experiment is to observe whether the dissolution starts from 
corners and edges. Acetaminophen crystals of sufficient size were prepared by 
recrystallization from water according to reported procedures.101 The recrystallized solids 
were found to be anhydrous Form I by powder X-ray diffractometry (model Ultima II D, 
Rigaku Corp., Tokyo, Japan). The faces of the crystals were not indexed by single crystal 
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X-ray diffraction since the observation will be focused on corners and edges. The crystals 
were stored in a tightly closed jar with desiccants at room temperature until use. 
A crystal (size of ~3 mm in length and 1.2 mm in width) was placed on a glass slide 
under a polarized light microscope (model Eclipse E-600 POL, Nikon Corp., Garden 
City, NY) with 4× magnification lens. Images were taken using MetaMorph imaging 
system (version 4.6R8, Universal Imaging Corporation, Downingtown, PA). Drops of 
dissolution medium (0.15 M sodium chloride in water) were added to completely cover 
the crystal. Dissolution of the crystal was monitored visually by capturing images 
periodically. 
Results 
Model compound APAP is a small molecular drug (molecular weight of 151.16 g/mol). 
Its chemical structure is shown in Figure 10a. The drug is weakly acidic with a pKa of 
9.5102 at 25 °C attributed to the phenol moiety. Therefore APAP is neither ionized at 
physiological pH nor in a 0.15 M aqueous solution of sodium chloride, the dissolution 
medium used in this study. In a 0.15 M aqueous solution of sodium chloride, the 
equilibrium solubility of APAP Form I was measured to be 20.0 ± 0.2 mg/mL or 
0.132 ± 0.001 M (n = 6) at 37 °C. The reported solubility under the closest conditions is 
21.02 ± 0.13 mg/mL in water at 37 °C.103 
APAP anhydrous Form I has a monoclinic structure98 with space group P21/a, and 
a = 12.93 Å, b = 9.40 Å, c = 7.10 Å, α = β = 90.0° and γ = 115.9°. Each unit cell contains 
four APAP molecules, as shown in Figure 10b. By four times repetition of the three-
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dimensional translation of the unit cell, the constructed 4 x 4 x 4 crystal assembly 
comprises 256 APAP molecules with a size of 51.7 x 37.6 x 28.4 Å3 (Figure 10c). Of the 
six surfaces of the crystal, two are (100) type, another two are (010) type, and the last two 
are (001) type of surfaces. The water box consisting of a total of 58622 water molecules 
as well as 0.15 M sodium chloride extends 40 Å from each side of the crystal to create a 
water box size of 131.7 x 117.6 x 108.4 Å3 (Figure 10d). The size of the water box was 
so designed that if the crystal were completely dissolved, the concentration would be 
0.28 M, that is, about 2-fold of the solubility. Analogous to a physically performed 
solubility measurement, extra solids were added to the medium, and the dissolution 
process was monitored by MD simulation. At the end of 10 ns simulation, the APAP 
concentration in the water box was about 40% of the solubility. 
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Figure 10. (a) Molecular structure of APAP. (b) Unit cell of APAP anhydrous Form I 
(dotted line indicating the two hydrogen bonds). (c) The 4x4x4 crystal of APAP 
anhydrous Form I built by repeating the unit cell four times in all three dimensions, 
viewed down crystallographic c axis. (d) 4 x 4 x 4 crystal of APAP Form I in the 131.7 × 
117.6 × 108.4 Å3 water box. 
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Grouping of APAP Molecules 
For the purpose of tracking the molecules that are released, the surface molecules 
on the crystal were divided into seven groups based on structural insights and the 
symmetry of the parallelepiped shaped crystal, which has eight corners, twelve edges, 
and six surfaces. Figure 11 illustrates how the surface bound molecules are grouped. The 
molecules located on the 8 corners are named as “corner group”. Similarly, the molecules 
on the 12 edges (except for those in the corner group) formed the “edge group”. The 
differences among the molecular orientation on the surfaces are significant; the two (100) 
surfaces are made of APAPs with the phenol group pointing toward external water phase. 
The two (010) surfaces have the methyl group exposed to the outside, and the molecules 
on the two (001) surfaces form crossed structures. Further, the top layer of APAP 
molecules on the (100) and (010) surfaces is completely exposed to water, but the second 
layer right beneath appears to be partially accessible to water. On the (001) surfaces, on 
the other hand, the APAP molecules are intertwined, forming a single surface layer 
accessible to water. Therefore, besides the corner group and edge group described above, 
other surface bound molecules are logically divided into five additional groups: (100) 
layer 1 (top layer on the 2 surfaces of (100)), (100) layer 2 (second layer on the tow 
surfaces of (100)), (010) layer 1 (top layer on the two surfaces of (010)), (010) layer 2 
(second layer on the two surfaces of (010)), and (001) layer 1. 
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Corners and Edges (100) and (010) Types (001) types 
 
Figure 11. Illustration of seven groups: (left) Circles indicate positions of corner group molecules; bars indicate positions of edge 
group molecules. (middle) Surfaces of (100) and (010) types viewed down crystallographic c axis, both with layer 1 (bulky VDW 
style) and layer 2 (smaller VDW style). (right) Surfaces of (001) type (viewed down crystallographic a axis).  
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Observation of the MD Simulation 
The crystal in the water box was first equilibrated to reach lower energy. Figure 12a 
is the image of the crystal at the end of equilibration, which exhibits some interesting 
features. First, the crystal remained intact preserving the overall three- dimensional long-
range order as originally built. Second, each molecule moved around within limited 
boundaries, representing vibrational and rotational movements of molecules in the crystal 
lattice. Last, the molecules on outer layer appeared much more mobile than those located 
deeper inside the crystal. 
The simulation of dissolution was then initiated and continued for 10 ns. APAP 
molecules gradually left the crystal and over time accumulated in the water phase. The 
dissolved molecules display thermal motions. They move around within the water box in 
a random manner, sometimes wandering back to positions close to the crystal surfaces. 
Figure 12b,c shows snapshots of the system at 3 and 10 ns respectively. It is obvious that 
with time the crystal became smaller, and the released numbers of APAP molecules were 
increased. It is also noticeable that only the molecules located on surface layer of the 
crystal dissolve, and the crystallinity (long- range order) is preserved in the center of the 
solid. These observations are consistent with the visual observation of a dissolving 
crystal. 
  
 
58 
 
a b c 
 
 
Figure 12. (a) The 4 x 4 x 4 crystal of APAP after equilibration (at 0 ns) viewed down crystallographic c axis. (b) Image taken at 3 ns. 
(c) Image taken at 10 ns. 
59 
 
 
Order of Molecule Dissolution 
As expected, the molecules located on the surfaces of the crystal dissolve into the 
solution first. To gain understanding in the molecules dissolved and their relationship 
with the crystal, we used the VMD software to examine the order of release for the 
molecules. The hypothesis is that a predictable pattern exists between the location of the 
APAP molecules and their order of release. 
In Figure 13, a series of images were captured at different times of dissolution (0.3–
10 ns). A clear trend was observed when the dissolved APAP molecules were correlated 
with the groups that reflect their original locations on the crystal. The preference of initial 
release is more toward the corners of the crystal, especially along the two more acute 
corners (sharper corners). The secondary release is from the edges, and finally the flat 
surfaces release APAP last. This indicates that the molecules are not leaving the crystal 
surfaces randomly but in an organized fashion. 
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Figure 13. Demonstration of the molecule release profile with time. Undissolved APAPs 
are shown in line style. Dissolved APAPs are shown in bulky VDW style. From left to 
right and from top to bottom, 0, 0.3, 0.6, 0.9, 1.8, 2.7, 4.5, 7.5 and 10 ns. All are viewed 
down crystallographic b axis. 
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Interaction Energy Calculation among 
  
APAP Molecules 
To determine the theoretical basis of the observed position-dependent release, total 
interaction energies were calculated between each individual of the 256 APAP molecules 
and their immediate surrounding APAP molecules within 4 Å over the 10 ns time frame. 
The total interaction energies are a sum of the van der Waals and electrostatic forces. To 
illustrate the calculated results, the following APAPs were chosen to represent different 
initial positions: (1) two molecules that are located in the center of the crystal and have 
never left their original locations during the 10 ns simulation; (2) a molecule located on 
(010) layer 2 that has never dissolved; (3) a molecule located on (100) layer 1 that was 
not dissolved within 3 ns but eventually left at 8.1 ns, and (4) two APAPs that dissolved 
within 3 ns including one released at 1.2 ns in the corner group and another released at 
1.9 ns in the edge group. It was expected that at time zero the APAP molecule being 
evaluated should interact through electrostatic and van de Waals forces with its 
surrounding APAPs. When an APAP is dissolving into water, such interactions should 
decrease significantly or completely since the dissolved APAP is no longer in contact 
with the neighboring APAP molecules that are initially surrounding it. At the same time, 
the interaction with the solvent molecules should increase. 
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Figure 14. The change of total interaction energy as a function of time for selected APAP 
molecules: solid blue line (▬▬▬): energy between APAP and its surrounding APAP 
molecules; dotted pink line (– – – –): energy between APAP and all water molecules; 
solid light blue line (▬▬▬▬▬▬): energy between APAP and all chloride ion [Cl]-1); solid 
red line (▬▬▬▬▬▬): energy between APAP and all sodium ion [Na]+1). (a, b) two APAPs 
located in the center of the crystal that have never been released. (c) an APAP located on 
(010) layer 2 that has never been released. (d) an APAP on (100) layer 1 that released at 
8.1 ns (later than 3 ns). (e, f) two APAP molecules released within 3 ns, one on corner 
released at 1.2 ns and one on edge released at 1.9 ns. 
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A series of plots in blue colored solid lines in Figure 14 depicts the calculated total 
interaction energy with surrounding APAPs over the course of 10 ns for the preceding list 
of APAP molecules. The data demonstrate the outcome as what has been predicted. In 
every plot, the initial total energy is always negative, and the energy level fluctuates from 
time 0 to 10 ns. However, there are profound differences in the interaction energy profiles 
among these different APAP molecules. Molecules that are located in the center of the 
crystal exhibited the highest interaction energies (the most negative) with the surrounding 
APAP molecules. The total energy exceeded –250 kJ/mole initially and remained with 
little or no change throughout since their local environments do not change during the 
course of simulation. The molecule in the (010) second layer also never escaped and 
started with the total energy close to –200 kJ/mole, which gradually changed to about –
125 kJ/mole at the end of 10 ns. However the interaction energy of this molecule never 
went to 0, suggesting that it maintained strong enough interaction with its neighboring 
APAP molecules to prevent it from leaving the crystal surface. The APAP molecule 
located on layer 1 of (100) has an initial energy of about –130 kJ/mole (much less than 
those of those two preceding cases), but the energy drifts downward to –10 kJ/mole at 1.5 
ns, and at 8.1 ns, the energy takes a deep dive down to 0 kJ/mole. This is precisely what 
was determined by the visual observation using VMD. As illustrated in Figure 15, this 
(100) Layer 1 molecule was initially wrapped inside a group of adjacent APAPs. At 1.5 
ns, the molecule moved half way out of the pocket and lost contact with most of the 
surrounding APAPs, which is consistent with the interaction energy dropping to –10 
kJ/mole. At 8.1 ns, it dissolves and no longer associated with any of the APAPs initially 
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surrounding it, resulting in the interaction energy decreasing to 0. The earlier released 
APAP molecules, in the corner group and in the edge group have smaller initial 
interaction energy (–64 to –70 kJ/mole) and released earlier at 1.2 and 1.9 ns, 
respectively. In all cases, the timing when the total energy changes to zero always 
corresponds to the time of molecule dissolving into water phase. 
The total interaction energies of –250 kJ/mole for the APAP located in the center of 
the crystal would seem to be too large a number from lattice energy perspective (ΔHf of 
APAP Form I is 28.1 ± 2.2 kJ/mole104). The reason is that for the entire crystal, this 
calculation would multiply count interactions. Thus, if an APAP molecule in the center of 
the crystal is surrounded by 10 other APAP molecules then the actual lattice energy 
would be 1/10th of the value we calculated. The range of interaction energy values 
reported by us is in line with other studies.64 
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Figure 15. Visual depiction of events occurring at sudden alterations in APAP/APAP 
interaction curve of the molecule on (100) layer 1 (panel d in Figure 14). From left to 
right, (1) the molecule surround by nine APAP molecules at t = 0 ns; (2) status of the 
molecule at t =1.5 ns (it only has contact with two of the nine surrounding APAPs; (3) 
position at t = 8.1 ns (it dissolved, losing contact with all APAPs initially surrounding it 
with interaction energies decreasing to zero). 
 
Interaction Energies between APAP and 
  
NaCl Molecules 
The MD simulation was conducted in the presence of 0.15 M NaCl. The effect of 
NaCl on the solubility of APAP was evaluated also through the perspective of interaction 
energies. The total interaction energies for the same set of selected APAP molecules in 
Figure 5 with surrounding Na+ and Cl- within 4 Å were calculated in the course of 10 ns 
simulation. The APAP molecules in the center of the crystal (Figure 5a,b) and in the 
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second surface layer (Figure 5c) have little or no contact with the dissolution medium; 
therefore, the interaction energies with Na+ or Cl- are zero or almost zero. The surface 
layer APAP molecules (Figure 5d,e,f), on the other hand, were shown to have interactions 
with Na+ or Cl-, especially when the molecules are released into the water phase. The 
interaction with Na+ or Cl- is sporadic and weak in general when compared with the 
strength of APAP–water interactions. Only rarely the APAP/Na+ interaction became as 
strong as the APAP–water interactions. 
Interaction Energies between APAP and  
 
Water Molecules 
During the dissolution process, drug molecules interact with water. One way of 
investigating this interaction is to look at the changes in van der Waals and electrostatic 
energies between APAP and water molecules over the 10 ns period. The interaction 
energies between a specific APAP molecule (same groups of APAPs as shown above) 
and the waters were calculated at 0.03 ns intervals and overlaid with the APAP/APAPs 
interaction curves in Figure 14. It is clear that the water interaction is complementary to 
the APAP intermolecular interactions. The loss in interaction between APAPs was gained 
back from their interaction with water. However, these APAP/water interaction energy 
profiles are somewhat different from those of APAP/APAPs in that they fluctuate 
significantly in amplitude after the APAP molecules dissolve. In order to understand this, 
we calculated the numbers of water molecules within 4 Å of the designated APAP at 0.03 
ns resolution. The resultant water number vs time profiles were compared with values of 
APAP/water and APAP/NaCl interaction energies in Figure 16. It is interesting to note 
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that the variation in number of waters is completely superimposable with the fluctuation 
in APAP/water interaction energies, indicating that the primary cause for the big swings 
in APAP/water interaction energy is the change in numbers of water molecules 
interacting with the APAP molecules (solvation number). A minor contribution lies in the 
interaction with NaCl; a few downward spikes (significant decreases) in the APAP/water 
interaction energies can be attributed to the increases in the APAP/NaCl interactions. 
Over the entire time, the numbers of waters that are interacting with APAPs vary 
constantly and dramatically (numbers spanning from 9 to 37 in the case of the APAP on 
the corner). These results painted a realistic picture of how a molecule interacts with 
water in solution. The solvation number, if obtained experimentally, will be an average of 
these dynamics. The MD simulation is able to clearly capture this dynamic image. 
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Figure 16. Correlation of APAP–water interaction level fluctuation with the number of 
surrounding water molecules and the APAP–NaCl interaction. The first Y-axis on the left 
is the change of total interaction energy as a function of time for selected APAP 
molecules. Dotted pink line (– – – –): between APAP and all water molecules; Solid light 
blue line (▬▬▬▬▬▬): between APAP and all chloride ion [Cl]-1); Solid red line 
(▬▬▬▬▬▬): between APAP and all sodium ion [Na]+1). The second Y-axis on the 
right is the number of water molecules in the adjacent of the APAP molecule within 4 Å. 
Solid dark blue line (▬▬▬▬▬▬) is the change in number of water molecules over 
time. (a) an APAP on (100) Layer 1 that released at 8.1 ns (later than 3 ns). (b, c) two 
APAP molecules released within 3 ns, one on corner released at 1.2 ns, and one on edge 
group released at 1.9 ns. 
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Group Average Interaction Energies at Time 0 
The initial van der Waals and electrostatic energies among the different groups of 
APAP molecules were compared to further identify general relationships. This 
calculation accounted for average interaction energy per APAP residue obtained from the 
whole group at 0 ns. Both APAP/APAP and APAP/Water interactions for the seven 
groups were calculated (Figure 17). The corner group on average possesses the smallest 
interaction energy with their surrounding APAP molecules, followed by increasing 
energy order of edge group, (001) layer 1, (010) layer 1, (100) layer 1, and (001)/(010) 
layer 2 (Figure 17a). When the interaction energy with water molecules is considered 
(Figure 17b), the rank order is exactly reversed, with the corner group taking the lead 
followed by edge group, (001) layer 1, (010) layer 1, (100) layer 1, and (001)/(010) layer 
2. This comparison indicates there should be differences in dissolution rate among the 
different groups. Figure 18 correlates the percentage of molecules released at different 
times (3, 5 and 10 ns) with the differences in interaction energies. Since the interaction 
energy among the drug molecules would deter dissolution, while the interaction energy 
between the drug and water molecules would favor the dissolution, the difference 
between these two forces (total interaction energy of APAP with water minus that of 
APAP with APAP) was plotted along the x-axis. The percent of release was calculated by 
taking the ratio of released molecules in the specific group over the total APAP 
molecules in the same group and plotted on the y-axis. There is a clear trend with a rank 
order consistent with the preferential release profile among different groups at all three 
time points (Figure 18). These data demonstrate that a strong correlation exists between 
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the initial energy level and the extent of molecule release. The release rate follows the 
order of corner group, edge group, (001) layer 1, (010) layer 1, and (100) layer 1. 
Figure 17 also shows the different landscapes of van der Waals energy vs 
electrostatic energy among the different groups. The van der Waals energy comprises a 
significant portion in the total energies in groups of APAP/APAP interaction, while its 
role in the APAP/water interaction seems less important than the more dominant 
electrostatic forces. In the APAP/APAP interaction, electrostatic energy varies greatly 
among different groups, while the interaction contribution by van der Waals interactions 
is relatively more uniform. 
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a 
b 
 
Figure 17. Initial interaction energies expressed as an average for each group. (a) Energy 
between APAP and its surrounding APAPs; (dark green bar) van der Waals, (light green 
bars) electrostatic. (b) Energy between APAP and surrounding water molecules; (dark 
blue bars) van der Waals, (light blue bars) electrostatic. 
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Figure 18. Total interaction energy differences between APAP/APAP and APAP/water 
and their correlations with percent of molecules released with time. Top graph, t = 3 ns; 
middle graph, t = 5 ns; bottom graph, t = 10 ns. 
Corners
Edges
{100} Layer 1{010} Layer 1
{001} Layer 1
0
10
20
30
40
50
60
70
80
90
-120-100-80-60-40-20020406080100120
TotalAPAP/Water – TotalAPAP/APAP (kJ/mole)
%
 R
el
ea
se
d 
in
 3
 n
s
Corners
Edges
{100} Layer 1
{010} Layer 1
{001} Layer 1
0
10
20
30
40
50
60
70
80
90
-120-100-80-60-40-20020406080100120
TotalAPAP/Water – TotalAPAP/APAP (kJ/mole)
%
 R
el
ea
se
d 
in
 5
 n
s
Corners
Edges
{100} Layer 1
{010} Layer 1
{001} Layer 1
0
10
20
30
40
50
60
70
80
90
-120-100-80-60-40-20020406080100120
TotalAPAP/Water – TotalAPAP/APAP (kJ/mole)
%
 R
el
ea
se
d 
in
 1
0 
ns
73 
 
 
Physical Observation of APAP Crystal Dissolution 
The molecular dynamic simulation of a nanoscale dissolution showed that the first 
groups of molecules to leave the crystal surface are located on the corners and along the 
edges. To test whether this phenomenon would occur during macroscale crystal 
dissolution, a visual dissolution was performed while observing a large size APAP crystal 
under a microscope. The visual dissolution results are captured in Figure 19. In the 
beginning, the crystal has well-defined shape and sharp edges (Figure 19a). However, as 
dissolution progressed, the corner quickly changed shape, and the edges became blurred 
and dull (Figure 19b). If the molecules had left all surfaces at a same rate without any 
preferences, the original shape of the crystal should have remained. Therefore, 
experimental observations support the simulation results. 
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Figure 19. Visual observation of dissolution of an APAP crystal in 0.15 M sodium 
chloride solution under a polarized light microscope at 4× magnifications. (a) Initial 
image before adding dissolution medium; (b) Seven min after adding dissolution 
medium. 
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Discussion 
Molecular Release in Dissolution Process and  
 
Interaction Energies 
The MD simulation clearly showed how each molecule leaves the crystal surface to 
enter the water phase. The dissolution process is far from simply a random action. The 
sequence at which the molecules leave the crystal surface follows a defined pattern: the 
molecules located at corners, especially at the sharper corners, follow a trend of 
dissolving earlier, followed by those on edges, and very few from the center of flat 
surfaces have dissolved (Figure 13). According to Wang and Flanagan,6 neighboring 
molecules on a solid (either crystalline or amorphous) are closely associated with each 
other through intermolecular forces. Dissolution involves the breaking of these existing 
intermolecular interactions, and then the formation of new interactions with dissolution 
medium (0.15 M NaCl in our simulation experiment). In the present study, the interaction 
energies among the molecules located in different places of the crystal were calculated as 
the sum of the electrostatic forces and van der Waals energies. The APAP molecules 
located on corners and edges are relatively loosely associated with their surrounding 
APAP molecules (Figure 17a) indicated by total interaction energies (–60 to –106 
kJ/mole) at time zero being smaller than the total energies of their surface bound 
counterparts (in the vicinity of –130 to –170 kJ/mole) and even smaller than those in the 
second layers (~ –200 kJ/mole) or buried inside the crystals (total initial energies around -
 250 kJ/mole) in Figure 14a,b. The larger the bound energy the molecule possesses, the 
more difficult it is for it to release into the water. Once the molecule is released into the 
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water phase, the total interaction energy between APAP and surrounding APAP 
molecules immediately disappears (Figure 14). 
Sometimes, the total interaction energy vs time profile for a single APAP molecule 
(Figure 14b,d) undergoes changes not related to dissolution of the molecule, which were 
found by visual inspection with VMD to be directly linked to the physical movement of 
the molecule. For example in Figure 15, both sudden decreases at 1.5 and 8.1 ns in 
Figure 14d are caused by the loss of contact with its surrounding molecules. In another 
example, the change at ~1.5 ns to the molecule located in the center of the crystal 
(Figure 14b) is due to the dissolution of a molecule that initially binds to this center 
molecule, resulting in some exposure to water (graphical illustration not shown). By 
plotting the total interaction energy of APAP molecules with their surrounding APAP 
molecules vs time (Figure 14), one can determine when a molecule dissolves (interaction 
energy changing to 0) or has changed in its relationship with adjacent molecules. This has 
been demonstrated in all 256 APAPs (data not shown for all). These results indicate that 
the energy computational method is a powerful tool in analyzing the dissolution 
simulation data. 
Sodium chloride at 0.15 M to mimic the ionic strength of biological fluid was 
present in the solubility simulation of APAP. Electrolytes such as sodium chloride are 
known to potentially affect solubility. They can attract water molecules and reduce the 
density of the aqueous environment adjacent to the solute molecules, causing lower 
solubility (salting out effect). They may also interact directly with the solute molecules, 
resulting in higher solubility (salting in effect). The total interaction energies between 
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APAP and Na+ and Cl– for select APAPs are plotted in Figure 5. As expected, only the 
surface layer APAP molecules (Figure 5d,e,f) were shown to have interactions with Na+ 
or Cl–. Compared to APAP/water interactions, such interactions take place sporadically 
with much smaller energy in general. Most of the time, the interaction energies are in the 
range of –50 to –100 kJ/mole which are much less than the strength of APAP–water 
interactions (on average at –250 kJ/mole). Only very occasionally and for very short 
durations, the APAP/Na+ (ion-dipole) interactions reached the level of APAP–water 
interactions. The reason for the relatively much smaller overall interaction energy is the 
overwhelmingly larger number of waters vs NaCl molecules present in the system; for 
every NaCl molecule, there are 370 water molecules. As a result, the effect of 0.15 M 
NaCl on the solubilization of APAP in water is minimal. This is consistent with the 
measured solubility values of APAP in the presence and in the absence of NaCl, which 
are hardly distinguishable (20.0 ± 0.2 in our study vs 21.03 ± 0.13 mg/mL103). 
The water molecules play a significant role in “dragging” the drug molecules into 
the aqueous phase, which is the second step in the dissolution process. This can be 
demonstrated by calculating the interaction energies between APAP molecules and the 
water molecules. As shown in Figure 14, water molecules do establish new interactions 
with those APAP molecules that are dissolved, and they have fewer interactions with 
those APAP molecules that are not dissolved. The group average initial interaction 
energies with water (Figure 17b) followed the opposite trend as those between APAP 
molecules (Figure 17a). The stronger interaction with water positively contributed to 
dissolution.  
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Figure 14 and Figure 17 revealed that the dissolution pattern observed at the 
molecular level (Figure 13) is governed by the interplay between the interaction energies 
formed among the APAP molecules and between the APAP and water molecules. 
Figure 18 demonstrates that the net difference between these two types of interaction 
energies is the underlying cause for the differences in dissolution rate from different areas 
of the crystal. Dissolution rate has been long established to be directly correlated to 
solubility,4 a thermodynamic property. The dissolution process can be viewed as a 
pseudochemical reaction, which is governed by thermodynamics. The Gibbs free energy, 
ΔG, is the balance between enthalpy, ΔH, and entropy, ΔS, at given temperature T (ΔG = 
ΔH – TΔS). ΔG needs to be negative in order for dissolution to occur. Since dissolution 
produces more randomness of molecules in the entire system (including solid and 
solution states), the ΔS term is generally positive. Thus, net enthalpy is the term to 
determine whether or not ΔG will become negative.6 Further, the contribution of entropy 
to dissolution is the same regardless the location of molecules on the crystal. Therefore, 
the differences in dissolution rates are determined by the interaction energy based on the 
location of the molecules. When the net interaction energy difference is negative 
(interaction of APAP/water overwhelms that of APAP/APAP), dissolution of APAP into 
water becomes favorable. This can explain why the dissolution in the corner group (with 
net interaction of –89 kJ/mole) and the edge group (with net interaction energy of –
24 kJ/mole) is facile, and why the release percentage of the corner is higher than the edge 
at early stages. In the surface layers of (100), (010) and (001), the APAP/APAP 
intermolecular binding energy exceeded that of APAP/water. In this case, the molecules 
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would favor staying on the crystal surface until the other term, ΔS, overcomes the 
enthalpy barrier. This explains the very slow initial dissolution of the surface groups. 
Among the surface groups, however, differences also exist. The (100) layer 1 started with 
significantly higher water interaction (–108 kJ/mole) than the (010) layer 1 and (001) 
(both at –72 kJ/mole) owing to the out-facing hydrophilic phenol moiety that presumably 
facilitates the interaction with water molecules. As a result, this group as a whole is able 
to dissolve much faster than the other two surface groups. The (010) and (001) crystal 
faces which are not as hydrophilic have similar level of interactions with water 
(Figure 17b), and consequently the initial dissolution rate is at a similar level too. 
Eventually the dissolution of the (010) surface moved ahead of the (100) surface (Figure 
8, bottom panel) because (010) surface is smaller than (100) in the 4 x 4 x 4 crystal and 
closer to the edges and corners. Overall, the correlation is evident: with the decrease of 
net interaction differences, the extent of dissolution from the fastest to the slowest 
follows the rank order of corner group > edge group > (100) layer 1 > (010) layer 1 > 
(001) layer 1 (Figure 18). Explained physically, corners have larger surfaces accessible to 
water, resulting in more interactions with more water molecules. The same physical 
argument can explain why edges have higher interaction with water than the flat surfaces. 
We have discussed above the total interaction energies that have profoundly 
influenced the rate of dissolution. The total interaction energies originate from two types 
of forces: electrostatic (charge–charge, ion–dipole and hydrogen bonds) and van der 
Waals (dipole-dipole, dipole–induced–dipole and dispersion forces). Various electrostatic 
interactions are specific and directional. H-bonding has been viewed as the most 
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important force to hold together organic solid crystals.105 H-bonding is also responsible 
for solubility behavior of polar molecules such as drugs in solvents especially polar 
solvents (e.g. water).106 Van der Waals interactions are nonspecific attraction forces and 
proportional to radius–6 which fall off rapidly with increase of intermolecular distance.107 
In the literature, the importance of van der Waals forces in the crystal lattice and 
solubilization has not been emphasized to the degree that the H-bond has been. In 
Figure 17a, we plotted the group average APAP intermolecular interaction energies 
divided into electrostatic and van der Waals contributions. These plots revealed that H-
bonding is an important force but not the only important force. Van der Waals comprises 
a significant percent of the total interaction energy in all seven groups. Its contribution in 
the corner and edge groups is almost at 50%. Similar plots were made to describe the 
APAP/water interactions at the crystal/water interface (Figure 17b), in which the 
electrostatic force is shown to be a much more dominating factor because water has an 
exceptional capability to form H-bonds. Yet the portion of van der Waals contribution is 
still not negligible. The strong correlation between percent of release and net interaction 
energy shown in Figure 18 would have been lost if the van der Waals interactions were 
excluded from consideration. The data in Figure 17 have demonstrated the significance of 
both H-bond and van der Waals in lattice energy and in energetics of crystal dissolution. 
Since both the electrostatic and van der Waals energies will depend on the structure of 
the molecule, the relative importance of these two factors would vary for different 
compounds. 
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The distribution of van der Waals and electrostatic energy in two crystal surfaces, 
(100) and (010) (Figure 17), warrants more discussion. These two groups of surface 
molecules are packed similarly (Figure 11) so the van der Waals force is almost identical. 
What is intriguing is the much larger electrostatic interaction energy of the (010) face 
compared with that of (100) face. The answer was found after examining the H-bond 
motifs on (100) and (010) faces. Each APAP on the (100) layer 1 forms two H-bonds: 
O=C–N–H (1st layer) → O–H–Phe (2nd layer) and Phe–O–H (2nd layer) → O=C–N–H (1st 
layer), while each APAP on (010) layer 1 is bound by three H-bonds to two APAPs in the 
second layer: Phe–O–H (1st layer) → NH–C=O (molecule no. 1 in 2nd layer), Phe–O–H 
(molecule no. 2 in 2nd layer) → O=C–NH– (1st layer) and O=C–NH (1st layer) → O–H–
Phe (molecule no. 2 in 2nd layer). Therefore, the (010) surface is associated with higher 
electrostatic energy and should be more stable than the (100) surface just as demonstrated 
in Figure 18. 
The surface correlated dissolution indicates that different morphologies of the 
crystals should exhibit different dissolution rates. Earlier theoretical assessment of shape 
factor in dissolution rate suggested minimal influence,74 however, later reported 
experimental evidence indicated otherwise. In a dissolution study of five single crystals,71 
the shape factor changed significantly after 50% dissolution, which points to preferential 
dissolution of different faces. In another theoretical study, the flux of aspirin from crystal 
phase (100) is approximately 6 times faster than that from phase (001), which is 
correlated with reported variations in the dissolution behavior of commercial aspirin 
products.108 In one more report, single crystal dissolution was studied on APAP crystals 
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and different dissolution rates from phase (001) and (110) were found.109 Chow and 
Grant conducted extensive studies on the physical factors (such as shape) affecting the 
dissolution rate of APAP crystals.110 They found that the aspect ratio played a significant 
role in the intrinsic dissolution rate of APAP, and an empirical equation can be 
established to correlate the intrinsic dissolution rate with aspect ratio and other physical 
factors such as incorporated impurity levels. In their empirical equation, the intrinsic 
dissolution rate is exponentially proportional to the aspect ratio, l/w (length/width) [ln 
(rate) = constant × ln l/w]. The aspect ratio affects the morphology and consequently the 
amount of material in edges. Assume two rectangular crystals have the same solid 
volume of 1000 nm3. Crystal no. 1 is a cube with l = 10 nm, and w = 10 nm, so the total 
length of edges will be 120 nm (four times 10 nm times three). Crystal no. 2 is a needle 
with l = 100 nm, and w = 1 nm, which will result in a total length in edges of 444 nm, 
almost 4-fold of the edges as in a cubic crystal. Therefore, increasing l/w ratio results in 
more abundance of edges. In a follow-up study,111 Chan and Grant confirmed that crystal 
habit is the major factor that determines the intrinsic dissolution rate of acetaminophen 
crystals. Their experimental findings are consistent with what we have observed here in 
our MD simulation. The MD simulation demonstrates that morphology is expected to 
affect the dissolution rate due to different interaction energies intrinsically presented in 
different surfaces of APAP crystals. Since corners and edges have fewer APAP–APAP 
interactions and more APAP–water interactions, increasing the aspect ratio would boost 
the dissolution rate. 
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Solubility and Dissolution Rate 
vs Particle Size 
Upon completion of the simulation, one question immediately became obvious: 
why is the dissolution so fast? Within 10 ns, the APAP concentration in the water box 
reached about 40% of the solubility. The APAP crystal built for dissolution simulation 
consists of 256 molecules with 5120 atoms. The volume of the crystal is 5.0 × 103 Å3 
which translates to a diameter of about 4.6 nm (radius of 2.3 nm) for a spherical crystal. 
Based on classical nucleation theory, a crystalline lattice structure will be stabilized when 
it reaches the critical radius, rc. Particles smaller than rc will dissolve or evaporate.112 The 
size of a critical nucleus typically falls in the range of 100–1000 atoms,113 which is far 
exceeded by the 5120 atoms in the APAP 4 x 4 x 4 crystal lattice. The fact that the 4 x 4 
x 4 nanocrystal did not dissolve after being subjected to the initial equilibration step 
(Figure 12a) further confirmed its stability. Hence, using this 4.6 nm crystal to simulate 
crystal dissolution is proper and justified. 
It is known that the saturation solubility can be increased when the particle size is 
decreased to smaller than 100 nm and the extent of solubility increase can be calculated 
by the Thomas–Freundlich equation.114 
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Where Cs,r/Cs,∞ is the ratio of solubilities when particle size is decreased from a large 
particle (∞) to a smaller one with radius of r, γ is the interfacial tension, Vm is the molar 
volume of the particle (the molecular weight divided by the density), R is the gas 
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constant, and T is the absolute temperature. With APAP’s molecular weight of 
151.16 g/mol, density of 1.2 g/cm3, the interfacial free energy of 30 mJ/m2 at 310 K 
(37 °C),114 the solubility of a r = 2.3 nm APAP crystal is calculated to be 3.6 times of the 
solubility of a macro crystal. 
It is also known that the dissolution rate of the nanosized crystal will increase over 
that of a large particle. The dissolution rate constant, k, can be calculated by Higuchi and 
Hiestand equation (also known as two-thirds-root expression), which was derived for 
diffusion layer based dissolution of very small particles:6  
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Where ρ is the density of the particle, N is the number of particles, D is the diffusion 
coefficient, and Cs is the solubility. 
The dissolution rate constant of a small particle, kS, vs the dissolution rate constant 
of a large particle, kL, can be calculated by taking the ratio of kS/kL from eq 2. When 
comparing kS with kL in this calculation, it is assumed that the same amount of drug 
sample was added into the dissolution medium so that the weight portion from the ρ term 
can be canceled out. It is also assumed that diffusivity, D, between the large and small 
particles is similar. After simplification of eq 2, the ratio of kS/kL is expressed in the 
following equation: 
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where Csol,S is the solubility of the small particle, Csol,L is the solubility of the large 
particle, rL is the radius of a large particle and rS is the radius of a small particle. Notice 
that the solubility of the nanocrystal of APAP is 3.6 times that of the large particle from 
the Thomas–Freundlich equation. Assuming a large particle has a particle size of 10 µm 
(a commonly used particle size for drugs), the dissolution ratio, ks/kL, is 3.6 × 
(10000 nm/ 2.3 nm)2 = 6.8 × 107. Putting this value in practical perspective, if the large 
particle (10 µm) takes 20 min to reach 40% saturation, the 2.3 nm nanocrystal will take 
17.6 µs (20 × 60 s/6.8×107) to reach the same level of saturation. This 17.6 µs dissolution 
time is still 3 orders of magnitude longer than the 10 ns simulation time. Thus, in our MD 
simulation of the dissolution, the crystal takes a shorter time to dissolve than it would in a 
conventional experiment. The reason is not clear; however, it is consistent with the other 
published MD simulations. For example, Parker and co-workers48 simulated dissolving a 
small surface layer of a calcium carbonate crystal over 200 ps (0.2 ns). In another paper 
by Bhargava and co-workers,115 the initial aggregation of surface active ionic liquid was 
simulated within 4 ns although the complete aggregation process takes microseconds to 
milliseconds. In a recently published work by Yani and co-workers,64 the production run 
on the interaction between polymer and salbutamol sulfate crystal utilized simulation 
time less than 1 ns. Apparently, the time scale differences will not discount the important 
findings discovered by MS simulations. 
Corner and Edge Effect 
A perfect crystal surface is more difficult to dissolve. Indeed there are no molecules 
from the center of the perfect APAP 4 x 4 x 4 crystal surfaces to dissolve initially 
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(Figure 13). In our simulation, the first three dissolved molecules are all located at 
corners, followed by several on edges. The strong trend where the APAP molecules at the 
corners and edges, especially at the corners, dissolved before other molecules persisted 
all the way to the end of the 10 ns in this simulation. The same was observed in another 
two MD simulations we have completed earlier using different sizes of crystal and water 
box (detailed data not shown). The first simulation was done on a much smaller crystal (3 
x 3 x 3 crystal lattice, 27 APAP molecules) in a 20 Å water box. The second one was on 
the same large size crystal (4 x 4 x 4 lattice, 256 APAPs) but in a smaller 25 Å water box 
containing about 1/5 of the water molecules presented in the 40 Å water box. Both of 
these additional MD simulations also show without doubt that molecules released first 
from corners and edges. We have also conducted a real dissolution experiment of a large 
crystal, millimeter size (Figure 19). The results confirmed that corners and edges 
disappear first, which rendered dull the edges of the crystal. Therefore, the corners and 
edges serve as the initial sites for dissolution in perfect single crystals. 
The corner and edge effect has an underlying theoretical basis. In a reported study 
using bond valence calculations, Schindler and Mutter116 explained that the cluster of 
crystals on the edge of a mineral sheet would develop activated sites first and dissolve 
into aqueous solution. In our MD simulation, the order of molecule dissolution is a result 
of the interplay between the interaction energies formed among the APAP molecules and 
between the APAP molecules and water with the corner and edge groups clearly 
differentiating themselves from the surface groups (Figure 18). This interaction energy 
calculation provides strong evidence that corners and edges should dissolve first in a 
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perfect crystal. Once a molecule breaks free from the corners or edges, new corners and 
edges will be created instantaneously, forming new sites for the next wave of molecules 
to dissolve. This domino wave will gradually reach the molecules originally on surfaces, 
where the relatively weakly associated surface molecules will dissolve prior to the more 
tightly bound surface molecules. Such a dynamic dissolution process will proceed until 
the whole crystal disappears or until saturation is reached. In practical crystallization 
processes, a variety of surface imperfections can be produced as a result of mechanical or 
thermal stress or irregular growth.112 In this case, besides corners and edges, the 
imperfect surface spots can also take the lead in dissolution, creating new corners and 
edges on the way. 
It was widely accepted that the dissolution rate correlates with the total particle 
surface area. Now based on our findings, the initial dissolution rate probably is more 
correlated with the number, the length and the shape of the corners and edges in the 
particles. The knowledge of the corner and edge effect allows us to better understand 
particle size reduction, a very useful technology to increase dissolution rate of poorly 
water–soluble drugs. Common knowledge holds that particle reduction technology works 
by creating more surface area. Based on our study, the important underlying mechanism 
is, at least in part, the creation of proportionately more corners, edges, and other defects 
when the particles are turned into smaller ones. The advantage of smaller particles lies in 
the superior accessibility to dissolution media; the molecules in the center of the smaller 
particles need not wait as long as those in the center of the bigger ones to “see the light at 
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the end of the tunnel”. The presence of larger numbers of the faster dissolving defect 
spots in milled tiny particles essentially accelerates the accessibility to dissolution media. 
Conclusions 
We have presented here molecular dynamic simulation of acetaminophen Form I 
dissolving into an isotonic aqueous medium at 37 °C. The results clearly demonstrate that 
dissolution from a crystal is not a random process. It is strongly governed by the 
electrostatic and van der Waals interaction energies among the solute molecules and 
solute–solvent molecules, with a non-negligible contribution from van der Waals forces. 
The distribution of the interaction energies has a unique geometric entity: the molecules 
located on corners and edges of the rectangular parallelepiped crystal are not as tightly 
bound to their surrounding neighbors as those located in other surfaces. Therefore they 
are less restricted and tend to dissolve more readily. Furthermore, the simulation results 
were confirmed by the dissolution experiment. These results prompted us to rethink the 
fundamentals of particle size reduction in enhancing dissolution rate. The presence of 
larger numbers of the faster dissolving corners, edges, and other defect spots produced by 
milling accelerated the accessibility of small particles to dissolution media. This is 
different from the conventional view of attributing to the flat surface area, although the 
accompanying consequences, the increases in dissolution rate, are the same. The findings 
presented here are very relevant in the context of particles size reduction and delivery of 
poorly soluble compounds. 
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CHAPTER FOUR 
UNIQUE MECHANISM OF FACILE POLYMORPHIC CONVERSION  
OF ACETAMINOPHEN IN AQUEOUS MEDIUM 
Abstract 
For acetaminophen (APAP), the fast conversion from the metastable orthorhombic 
crystal Form II to the stable monoclinic Form I in solution has been observed ever since 
the Form II was discovered decades ago. Since the conversion taken place when the solid 
comes in contact with solutions, it has been believed that the process followed a solution-
mediated phase transformation. However, little has been understood as to exactly which 
factors are contributing to the fast kinetics. The present study was undertaken to examine 
both thermodynamic and kinetic driving forces that lead to this facile polymorphic 
conversion. The thermodynamic solubility of Form II in 0.15 M aqueous NaCl solution at 
37 °C was obtained for the first time using a new solubility method with the aid of low 
level (0.02%) of poly(vinyl pyrrolidone) (PVP) to inhibit crystallization of Form I. The 
solubility ratio of Form II over Form I, which represents the thermodynamic driving force 
for the conversion, is only 1.27 ± 0.04. Further experiments to monitor crystallization at 
supersaturation levels at or even much greater than Form II solubility did not result in any 
crystallization in ten days at 37 °C. Essentially, Form II is not able to generate 
sufficiently high supersaturation to nucleate Form I through dissolution at 37 °C. In other 
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words, the fast conversion is not possible through the solution-mediated phase 
transformation. To identify other possibilities, molecular dynamics (MD) simulations 
were conducted that investigated the molecular level dissolution behavior and the solid 
state differences between the two crystalline forms. It was found that Form II behaves 
very differently from Form I when exposed to solution. Form II showed much higher rate 
of H-bond breaking, causing the accumulation of large numbers of APAP molecules on 
the crystal surface. This thick disordered molecular layer on Form II surface provides 
high local acetaminophen concentration for fast Form I crystallization. This was further 
supported by the rapid surface recrystallization from a Form II crystal in solution 
monitored under polarized light microscopy and by powder X-ray diffraction. Therefore, 
the hydrated surface layer is the “catalyst” for the facile phase conversion. This new 
mechanism, termed as SurFPT (surface facilitated phase transformation), could be much 
more powerful in promoting polymorphic transformation in solutions than the well-
known solution-mediated phase transformation. 
 
Key words: acetaminophen, molecular dynamics simulation, dissolution, metastable 
form, solubility, orthorhombic, monoclinic, crystallization inhibition, polymorphic 
transformation, and surface facilitated phase transformation. 
Introduction 
Polymorphic transition has been extensively studied in the pharmaceutical field due to its 
significant impact on manufacturing and in vivo performance of pharmaceutical dosage 
forms.17,117-119 A metastable solid form is energetically unfavorable and can convert to the 
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thermodynamically stable form either through solution-mediated transformation in 
solution or solid-solid transition over-time.17,120  
Acetaminophen, a widely used analgesic and fever reducing medicine, has multiple 
crystal forms. Among them, monoclinic Form I and orthorhombic Form II are the most 
widely studied.121-126 Form I and Form II are monotropically related, Form I being more 
stable127 and used commercially. Form I is difficult to compress into tablets. Thus, a more 
costly wet granulation process needs to be performed prior to tableting.128 The dry blend 
of orthorhombic Form II can be compressed directly to reduce manufacturing cost.124,128 
Unfortunately, efforts to produce Form II on an industrial scale have proved unfruitful 
because of the facile conversion to Form I in crystallization solvents.129 In aqueous 
solutions, Form II also converted quickly to Form I130 which is why accurate Form II 
solubility and dissolution data are missing from the literature for such a well-known drug 
and polymorphic system. Even a large single crystal of Form II gradually recrystallized 
into Form I at ambient temperature due to the inclusion of a small amount of water.131 
Since the conversion occurs in the presence of solution, it was assumed that the solution-
mediated polymorphic transformation is the mechanism responsible for such a 
conversion.121,125,132 However, the details of the transformation have not been understood, 
and the reasons for such fast conversion are mostly unknown. In particular, the following 
important questions have not been addressed. 
 
1. What is the thermodynamic driving force for the Form II to Form I 
transformation? 
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2. Will Form II dissolution be able to generate the supersaturation level 
necessary for Form I to nucleate? 
3. Are there other pathways to create the required supersaturation? 
4. Are there alternative mechanisms that can account for the faster conversion? 
Our present work is directed toward elucidating the mechanism of APAP Form II to 
Form I conversion in 0.15 M aqueous solution of NaCl (designated as solubility medium 
hereafter) at 37 °C. First, solubility measurement of Form II in the solubility medium at 
37 °C was done accurately for the first time using a new experimental procedure. This 
answers the first question regarding thermodynamic driving force. Molecular dynamics 
(MD) simulations were then conducted to elucidate the structures of the solid phases 
during dissolution of both Form I and Form II. The energetics of the molecule association 
in the residual solids was studied through hydrogen bonding, pair correlation functions 
and interaction energy calculations, which provide molecular or even atomic level 
analysis that is not possible for any existing experimental methodology. The findings 
from MD simulation led us to propose a new solid-form conversion mechanism (surface 
facilitated phase transformation, SurFPT). Further experimental evidence is consistent 
with this new mechanism. 
Experimental 
Material 
Acetaminophen anhydrous monoclinic polymorph (Form I) with high purity was 
purchased from Sigma (SigmaUltra, lot 116K0124). Deionized, distilled water for 
preparing all solutions was purified to 18.2 mΩ/cm resistivity by passing distilled water 
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through a deionizer/charcoal filter (Milli Q academic model, Millipore Corp., Bedford, 
MA). Poly(vinyl pyrrolidone) (PVP) grade K30 was from Spectrum (lot XM3057). 
Sodium chloride and other solvents and reagents used met ACS Reagent specifications. 
Powder X-ray Diffractometry (PXRD) 
Powder X-ray diffraction patterns of the samples were obtained using an Ultima+™ 
diffractometer controlled by DMAX2000 software (Rigaku Corp., Tokyo, Japan). The X-
ray source was a copper filament X-ray tube operated at 50 kV and 40 mA. Calibration of 
the goniometer was monitored using standards (Sodalite and Si) prior to use. Micro cover 
slides (0.15 mm in thickness) with a thin layer of samples were top-loaded onto a zero 
background holder, and were scanned from 2–40° 2θ at 2–3°/min in a non-spinning 
mode. Data analysis was accomplished using Jade software (Version 6.5, Materials Data, 
Inc., Livermore, CA).  
Preparation of APAP Form I and Form II Crystals 
Form I 
Crystals of Form I of sufficient size were prepared by recrystallization from water 
according to reported procedures.133 The recrystallized crystals were monoclinic Form I 
by PXRD (data not shown). The crystals in a sealed bottle were stored in a desiccator at 
ambient temperature until use. 
Form II 
Multiple solution crystallizations were attempted in order to obtain sufficient 
amount of metastable Form II. In one method, crystallization was conducted from ethanol 
at 0 °C with seeding of melt-quenched Form II and harvesting crystals at 15 min.125 
95 
 
 
Many repetitions of this method resulted in Form II contaminated with Form I. Variations 
to this method by harvesting crystals at 2.5 min, by adding polymers (PVP or HPMC) to 
crystallization medium, by switching to a different solvent with lower APAP solubility 
(i.e. ethyl acetate and acetonitrile), and by lowering temperature using dry ice, all resulted 
in mixture of Form I and II in repeated experiments. Additionally, crystallization in the 
presence of 10 mg/mL alginic acid sodium salt was conducted according to a published 
method,134 but without success. 
Pure metastable Form II used in the studies was crystallized from the melt of Form I 
following a published method125 with some modifications. A thin layer (~10 mg) of Form 
I powder was spread in the center of a micro cover glass (18 × 18 × 0.15 mm, no. 1, 
VWR International, Pennsylvania, US), which was heated for ~3 seconds on a hot plate 
set at 170 °C (above m.p. of 168.6 °C104). The clear melt on the cover glass was cooled 
down to ambient temperature (~23 °C). Crystallization started at about 5 min. After 30–
60 min, the cover glass was stored flat in a sealed glass petri dish under ambient 
conditions. The sample was allowed to age for at least two days. Right before use, each 
cover glass was directly placed on an X-ray sample holder for PXRD analysis. Only 
those confined to pure Form II according to PXRD were selected in solubility and surface 
crystallization studies. 
Solubility Measurement of Form I and Form II 
Form II 
The first step was to identify a polymer that can retard or inhibit the conversion of 
Form II to Form I in solubility medium. PVP was selected based on its interaction with 
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APAP.135 The PXRD-confirmed pure Form II on the cover glass was topped with the 
solubility medium in the absence and presence of 20 µg/mL PVP (0.002%). After 45 min 
at ambient temperature, the liquid was removed by a filter paper, and the cover glasses 
were brought for PXRD scan. The sample without PVP was found to contain Form I 
peaks, while PVP was shown to effectively prohibited the formation of Form I (data not 
shown). Therefore, 20 µg/mL PVP was added to the solubility medium in the solubility 
measurement. 
Equilibrium solubility of Form II was carried out at 37 °C in the solubility medium 
containing 20 µg/mL PVP. A procedure very different from conventional shake flask 
method was designed to enable this measurement. Solubility medium with PVP (150 µL) 
was added to the cover glass to top the surface of the Form II crystal layer. The cover 
glass, supported by an X-ray sample holder, was placed inside a container with a loose lid 
(i.e. a 60 mm × 15 mm cell culture dish). The dish was then loaded into a large diameter 
glass bottle (100 × 50 mm) and tightly sealed with a lid. Further, to prevent the loss of the 
solubility medium through evaporation which might lead to inaccuracy of the solubility, 
the water vapor pressure inside the glass bottle was maintained by including two beakers, 
each holding 5 mL of solubility medium with 20 µg/mL PVP. Finally, the whole 
assembly was equilibrated at 50 rpm in a horizontal shaker (Incubating Orbital Shaker, 
VWR International, Pennsylvania, US) set at 37 °C. Sampling was made by taking out 
the X-ray sample holder and inserting a pipette tip into the clear solution phase at 
multiple time points of about 20, 40 and 60 hrs. The clear solution sample was diluted 
with water in a volumetric flask and analyzed by a HPLC assay using a five-point 
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external standard curve. After taking the last sample, the residual solid on the cover glass 
was again scanned for PXRD patterns. A total of 11 replicates were tested. The solubility 
values obtained from samples with final solid form remaining as pure Form II or mostly 
Form II were averaged and reported as the solubility of Form II. 
Form I 
Equilibrium solubility was determined at 37 °C in the solubility medium in the 
absence and presence of 20 µg/mL PVP (0.002%). Several crystals of recrystallized Form 
I (total weight of ~35 mg) were weighed into a 4 mL glass vial and 0.5 mL of solubility 
medium was added. The glass vials, in triplicate under each condition, were agitated in 
the same way as the Form II samples on the horizontal shaker. Sampling and 
concentration analysis were also performed following the same procedure used for Form 
II. The average concentration of the saturated solutions was reported as the solubility at 
37 °C. 
Physical Stability of APAP Solutions Supersaturated 
at Concentrations of Form II Solubility and Above 
This experiment determined if Form I can crystallize in solutions when the APAP 
concentration is at or greater than saturation solubility of Form II. Concentrations 
selected to study were 25, 26, 27, 28, 29, 30, 32, 34, 35 and 45 mg/ mL in the solubility 
medium, each in triplicate. These supersaturated solutions were prepared by heating 
suspensions of APAP Form I in sealed 4 mL glass vials on a heating block initially at 
50 °C and then briefly at 60–70 °C with shaking. The 45 mg/mL samples were further 
heated at 80 °C for ~2 min. The clear solutions were quickly transferred to the orbital 
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shaker set at 37 °C and 50 rpm (same conditions as used in the solubility study). 
Crystallization was monitored visually up to 12 days. 
Theoretical Methods 
Building the Crystal 
Virtual crystals of Form I and Form II were constructed using the unit cell as a 
building block in Mercury software (Mercury 2.3, CCDC 2001-2009), following the 
method previously published in MD simulation of APAP Form I.41 The two crystal 
lattices were built to render the best match in terms of overall geometric shape. As 
reported before,41 the monoclinic anhydrous Form I lattice repeated the unit cell four 
times along all three axes. The resultant lattice is referred to as APAP I 4 x 4 x 4. The 
orthorhombic anhydrous Form II lattice extended the unit cell at a, b, and c directions for 
3, 3 and 4 times, respectively, producing the APAP II 3 x 3 x 4 crystal lattice. The single 
crystal structure of Form II was taken from HXACAN136 available from the Cambridge 
Structural Database (Cambridge, UK). More details of crystal lattice parameters of both 
APAP polymorphs built for MD simulation are listed in Table 2. 
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Table 2. Comparison of the Built Crystal Lattices of APAP I 4 × 4 × 4 and APAP II 3 × 3 × 4 
 
Polymorph 
Unit cell dimension (Å) 
Z Lattice built 
Crystal dimension  
(Å) no. of molecules 
in lattice 
Crystal 
surface area 
(Å2) 
Length of 
edges (Å) 
Crystal 
size (nm)
a b c a b c 
Form I, 
monoclinic 12.93 9.40 7.10 4 4×4×4 51.72 37.60 28.40 256 8.67×10
3 1430.9 4.56 
Form II, 
orthorhombic 
11.81 17.16 7.39 8 3×3×4 35.42 51.49 29.57 288 8.79×103 1426.0 4.69 
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Preparing the Crystal for Simulation 
The crystals constructed above were prepared using Visual Molecular Dynamics 
software (VMD, version 1.9, March 2011).99 First, the structure file of the crystal was 
built using the Automatic PSF Builder function from the input of the Mercury file and the 
APAP topology file. The topology and atom types for the CHARMM2739 force field for 
APAP were obtained by comparison with similar molecules already in the standard 
topology file. Second, a water box was built to surround the crystal. The water box 
(containing 0.15 M sodium chloride) extends 40 Å on each side of the crystals. The final 
size of APAP I 4 x 4 x 4 in water box is 131.7 × 117.6 × 108.4 Å3 (equal to 1.51 × 10-18 
milliliters, with 58622 TIP3 molecules), and that of APAP II 3 x 3 x 4 is 115.4 × 131.5 × 
109.6 Å3 (equal to 1.66 × 10-18 milliliters). The ratio of water molecules to NaCl 
molecules in the system is 370 to 1. 
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Figure 20. (1a) Unit cell of monoclinic Form I (dotted line indicating hydrogen bonds). 
(1b) APAP I 4 x 4 x 4 crystal in the 131.7 × 117.6 × 108.4 Å3 water box. (2a) Unit cell of 
orthorhombic Form II (dotted line indicating hydrogen bonds). (2b) APAP II 3 x 3 x 4 
crystal in the 115.4 × 131.5 × 109.6 Å3 water box. 
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MD Simulation 
The computer code used for the MD simulations was the parallel, scalable MD 
program NAMD version 2.5.100 Periodic boundary conditions were used. The cutoffs for 
nonbonding (van der Waals and electrostatic) interactions were 12 Å. The switch distance 
was 10 Å, and a 1.0 1–4 scaling factor was used. The crystal in the water box was first 
subjected to energy minimization (6000 steps) followed by slow heating from 10 to 
310 K over 30000 steps. The temperature and pressure of the system were equilibrated 
for 10000 steps using a Langevin piston. The system was then allowed to equilibrate for 
30000 steps at constant temperature (310 K) and pressure (1 atm) before production data 
was accumulated. Production simulations (10 ns) were performed at constant volume and 
temperature. 
Analysis of MD Simulation Data 
Calculation of Number of Molecules Dissolved vs Time 
The number of APAP molecules out of the sphere of the original crystal lattice and 
into the water box were tracked at 0.03 ns intervals for 10 ns simulations for both Form I 
and Form II, using a script written for the VMD program (version 1.9).99 The data were 
plotted using Microsoft Excel (Version 2010).  
Calculation of Interaction Energies 
Interaction energies were calculated as previously described41 using algorithms of 
the van der Waals and electrostatic energies and the NAMD program.100 These 
calculations were performed for APAP molecules located on corners and edges with their 
surrounding APAP molecules or water molecules within 4 Å. The electrostatic 
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interactions, including ion–dipole interactions and H-bonding, and van der Waals were 
calculated using the partial atomic charges (CHARMM 27 potential function39). The sum 
of electrostatic and van der Waals interaction energies is the total interaction energy 
reported here. 
Calculation of Hydrogen Bonds 
The numbers of hydrogen bonds formed throughout a trajectory among APAP 
molecules in both Form I and Form II were calculated by HBonds Plugin (version 12) in 
VMD program (version 1.9).99 A hydrogen bond was counted between an atom with a 
hydrogen bonded to it (the donor, D) and another atom (the acceptor, A) by defining that 
the distance D-A is less than 3.4 Å and the angle D-H-A is less than 30 degrees. The 
percentage of H-bond broken normalized to the initial H-bond numbers was constructed 
for both Form I and Form II, and plotted against the time scale. 
Calculation of Radial Distribution Function g(r) 
The radial distribution function g(r) of APAP, also called pair correlation function, 
over a given trajectory of Form I or Form II in the water box was computed by g(r) GUI 
Plugin (version 1.2) in VMD program (version 1.9).99 An APAP molecule located in the 
center of the crystal was the chosen origin. The spherical shell was defined as 50 Å from 
the origin. The periodic boundary conditions were enabled during the calculation. The 
calculated g(r) describes the variations in atomic density as a function of distance from 
the origin to the coordinates of other APAP molecules within the defined spherical shell. 
  
104 
 
 
Polymorphic Transformation Determined  
by PLM and PXRD 
Polarized light microscopy (PLM) was used to visualize the re-crystallization of 
Form I from Form II and the crystallization from amorphous form and PXRD was to 
confirm the polymorph transformation. Form II was prepared on a micro cover slide as 
described above. The amorphous form was made the same way; the melt-quenched 
amorphous solid was used prior to any crystallization. The sample was placed under a 
polarized light microscope (model Eclipse E-600 POL, Nikon Corp., Garden City, NY) 
with a 200× magnification lens. Images were taken using MetaMorph imaging system 
(version 4.6R8, Universal Imaging Corporation, Downingtown, PA). Droplets of 
solubility medium were added to completely cover the solid. Changes were monitored 
visually by capturing images periodically. In the end, the cover slide with the sample on 
the top (after the added liquid was removed) was loaded directly on a X-ray holder and 
scanned for PXRD patterns. 
Results 
Solubility of APAP Polymorphs 
Form I 
Solubility was measured by dissolving crystals in the solubility medium at 37 °C. 
The resulting clear solution phase was directly analyzed without phase separation through 
centrifugation or filtration. The thermodynamic solubility of Form I was found to be 19.7 
± 0.3 mg/mL in the absence of PVP, and 19.4 ± 0.3 mg/mL in the presence of PVP. The 
polymer at a low concentration of 20 µg/mL did not impact the solubility of APAP in 
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aqueous solution to any measurable level. These values are consistent with our previously 
reported solubility using the classical solubility method.41  
Form II 
The thermodynamic solubility was measured from dissolving Form II crystals on 
micro cover glasses. The clear solution phase was analyzed directly without 
centrifugation or filtration. Eleven of these micro cover slides with no detectable Form I 
by PXRD were subjected to solubility measurement at 37 °C. The solubility medium 
contained pre-dissolved 20 µg/mL of PVP. After about 57–62 hours of equilibration, 
seven of the eleven replicates were found to have changed to either pure Form I or mainly 
Form I by PXRD, resulting in concentrations reaching or approaching the solubility of 
Form I (data not shown). Data from these seven replicates were not used. However, four 
replicates remained as either pure Form II or mainly Form II at the end of equilibration 
(Figure 21). These four replicates maintained a higher concentration than that of Form I 
up to 60 hours (Figure 22). The slight conversion to Form I in some of the Form II 
replicates did not decrease the concentration at ~60 hours because substantial Form II 
was still present to feed into the solution. The concentration reached for the four 
replicates at time greater than 33 hours is taken as the thermodynamic solubility of APAP 
Form II. The average value of the Form II solubility was calculated as 24.7 ± 0.6 (n=4), 
about 5.3 mg/mL higher than Form I solubility at 37 °C. The solubility ratio between the 
two APAP polymorphs is thus calculated to be 1.27 ± 0.04, which corresponds to –0.62 
kJ/mole difference in free energy.  
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Figure 21. PXRD patterns of residual solid recovered from solubility measurement of 
Form II in 0.15 M aqueous solution of sodium chloride in the presence of 20 µg/mL of 
PVP at 37 °C. The four patterns from bottom to top correspond to Form II replicate no.1 
to replicate no.4 in Figure 22. Only one Form I peak was observed in three of the four 
replicates as marked with the star. PXRD pattern of pure Form I is shown in Figure 30. 
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Figure 22. Concentration vs time course during solubility measurement of APAP Form I 
(three replicates) and Form II (four replicates) in 0.15 M aqueous solution of sodium 
chloride at 37 °C. 
 
Physical Stability of  
Supersaturated APAP Solutions 
Supersaturated APAP solutions in the solubility medium at concentrations at and 
above solubility of Form II were studied for physical stability. Supersaturation (S) is 
defined as the concentration divided by Form I solubility. Ten APAP solutions at 25 (≈ 
Form II solubility), 26, 27, 28, 29, 30, 32, 34, 35 and 45 mg/mL (S = 1.27x – 2.28x), each 
with three replicates, were agitated at 37 °C, and the crystallization was monitored 
visually. As shown in Figure 23, no crystallization was observed for up to 10 days at 25–
30 mg/mL (S = 1.27x – 1.52x), and for 4.5 days at 32–34 mg/mL (S = 1.62x – 1.73x), 
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indicating that Form I is not able to nucleate from the solution at and even significantly 
above the Form II solubility within the time window of the solubility measurement. 
 
 
 
Figure 23. Physical stability of APAP supersaturated solutions in 0.15 M sodium chloride 
agitated at 50 rpm and 37 °C for 12 days. Supersaturation (S) levels tested were 1.27x – 
2.28x of Form I solubility (25 – 45 mg/mL). S of 1.27x (25 mg/mL) is at Form II 
solubility. Green color indicates clear solutions and red color band represents the time 
window during which crystallization occurred.  
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MD Simulation of  
APAP Polymorph Dissolution 
Molecular dynamics (MD) simulations were conducted to investigate the molecular 
level dissolution behavior and the solid state differences. The Form I and II virtual 
crystals for MD simulation were built to match each other as closely as possible in terms 
of total surface area, the numbers of APAP molecules, as well as the total length of edges 
(Table 2), all of which are important in dissolution rate comparison.41 Both crystals were 
placed in water boxes with additional 40 Å from each side. If the crystals were to 
dissolve completely, the theoretical molar concentration would be approximately the 
same (APAP I = 0.282 mM, and APAP II = 0.288 mM) that is about 2-fold of the Form I 
solubility.41 
The MD simulation visualized the departure of APAP molecules from the crystal 
surface into the water phase, which then displayed them by thermal motions (moving 
around freely in water). Images at 0, 3 and 10 ns are shown in Figure 24 to compare Form 
I and Form II. As expected, most of the dissolved APAP molecules are initially located 
on corners and edges for both forms (Figure 25) which has been demonstrated 
previously.41 The numbers of molecules leaving the solid surface were plotted as a 
function of time in Figure 26a. Under this treatment, Form I and II do not exhibit any 
significant difference in the rate of dissolution. Another comparison between APAP I and 
APAP II was made for the initial interaction energies for the APAP molecules located on 
the corners and edges. As we have demonstrated earlier,41 the interaction energy among 
the drug molecules would deter dissolution, while the interaction energy between the 
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drug and water molecules would favor the dissolution. Thus the driving force for 
dissolution is the difference between these two forces (total interaction energy of APAP 
with water minus that of APAP with APAP), which is plotted along the x-axis in Figure 
26b indicating that the driving force for dissolution for the molecules on the corner and 
edge molecules are strikingly similar between Form I and Form II. 
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(a) t = 0 (b) t = 3 ns (c) t = 10 ns 
(d) t = 0 (e) t = 3 ns (f) t = 10 ns 
 
Figure 24. Display of images of two crystals from MD simulations. a to c: APAP I. (a) At 0 ns viewed down crystallographic c axis. 
(b) At 3 ns. (c) At 10 ns. d to f: APAP II. (d) At 0 ns viewed down crystallographic b axis. (e) At 3 ns. (f) At 10 ns. 
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(a) 
 
(b) 
 
Figure 25. Demonstration of the corner and edge effect in dissolution simulation of a 
single crystal APAP in 0.15 M NaCl at 37 °C. Undissolved APAPs are shown in line 
style and dissolved APAPs are in bulky VDW style. (a) APAP I at 10 ns. (b) APAP II at 
10 ns.  
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 (a) 
 (b) 
 
Figure 26. Numbers of molecules leaving the crystal as a function of time and the 
correlation with the initial total inter- and intra-molecule interaction energies. (a) 
Numbers of APAP molecules observed outside of the crystal surface from MD simulation 
of stable polymorph APAP I and metastable polymorph APAP II in 0.15 M sodium 
chloride at 37 °C. (b) Initial (t = 0 ns) total interaction energy difference between the 
intra-molecule (APAP/water) and inter-molecule (APAP/APAP) interactions on corners 
or edges. This difference is the major driving force for initial dissolution. 
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Differentiation of Form I and II was noticed in the solid state during simulation. As 
illustrated in Figure 24, the difference between Form I and Form II solid phases is clearly 
visible. After 10 ns, the undissolved Form I solid retained its long range order shown as 
well-organized crystal lattice (Figure 24-c), while the crystallinity of the remaining Form 
II solid is limited only to a small area in the center, and the rest of outer layer molecules 
turned into a thick mass of disordered molecules (Figure 24f). This difference was 
analyzed quantitatively through two methods. Since hydrogen bonding is one of the 
major forces associating molecules in crystal lattice, the H-bond profile in the solid phase 
reflects the stability. The percentage of H-bonds broken over time for both crystals were 
calculated (Figure 27). The stable Form I is shown to be more stable maintaining a higher 
percentage of intact H-bonds. At 10 ns, 61% of the APAP II H-bonds were broken vs 
41% in APAP I. Another analysis of the solid state difference is the radial distribution 
function of both forms for time 0 and 10 ns (Figure 28). The decrease in the radial 
distribution function indicates that the molecules have moved from their lattice positions. 
APAP I retains most of the structural features at the end of 10 ns, with some difference at 
≥ 17.5 Å away from the center which can be attributed to a loss of molecules in the outer 
layers due to dissolution. However, APAP II displays a difference at 5 Å and beyond, 
indicating the loss of crystallinity in regions close to the center of the crystal. 
115 
 
 
 
Figure 27. Percentage of H-bonds broken vs time obtained from MD simulation of stable 
polymorph APAP I and metastable polymorph APAP II in the aqueous solution of 
sodium chloride at 37 °C. 
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(a) 
 
 
(b) 
 
 
Figure 28. Pair correlation function calculated on the solid phases before and after 
dissolution simulations in the aqueous solution of sodium chloride at 37 °C. (a) Stable 
polymorph APAP I crystal. (b) Metastable polymorph APAP II crystal. 
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Crystallization of APAP Form I on  
Surfaces of Form II and Amorphous Solids 
Surface-driven crystallization was studied by adding the solubility medium to films 
of Form II or to the amorphous form on a micro cover glass. The changes were viewed 
under polarized light microscopy (PLM) and further characterized by PXRD. The initial 
solid was pure Form II by PXRD (Figure 29f, bottom pattern). Under PLM, Form II 
crystal surface layers dissolved gradually as shown as the inward recess (Figure 
29b,c,d,e) compared to time 0 (Figure 29a). During the course of dissolution, signs of re-
crystallization are visible on the surface starting at 20 min, becoming especially evident 
at 40 min (Figure 29e). The PXRD obtained after 40 min exposure showed the appearance 
of Form I peaks (Figure 29f, top pattern), which demonstrates that the surface re-
crystallized solid is the result of Form II to Form I transformation. More importantly, no 
new crystals were observed in the solution phase, and no protruding crystals on the 
surface, indicating that Form I grew from Form II on surface, a truly surface 
recrystallization instead of the solution-mediated transformation. In the case of the 
amorphous form (Figure 30), crystallization was observed instantaneously upon contact 
with the aqueous solution (Figure 30b taken at 25 seconds). The immediate PXRD scan 
(within 3 min) already showed crystallization to pure Form I (Figure 30c). This indicates 
that when in aqueous solution, the amorphous material crystallizes to the stable Form I 
rather than to Form II as it does in air. 
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a (time = 0 min) b (time = 5 min) c (time = 20 min) 
 
d (time = 30 min) e (time = 40 min) f (PXRD before and after) 
 
 
Figure 29. APAP Form II → Form I conversions studied by PLM and PXRD in 0.15 M NaCl at ambient temperature. (a) to (e) PLM 
images captured at time 0 and at different times after aqueous phase was added. The part of the crystal on lower right corner was at a 
different height, and therefore was not well focused. (f) PXRD patterns before (bottom) and after (top) aqueous phase was added, with 
the Form I peaks marked with stars. 
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a (time = 0) 
 
b (time = 25 seconds) 
 
c (PXRD pattern at 3 min) 
  
Figure 30. APAP amorphous → Form I conversions studied by PLM and PXRD in 0.15 
M NaCl at ambient temperature. (a) PLM image of amorphous form before aqueous 
phase was added. (b) PLM image at 25 seconds after aqueous phase was added. (c) 
PXRD pattern of the final solid form shown on the bottom with overlaid pure Form I and 
Form II patters on the top. 
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Discussion 
Thermodynamic Driving Force for  
Solution-mediated Polymorphic Transformation 
Solution-mediated phase transformation (SMPT) is a process mechanistically 
defined by three consecutive steps:17,137,18  
 
1. Initial dissolution of the metastable phase into the solution to reach and 
exceed the solubility of the stable phase; 
2. Nucleation of the stable phase; 
3. Crystal growth of the stable phase coupled with the continuous dissolution of 
the metastable phase. 
Multiple publications report that APAP Form II converts to Form I through 
(SMPT).125,121,132 These observations were primarily made in crystallization solvents by 
cooling a hot organic solvent solution or by adding antisolvent. 121,132,138 Our objective 
was to understand how crystallization of APAP Form I occurs when Form II is added to a 
solution with no APAP initially, such as in a dissolution of Form II. 
How readily the stable form nucleates in step 3 of SMPT is correlated with the two 
forms’ difference in Gibbs free energy, ΔG. The larger the ΔG is, the higher driving force 
is for nucleation of the stable form. ΔG is a function of the activity ratio of the two solid 
forms expressed in the equation of ∆ܩூூ→ூ ൌ െܴ݈ܶ݊ ௔ಷ೚ೝ೘	಺಺௔ಷ೚ೝ೘	಺  where R is the ideal gas 
constant and T is the temperature in Kelvin. If the solubility (which approximates the 
activity) of the two solid forms could be accurately measured, obtaining the ΔG value 
would have been straightforward. Unfortunately, measuring APAP Form II solubility is a 
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two-decade long challenge mainly due to the facile conversion to the stable Form I in 
solutions.129,130 The only available and often-cited solubility ratio of 1.3 (APAP Form II 
over Form I) is from a single, short (60 min) powder dissolution test in water at 37 °C.139 
In the paper, the concentration of APAP measured by UV spectrophotometry plateaued at 
10 min with concentrations approaching 17 mg/mL for Form I and 22 mg/mL for Form II 
(which gives the ratio of 1.3). This Form I solubility of ~17 mg/mL is not consistent with 
many other publications. For example, at lower temperature of 30 °C the solubility in 
water is 17.4 mg/mL,140 at 37 °C the solubility increases to 21.02 ± 0.13 mg/mL in 
water141, and to 20.0 ± 0.2 mg/mL in water with 0.15 M NaCl.41 Therefore, it is probable 
that saturation had not been reached at 17 mg/mL. 
There have also been a number of reported attempts by calorimetry to determine the 
relative stability of acetaminophen Form I and Form II.127,104,131,142 The heat capacity (Cp) 
and fusion data were experimentally determined either by differential scanning 
calorimetry (DSC) on the in situ melt-quenched Form II from,104 by sublimation and 
solution calorimetry,127 or by adiabatic calorimetry on Form II single crystals.131 Based 
on the Cp, the thermodynamic functions (enthalpy, H, and entropy, S) were derived, 
which can then be used to calculate the ΔGII→I using the equation: ∆ܩூூ→ூ ൌ ∆ܪ െ ܶ∆ܵ. 
The ΔGII→I from three such reports displayed a large disparity, from approximately –3.0 
kJ/mole 104 to –3.9 kJ/mole127 to –13 kJ/mole131 at 25 °C, corresponding to Form II/Form 
I solubility ratios of 3.3, 4.8 and 197.2 respectively. Therefore, a conclusive answer to the 
energy difference (thus solubility ratio) between APAP polymorphs is still absent. 
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As discussed above, the free energy difference between the two solid forms is the 
key to understand the driving force of APAP Form II to I conversion in solution. The 
solubility measurement is a more straightforward way to determine the free energy 
difference. The challenge of obtaining accurate solubility measurements for Form II is 
two-fold. The first is the difficulties in obtaining pure Form II in sufficient quantity. Form 
II crystallization from ethanol was always contaminated with a small amount of Form I, 
consistent with the findings from others.143 Crystallization from the melt125,143 was found 
to be reliable, and pure Form II was made reproducibly. Therefore, we have adopted this 
method in our study. The second challenge is the physical instability of Form II in 
solution. To counter this, we applied a polymer as crystallization inhibitor to extend the 
window of physical stability. A very low concentration of PVP (0.02% or 20 ug/mL) was 
able to inhibit or delay the APAP form conversion without affecting the solubility in our 
study. Procedurally, changes to the traditional shake flask method are necessary for this 
difficult measurement. The measurement was directly performed on the micro cover glass 
which avoided complications such as Form I contamination when grinding and 
combining different batches. By this new method, minimal sample is required (since pure 
Form II is difficult to make in large amounts), the solution phase can be collected without 
filtration, and the residual solid can be easily recovered and analyzed by PXRD. 
This new experimental methodology resulted in a successful solubility 
measurement of APAP Form II in aqueous solution of 0.15 M NaCl at 37 °C. The Form 
II solubility of 24.7 ± 0.6 mg/mL is reliable supported by the reproducibility among the 
four Form II replicates (Figure 22), and most convincingly by the PXRD results 
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confirming the residual solid phase collected at equilibrium being pure or mostly pure 
Form II (Figure 21). Based on the Form I solubility of 19.7 ± 0.3 mg/mL measured under 
identical conditions, the solubility ratio of Form II over Form I is calculated to be 1.27 
± 0.04. This ratio is somewhat close to the predicted value using the Hoffman equation144 
(1.2), and is quite far from the predicted value using the ideal solubility equation (1.5).145 
A recent paper142 reported intrinsic dissolution rates (IDR) of 1.50, 1.33, and 1.31 
mg/mL/cm2, respectively for Form II prepared by melt quenching of three different 
APAP I materials (coarse, micronized and nano-silica coated), and 1.14 mg/mL/cm2 for 
Form I. IDR correlates with solubility, thus an average IDR ratio of Form II over Form I 
of 1.21 ± 0.09 can be calculated, which is lower but close to our measured solubility ratio 
although the data are more variable and the remaining tablets were not characterized to 
identify the final solid form. Our measured solubility ratio of 1.27 ± 0.04 (ΔGII→I = ca. –
0.62 kJ/mole) is significantly below the average solubility ratio (1.7) among the known 
polymorph systems surveyed by Pudipeddi and Serajuddin.145 Therefore, the 
thermodynamic driving force for From II to Form I conversion is quite low. 
Since we have determined the solubility ratio of APAP Form II over Form I at 
37 °C, we can now address the question: Is the dissolution of Form II able to reach the 
supersaturation level required for Form I to crystallize? Figure 23 demonstrates that Form 
I is not able to crystallize from solutions at supersaturations of 1.27x – 1.52x over Form I 
solubility (1.27x is at Form II solubility) over the course of up to 10 days of agitation at 
37 °C. Form II would have had ample time to dissolve and reach saturation before Form I 
is crystallized from the solution. But the reality is the opposite. This strongly suggests 
124 
 
 
that primary nucleation through solution-mediated polymorphic transformation is not the 
mechanism dictating the facile APAP Form II to Form I conversion in solution. The rapid 
conversion from Form II to Form I in solution must be due to other reasons. 
MD Simulation of Differences  
between APAP Polymorphs during Dissolution 
Simulated dissolution profiles of APAP I and APAP II nanocrystals (4.6–4.7 nm as 
shown in Table 2) were constructed. The numbers of molecules leaving the crystal sphere 
were found to be almost identical between the two crystals within the 10 ns simulation 
(Figure 26a). This appears to contradict the thermodynamic stability relationship of the 
stable Form I vs the metastable Form II at 37 °C. However, nanoparticles with sizes down 
to <100 nm can increase saturation solubility,114 and our calculation indicated a 3.4-fold 
solubility increase when the particle size is reduced to 4.6 nm.41 This 3.4 folds higher 
solubility could attenuate the difference between the two forms if such a difference is 
small to start with. More importantly, we have demonstrated41 that the initial dissolution 
rate is profoundly affected by the corner and edge effect (molecules at corners and edges 
dissolve first). In nanocrystals of APAP I and II, the molecules that dissolve within 10 ns 
came mainly from on the corners and edges (Figure 25a,b). A much higher percentage of 
molecules become edge or corner bound when the crystal is nanosized rather than 
macroscopic. Therefore, the corner and edge effect dominates the initial dissolution of a 
tiny nanocrystal. Further, the driving force for dissolution is the strength of drug 
molecule interaction with water being greater than drug-drug molecule binding energy.41 
This driving force is favorable since the net interaction energies are negative (Figure 
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26b). A striking closeness between Forms I and II was observed, with comparable net 
interaction energy values residing in the edges (–14.8 kJ/mole for Form I and –14.1 
kJ/mole for Form II), as well as in the corners (–77.4 kJ/mole for Form I and –83.8 
kJ/mole for Form II). The similar initial dissolution rate of Form I and II nanocrystals can 
thus be adequately explained by the similar dissolution driving force inherent in the 
corner and edges molecules which are the first dissolved molecules. The 3.4x saturation 
solubility increase over the normal size crystals further masked the real but small 
difference between the solubility of these two solid forms. 
The second analysis of the MD simulation data was to examine the differences in 
the remaining solid phase between APAP I and II. The results are consistent with the 
thermodynamic stability relationship. APAP II crystal is less stable than APAP I as 
shown by higher percentage of H-bond broken (Figure 27) over time. H-bonding is the 
major force contributing to lattice energy. Fewer H-bonds are associated with a decrease 
in the heat of fusion of the crystal. The van der Waal forces (the other major force for 
molecular association) is also expected to be smaller in APAP II based on the visibly 
more disordered lattice in Figure 24c,f. Furthermore, not only the corner and edge 
molecules but also those on the flat surfaces in APAP II have turned into a disordered 
state. The visible thick disordered layer surrounding the APAP II crystal was determined 
by pair correlation function (Figure 28) to be significant. The dense drug layer represents 
a high concentration of APAP molecules on the crystal surface. This discovery pointed 
out a link between crystal surface and Form I crystallization rate. 
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Facile APAP Form II to Form I Transformation  
through a Surface Facilitated Mechanism 
Based on the insight gained from the MD simulations, the Form II surface is poised 
to offer the supersaturation which the kinetics of Form I crystallization heavily depends 
on. The visual PLM experiment on Form II dissolving into aqueous solution (Figure 29a-
e) provides direct evidence of the involvement of the surface layer in the Form II to Form 
I transition. While the surface of Form II showed evident signs of re-crystallization 
(which was confirmed by PXRD to be Form II to Form I transformation), the solution 
phase appears to be completely clear without any nucleation and crystal growth. 
Furthermore, the conversion on the surface took place relatively quickly; in a matter of 
~40 min, Form I peaks were already present in PXRD pattern (Figure 29f). This indicates 
that the surface has cultivated the polymorphic transformation. 
Based on the data presented in Figure 29, it can be deduced that the concentration 
on Form II surface has to be much higher than a supersaturation of 1.52x over Form I 
solubility, or else the nucleation of Form I could not have taken place rapidly. It is 
reasonable to believe that such a highly concentrated APAP layer on the Form II surface 
is created due to the fact that the hydration rate is faster than the molecular diffusion rate 
from the surface to bulk solution phase. The existence of the high supersaturation sets the 
stage for potential polymorphic conversion. This phenomenon presumably also exists in 
other metastable solid systems, but why does it lead to fast solid form conversion in the 
APAP system? This can be interpreted by the crystallization tendency of APAP. APAP 
was reported to crystallize from the amorphous state more readily than other studied 
127 
 
 
compounds due to lower configurational entropy and higher molecular mobility.146 
Lower configurational entropy means higher probability to assume proper orientation and 
conformation for crystal nucleation, which is intrinsic to the molecular structure of 
APAP. The molecular mobility, on the other hand, is expected to increase drastically in 
the dissolution study when compared to the dry amorphous system since water is 
introduced. Therefore, on the highly supersaturated surface, APAP should have a high 
tendency to nucleate. This is supported by the data in Figure 30a,b where the amorphous 
phase of APAP crystallizes almost instantaneously once in solution. More specifically, at 
the hydrated amorphous surface which mimics the highly concentrated APAP molecule 
layer accumulated on Form II surface observed by MD simulation, it was the stable Form 
I that has been crystallized. The resultant PXRD pattern represents an unequivocally pure 
Form I (Figure 30c). These data imply that the highly concentrated APAP layer on the 
Form II surface has facilitated the Form I crystallization.  
The evidence presented above leads to the conclusion that the APAP Form II to I 
conversion in solution is through the surface-facilitated phase transformation (SurFPT), 
as opposed to the well-known solution-mediated phase transformation (SMPT). We 
envision the steps of SurFPT (Figure 31) in the following sequence: (a) The Form II 
surface molecules hydrate immediately once the water is introduced; (b) The hydrated 
molecules remain on the surface because of the barrier to diffuse into the bulk; (c) The 
concentration on the surface becomes high enough to crystallize as Form I. 
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Figure 31. Schematic Illustration of Surface Facilitated Phase Transformation (SurFPT). 
The metastable form hydrates immediately once the water is introduced. The hydrated 
molecules quickly accumulate on the surface, approaching a high enough supersaturation 
level which leads to crystallization into the stable solid form. 
 
As in SMPT, the presence of solvent (water in our study) is a prerequisite for 
SurFPT. Contrary to SMPT, however, in SurFPT the nucleation takes place on the 
metastable crystal surface coated with rapidly solvated drug-rich layer rather than in the 
solution. Sometimes, SMPT could nucleate on foreign particle surfaces (heterogeneous 
nucleation), however, the crystal growth usually is toward the solution phase creating 
protruding crystals147 because the solution phase is supplying the molecules. In the case 
of SurFPT, the crystal grows beneath the surface (Figure 29) following the seeding by the 
surface layer crystals. Since accumulation of drug concentration on the surface takes a 
shorter time, SurFPT mechanism promotes a faster polymorphic conversion for drugs 
129 
 
 
with higher intrinsic tendency for crystallization, such as APAP. Finally, it can be safely 
extrapolated that the SurFPT mechanism also should be responsible for the reported 
APAP Form II to Form I conversion in air under different relative humidity conditions.143 
Since the SurFPT mechanism could be used in other polymorphic systems, its 
implication goes beyond the APAP polymorphic pair. Understanding SurFPT benefits 
formulation and solid state scientists in the research and development of pharmaceutical 
products. For examples, in the effort to make metastable forms or to measure solubility of 
metastable forms or to use metastable form to gain solubility advantage, SurFPT is far 
more detrimental than SMPT. This has caused the failure in measuring the solubility of 
APAP Form II in the past and in preparing APAP Form II on a large scale which 
otherwise would provide a lower cost option for processing solid dosage forms. It would 
also decrease the solubility advantage of a metastable form when the drug is taken in 
vivo, because the solid does not have any chance to dissolve into solution within the 
absorption window before the stable form crystallizes. The outcome is analogues to the 
matrix crystallization occurring in amorphous solids which negated the dissolution 
advantage of the amorphous form.19 
Conclusions 
We presented strong evidence from a series of molecular dynamics simulations and 
experiments that reveal the root cause for the facile polymorphic conversion of APAP 
from orthorhombic Form II to monoclinic Form I. APAP Form II undergoes surface- 
facilitated phase transformation (SurFPT) in contact with the solution. In SurFPT, the 
nucleation takes place on the metastable crystal surface coated with rapidly solvated 
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drug-rich layer rather than in the solution where creating sufficient supersaturation takes 
a longer time. From MD simulations, such a drug-rich layer is evident on the APAP Form 
II surface but not on the Form I surface. The SurFPT mechanism we have demonstrated 
with APAP could also exists in other polymorphic systems. This mechanism promotes a 
faster polymorphic conversion for drugs with higher intrinsic tendency for crystallization, 
such as APAP. Understanding it helps us select appropriate strategies to circumvent the 
polymorphic conversion problems during manufacturing of active pharmaceutical 
ingredients and drug products. 
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CHAPTER FIVE 
DRUG–POLYMER INTERACTIONS AT WATER-CRYSTAL INTERFACES AND 
IMPLICATIONS FOR CRYSTALLIZATION INHIBITION: MOLECULAR 
DYNAMICS SIMULATIONS OF AMPHIPHILIC BLOCK COPOLYMER 
INTERACTIONS WITH TOLAZAMIDE CRYSTALS 
Abstract 
A diblock copolymer, PEG-b-PLA, is effective in modulating the crystal growth of 
tolazamide, resulting in a crystal morphology change from needles to plates in aqueous 
media. To understand the molecular mechanism of this crystal surface drug–polymer 
interaction, we conducted molecular dynamics (MD) simulations on crystal surfaces of 
tolazamide in water containing PEG-b-PLA. To ensure that the polymer structure was 
fully equilibrated, a 130 ns simulation of the polymer in a large water box was run before 
initiating 50 ns simulations with each of the crystal surfaces. The simulations 
successfully demonstrated the differentiated drug–polymer interactions and are consistent 
with experimental studies. Interaction of PEG-b-PLA with the (001) face occurred more 
rapidly (≤10 ns) and strongly (total interaction energy of –29.1 kJ/mole/monomer) than 
that with the (010) face (~35 ns, –21.02 kJ/mole/monomer). In addition, there was 
virtually no interaction with the (100) face. Interestingly, upon dissecting the various 
contributions to the total interaction energies, van der Waals interactions were identified
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 as the dominant forces (accounts for 77–93% of total interaction energies) that enabled 
such strong drug–polymer interactions. It suggests that polymers capable of forming 
strong hydrophobic interactions are more effective in inhibiting crystallization of poorly 
water-soluble and hydrophobic drugs in aqueous media (such as gastrointestinal fluid) 
than those with hydrogen bonding capacities. Such in-depth analysis and understanding 
facilitate the rational selection of polymers in designing supersaturation-based enabling 
formulations. 
 
Key words: Tolazamide, poly(ethylene glycol)-block-poly(lactic acid), molecular 
dynamics simulation, crystallization inhibition by polymers, drug-polymer interaction, 
crystal surface specific interactions, crystal morphology modification, van der Waals 
interaction.  
Introduction 
Synthetic and natural polymers have been widely used in developing and manufacturing 
pharmaceutical products. The applications include148,149 (but are not limited to) binding 
the particles of a solid dosage form, changing the flow properties of active 
pharmaceutical ingredient (API), masking unpleasant taste of a drug, modifying drug 
release characteristics, stabilizing suspensions, enabling drug delivery and inhibiting 
crystallization of APIs. The ability of polymers to inhibit crystallization of drug 
molecules has promoted intense research in recent years. Polymers are used to stabilize 
the metastable solid form in formulations, i.e. amorphous solid dispersions (ASD150-152), 
to deliver poorly water-soluble small molecular drugs (Class II and IV in 
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Biopharmaceutics Classification System153) which represent approximately 90% of 
current pipeline drugs across the pharmaceutical industry.154 Polymers also are used to 
maintain supersaturation during dissolution of enabling formulations for maximizing 
formulation performance.19,155-157 Finally, polymers can play an important role in 
modifying the crystal habit during solution crystallization.158-160  
Crystallization inhibition originates from drug–polymer interactions. Understanding 
the mechanism of how drug molecules interact with a polymer will help us to select a 
better polymer for formulating and delivering drug molecules. Molecular dynamics (MD) 
simulations are well suited for adding insights that would otherwise difficult to gain by 
experimental methods. The reported use of MD simulation in drug crystallization 
inhibition by polymers can be divided into two main areas: polymer–drug interactions in 
amorphous systems which primarily deal with solubility or miscibility58-63 and crystal 
systems which address crystal growth inhibition. In the latter, there are only a few 
published studies in recent years. Zhu et al. simulated the interaction of several additives 
(such as hydroxypropyl methylcellulose, HPMC) in water with crystal surface of 
fenofibrate66 and griseofulvin.65 A short HPMC chain (five repeating units) was 
constructed and placed into a small water box (1500 water molecules) with the simulation 
carried over a short duration (600–800 ps). The simulated binding energies between the 
additives and crystal surface were correlated with the experimental results when these 
additives were found to reduce the particle size of recrystallized griseofulvin. In 2012, 
Yani, Chow and Tan reported a 400 ps MD simulation of large polymers (225 monomers 
for PVP and 62 for HPMC) with different crystal phases of salbutamol sulfate in 
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vacuum.64 Hydrogen bonding between PVP and salbutamol sulfate, which was ~40% of 
the total binding energy, was thought to dominate in prohibiting crystal growth. The 
water soluble polymers used in drug crystallization inhibition strongly interact with water 
molecules. As a result, the interaction with drug molecules is expected to change in the 
presence of water. For examples, Taylor and her group reported that 
poly(vinylpyrrolidone) (PVP), which is an effective crystallization inhibitor to felodipine 
in amorphous solid dispersions at low relative humidity (RH) significantly reduced its 
effectiveness at high RH161 and even lost its ability in aqueous dissolution medium.162 
The loss of effectiveness was ascribed to the strong interaction of PVP with water 
molecules. Apparently, more studies are needed to improve upon the MS simulation 
methodologies (i.e. sufficiently long simulation time under more realistic conditions) in 
order to demonstrate the validity and utility of MS simulation as an emerging and 
powerful technique for such applications. More importantly, it is necessary to conduct 
more careful analysis in interaction energies involved in the drug–polymer interaction for 
the purpose of understanding the mechanism of crystallization inhibition by polymers in 
aqueous solutions. The purpose of our present work, therefore, is to develop improved 
MD simulation methods to study the molecular level mechanism and energetics involved 
in crystal growth inhibition by polymers in an aqueous solution.  
The model system chosen for this study is comprised of tolazamide (TLZ), an oral 
hypoglycemic agent, and poly(ethylene glycol)-block-poly(lactic acid) (PEG-b-PLA), an 
amphiphilic block copolymer. Based on the interesting work published by Kuldipkumar 
et al,158,163,164 PEG-b-PLA selectively interacted with the (001) phase of the TLZ crystal, 
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changing the crystal habit from needle to plate shape158 (shown in Figure 32). PEG-b-
PLA exerts this strong habit modification at very low concentration (3–10 ppm) 
regardless of PEG to PLA monomer ratios in the polymer.164 Atomic force microscopy 
with the tip tethered with the polymer or parts of the polymer (PEG or PLA) determined 
the adhesion forces to individual faces of the single crystals. The adhesion forces were 
the strongest (264 nN) with (001), the weakest (~5 nN) with (100) and intermediate (170 
nN) with (010).164 
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(a) (b) 
 
 
Figure 32. Tolazamide crystals obtained (a) in the absence of PEG-b-PLA and (b) in the presence of 50 µg/mL of PEG-b-PLA.158 
(Photomicrographs used with the permission of Crystal Growth and Design). 
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Our MD simulation was designed to investigate the interactions between TLZ 
crystals and PEG-b-PLA in water. Large crystal surfaces of (001), (010) and (100) were 
built respectively into a sizable water box. A representative PEG-b-PLA was constructed, 
first equilibrated with a 130 ns MS simulation in water and then added to another water 
box containing the crystals. The assembly was simulated for 50 ns to determine how the 
polymer molecule interacts with each crystal surface. The nature of the polymer 
interaction with TLZ molecules was quantitatively determined through van der Waals 
and electrostatic interaction energies. The results from the study strongly correlated with 
the reported experimental data, allowing an in-depth view of how the molecular 
interactions responsible for the crystallization inhibition take place at the crystal-water 
interface. This correlation with experimental results established our MD simulation 
method, which will allow future applications of this method in studying other drug 
crystal–polymer interactions. 
Experimental 
Building the Crystals 
The single crystal structure of tolazamide (TLZ, molecular structure in Figure 33a) 
was taken from CABCUD01165 in the Cambridge Structural Database (Cambridge, UK). 
The crystal system is triclinic with space group P1, Z = 2 and a = 6.355 Å, b = 9.223 Å, c 
= 13.510 Å, α =101.104°, β = 92.80 ° and γ = 85.72° (Figure 33b). The molecules are 
dimerized by NH-O hydrogen bonds and dimers are packed together through van der 
Waals interactions only.165 TLZ is poorly water-soluble (intrinsic solubility of ~70 
µg/mL), hydrophobic (CLogP of 2.69) and weakly acidic (pKa of 5.9 assigned to the 
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sulfonamide hydrogen).158,166 Three virtual crystals were constructed from the unit cell 
using Mercury software (Mercury 2.3, CCDC 2001-2009) following our previous 
method41 with some modifications. The (001) surface crystal was built by extending the 
unit cell at a, b, and c directions for 17, 2 and 8 times, producing the 17 x 12 x 2 crystal 
lattice. Similarly, the (010) and (100) surfaces were made at 17 x 2 x 8 and 2 x 12 x 8 
unit cell repetitions (detailed in Table 3 and Figure 34). 
 
a b 
c  
 
 
 
Figure 33. (a) Molecular structure of tolazamide. (b) Unit cell of tolazamide. (c) 
Molecular formula of PEG-b-PLA. 
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Table 3. Three Crystal Lattices of Tolazamide Built with large (001), (010) and (100) Surfaces. 
 
Surface 
Lattice with 
unit cells 
Crystal Dimension (Å) 
no. of molecules 
Surface Size 
× 104 (Å2) 
a b c 
(001) 17×12×2 108.04 110.68 27.02 816 1.19  
(010) 17×2×8 108.04 18.45 108.08 544 1.17  
(100) 2×12×8 12.71 110.68 108.08 384 1.17  
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(a) (001) surface 
(b) (010) surface 
(c) (100) surface 
 
Figure 34. Illustration of the tolazamide molecular packing on three surfaces of crystals 
used in simulation. (a) (001) surface with the flat face of the methyl benzene ring toward 
water. (b) (010) surface with the methyl benzene ring oriented toward water 
perpendicularly. (a) (100) surface with the azepane ring toward water perpendicularly. 
 
The crystals constructed above were prepared using Visual Molecular Dynamics 
software (VMD, version 1.9, March 2011).99 The topology and parameters of TLZ for the 
CHARMM2739 force field were obtained from the Swiss Institute of Bioinformatics 
(http://swissparam.ch/).  The structure file of the crystals was built using the Automatic 
PSF Builder function in VMD from the input of the Mercury coordinate file and the TLZ 
topology file. 
  
141 
 
 
Building the Polymer and  
Obtaining the Hydrated Polymer Structure 
The polymer used was a poly(ethylene glycol)-block-poly(lactic acid) (PEG-b-
PLA) (general formula shown in Figure 33c), within the class of amphiphilic diblock 
copolymers. The PEG-b-PLA polymer built for this study contains 22 and 8 repeating 
units of PEG and PLA, respectively, mimicking a PEG: PLA ratio of 110: 40 in a 
commercially available PEG-b-PLA polymer which was used in the reported TLZ habit 
modification study.164 The molecular weight of PEG22-b-PLA8 is 1600 g/mol, or 20% of 
the real polymer. The chemical structure was drawn using ChemDraw (ver 9.0.7, 
Cambridge, Massachusetts) which was then input into Spartan O2 (Wavefunction, Inc., 
Irvine, California) to calculate the three-dimensional molecular structure in mol2 format. 
This was submitted to Swiss Institute of Bioinformatics (http://swissparam.ch/) to obtain 
the topology and parameters for the CHARMM2739 force field. 
Prior to simulating the polymer-crystal surface interaction in water, the polymer 
must be equilibrated with water. This was accomplished through a 130 ns MD simulation 
in water. The steps of energy minimization and production run followed the conditions 
described in the following section. The polymer was first simulated in a 64×62×53 Å 
water box for 100 ns, and then in a larger size water box (106×118×114 Å) for another 30 
ns. The polymer structure from the end of 130 ns was combined with that of the crystals 
to simulate the polymer crystal interactions in a water box. 
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Building the Polymer  
and Crystals together in Water 
Water rather than buffer was selected as the aqueous medium in this simulation 
since neither the rate of crystallization nor the morphology of TLZ in the presence of 
PEG-b-PLA was affected by changing buffer pH values.164 The hydrated PEG-b-PLA 
polymer structure and TLZ crystals were built together using VMD software (version 1.9, 
March 2011).99 The center of the polymer was positioned at 20 Å away from the center of 
each crystal surface, and about 4.9×104 water molecules (~100 Å distance from the 
crystal surface) were added to cover the crystal surface and the polymer. The combined 
structural files were created using the Automatic PSF Builder function in VMD.99 
MD Simulation 
The computer code used for the MD simulations was the parallel, scalable MD 
program NAMD version 2.9b1.100 Periodic boundary conditions were used. The cutoffs 
for nonbonding (van der Waals and electrostatic) interactions were 12 Å. The switch 
distance was 10 Å, and a 1.0 1–4 scaling factor was used. The polymer and crystal in the 
water box were first subjected to energy minimization (6000 steps) followed by slow 
heating from 10 to 298 K over 30000 steps. The temperature and pressure of the system 
were equilibrated for 10000 steps using a Langevin piston. The system was then allowed 
to equilibrate for 30000 steps at constant temperature (298 K) and pressure (1 atm). After 
equilibration, the crystal was fixed so that it does not dissolve into water in the following 
production run so that the polymer’s interaction with the intact crystal surface can be 
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simulated. Production simulation of the polymer interaction with the intact crystal surface 
was performed at constant volume and temperature (298 K) for 50 ns. 
Analysis of MD Simulation Data 
Simulated results were viewed using VMD (version 1.9, March 2011).99 Interaction 
energies were calculated using algorithms for the van der Waals (VDW) and electrostatic 
energies in the NAMD program.100 These calculations were performed for the whole 
polymer (PEG22-b-PLA8) and the PEG22 and the PLA8 portions of the polymer within 
4 Å of the TLZ molecules. Because partial charges exist in an atom due to the different 
electronegativities of the atoms, the potential function used in the molecular dynamics 
simulation considers the partial charge in every atom even when the molecules are 
neutral. The electrostatic interactions, including ion–dipole interactions and H-bonding, 
and van der Waals interactions, including London dispersion forces and electronic 
repulsions, were calculated using the partial atomic charges and van der Waals 
parameters in the CHARMM potential function.39 Since the block polymer contains more 
PEG repeating units than PLA, the interaction energy was reported as energy value per 
monomer. This allows comparison in interaction strength among polymers with different 
chain lengths. 
Results 
 
Visual Analysis 
Surface (001) 
Initially the polymer moved freely in water but quickly (at 0.5 ns) it approached the 
surface (Figure 35a). At 2 ns the PLA tail made a contact with the surface (Figure 35b). 
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The polymer bent toward the surface (Figure 35c). At 4.5 ns, the PEG tail also touched 
down (Figure 35d). Both PLA and PEG ends gradually pulled the whole polymer down 
to the surface (Figure 35e,f). At 10 ns the polymer flattened itself on the surface (Figure 
35g), after which there were no further position changes through the end of the 50 ns 
simulation (Figure 35h), although the polymer kept making small movement (vibrating) 
from 10 to 50 ns. A view from the top of the crystal surface at 50 ns (Figure 35i) shows 
the polymer lays curled and flat on the surface. It appears that the tails of the polymer 
play a bigger role in initiating the interaction than the other parts of the polymer. 
  
145 
 
 
 
(a) t = 0.5 ns (b) t = 2 ns (c) t = 3.5 ns 
 
(d) t = 4.5 ns (e) t = 6.5 ns (f) t = 8 ns 
 
(g) t = 10 ns (h) t = 50 ns (i) t = 10 ns, top view 
 
 
Figure 35. Display of images of MD simulation of PEG-b-PLA polymer with TLZ crystal 
surface (001) at different times. PLA portion is shown as red/blue/white (oxygen is red, 
carbon is blue and hydrogen is white). PEG as red/beige/pink (oxygen is red, carbon is 
beige and hydrogen is light pink). For clearer views, water molecules are not shown. 
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Surface (010) 
The polymer behaved differently with the (010) face. The PEG tail was already at 
the surface at time 0 (Figure 36a) indicating this has occurred earlier during the 
equilibration. However, the faster interaction with the PEG tail did not bring about any 
faster interaction with the whole polymer. During the period of 0 to 20 ns, there has been 
simply a single contact between the PEG end and the surface (Figure 36b,c), while the 
PLA part moved around in the water phase. Changes finally took place at 23 ns when the 
PEG chain gradually lowered to the surface (Figure 35d,e). At 50 ns (Figure 35f), most of 
the PEG lied down as a linear chain, but is not coiled as on the (001) surface. As seen 
with the (001) surface, the initial contact with the crystal surface was made through the 
tail of the polymer. Interestingly, only a small part of PLA made contact with the (010) 
surface. 
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(a) t = 0 ns (b) t = 10 ns (c) t = 20 ns 
 
(d) t = 23 ns (e) t = 30 ns (f) t = 50 ns 
 
 
Figure 36. Display of images of MD simulation of PEG-b-PLA polymer with TLZ crystal 
surface (010) at different times. PLA portion is shown as red/blue/white (oxygen is red, 
carbon is blue and hydrogen is white). PEG is shown as red/beige/pink (oxygen is red, 
carbon is beige and hydrogen is light pink). For clearer views, water molecules are not 
shown. 
 
Surface (100) 
The polymer did not interact with the (100) face. From 0 to 10 ns, the polymer 
sometimes moved closer to the surface (Figure 37a), and sometimes moved further away 
(Figure 37b). Starting from 12 ns it gradually diffused from the center toward the edge of 
the water box (Figure 37c). The polymer moved across the (100) surface until it found the 
(001) face at ~17 ns (Figure 37d). Evidently the polymer has little affinity to (100) but its 
binding to (001) is favored. The polymer settled on the edge of (001) and (100) at 35 ns 
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(Figure 37e) with no changes afterwards. The PEG part interacted with (001) phase, 
while the PLA part found a space on the edge between (001) and (100) (Figure 37f). 
(a) t = 1 ns (b) t = 4 ns (c) t = 15 ns 
 
(d) t = 17 ns (e) t = 35 ns (f) t = 35 ns, enlarged 
 
 
Figure 37. Display of images of MD simulation of PEG-b-PLA polymer with TLZ crystal 
surface (100) at different times. PLA portion is shown as red/blue/white (oxygen is red, 
carbon is blue and hydrogen is white). PEG as red/beige/pink (oxygen is red, carbon is 
beige and hydrogen is light pink). For clearer views, water molecules are not shown.
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Interaction Energy Analysis 
Interaction energies between each block of the polymer (PLA or PEG) and the three 
crystal surfaces were calculated to characterize how the crystal surface differentiated 
interactions with the polymer. The energy level was normalized by the number of 
monomers in each block in order to compare PLA with PEG. Six plots demonstrating the 
dynamic changes in VDW and electrostatic energies as a function of simulation time are 
shown in Figure 38. 
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(a) (001) face (b) (001) face 
(c) (010) face (d) (010) face 
(e) (100) face: 0–17 ns (f) (100) face: 0–17 ns 
 
Figure 38. The interaction energies vs time between the polymer (including PEG portion, 
PLA portion and the whole polymer PEG-b-PLA) and the three TLZ crystal surfaces 
calculated as VDW and electrostatic energy per monomer in both blocks of the polymer. 
 
151 
 
 
The onset of increase in interaction energy in Figure 38 exactly coincided with the 
visually observed polymer-crystal interactions (Figure 35, Figure 36 and Figure 37). 
Since interaction energy levels plateau after 35 ns, it can be assumed that the interaction 
between the polymer and the surfaces had approximately reached equilibrium, and the 
degree of interaction could be estimated by the averaged energy values from 35 to 50 ns 
for both VDW and electrostatic forces. When the VDW of the whole PEG-b-PLA is 
compared at equilibrium, (001) phase shows significantly stronger interaction (–
27.1 ± 1.8 kJ/mole of monomer) than that of the (010) surface (–16.4 ± 1.7 kJ/mole of 
monomer). When PEG and PLA are compared separately, at the (001) face both PLA and 
PEG portions contributed to the VDW energy (Figure 38a), while at the (010) surface the 
PEG portion provides the major contribution since the PLA hardly interacted with (010) 
(Figure 36). There is no interaction with the (100) face for either portion of the block 
polymer (Figure 38e,f). 
The van der Waals interaction energy obtained is much larger than the electrostatic 
interaction energy. This is true regardless of crystal faces and different parts of the 
polymer. In addition, the electrostatic interaction is mostly contributed by the PLA part. 
Discussion 
Dependence of Drug Molecular Packing  
on Drug–Polymer Interactions 
The MD simulation indicates that PEG-b-PLA in water interacts most strongly with 
the TLZ (001) phase (Figure 35 and Figure 38a,b), less strongly with the (010) face 
(Figure 36 and Figure 38c,d) and almost not all with the (100) face (Figure 37 and Figure 
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38e,f). This is consistent with reported experimental results that the adhesion forces 
between the polymer and TLZ crystal faces followed the rank ordering of (001) > (010) > 
(100) with very low measurable forces toward (100).164  
Intuitively the surface differentiated interaction is due to different TLZ molecular 
packing on the crystal surface since it is the only variable in the simulation experiment. 
On the (001) face, the methyl phenyl ring lays almost flat on the surface (Figure 34a), 
providing larger effective surface area to interact with the polymer. When the polymer 
molecular comes in contact with the (001) face, the sheet of benzene rings offer strong 
interactions (i.e. van der Waals and hydrophobic interactions). The total van der Waals 
interaction energy with (001) per monomer exceeded –27 kJ/mole (Figure 38a) which 
leads to stable interactions once contact is made between the polymer and the surface. 
Within 10 ns, the polymer has already fully coiled on the (001) surface.  
The (101) surface also consists of the methyl phenyl ring; however, the ring “stands 
up” with the methyl group pointing outward (Figure 34b). When the polymer comes to 
this surface, it first encounters the methyl group that is expected to provide fewer VDW 
and hydrophobic interactions with the polymer. The polymer has to penetrate deeper in 
order to interact with the benzene ring which takes longer time. The total van der Waals 
interaction energy per monomer decreased to –16.4 kJ/mole on (010) (Figure 38c), a 40% 
reduction compared to that on (001). This may have contributed to the much slower 
interaction. Since the weaker interaction compared to the (001) face allows for more 
movement after contact is made, it took 35 ns for the PEG chain to bind to the (010) 
surface. Interestingly, the PLA part could not find a place to “lay down” on (010) after 
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“searching” for 50 ns. This is quite different than the fast and tight binding between PLA 
and (001). The details of the interface of water–polymer–(001) surface at 50 ns is shown 
in Figure 39. Parts of the PLA chain snuggly fit into the gaps formed between two layers 
of the methyl phenyl ring. On (010), the surface molecules appeared to be more mobile 
and did not form a groove to accommodate the PLA chain (Figure 36f). Thus, there is less 
interaction of the PLA with the (010) surface. 
 
 
Figure 39. Enlarged image at (001) crystal–water interface to demonstrate the PEG-b-
PLA polymer–TLZ interaction at 50 ns. The PLA part is located at the left side (color 
code of the atoms: oxygen is red, carbon is blue and hydrogen is white). The PEG part is 
at the right side (color code of the atoms: oxygen is red, carbon is beige and hydrogen is 
light pink).  
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Lastly, on the (100) surface, the dominant molecular moiety is the azepane 
perpendicularly facing the water phase (Figure 34c). The van der Waals interactions to 
hydrocarbons on the azepane are expected to be weaker compared to the phenyl rings. 
This perhaps explains the lack of the polymer interaction with the (100), and why the 
polymer prefers to move toward (001) which is adjacent to (100) and interacted with the 
(001) face instead. 
The simulations were able to visualize the crystal surface specific interactions, thus 
providing direct evidence for understanding the crystal growth inhibition by polymers. As 
described in the diffusion theory for crystal growth,25 the overall crystal growth rate in a 
first order process is controlled by the rate of molecular diffusion from the bulk solution 
to the crystal surface and the rate of molecule integration into the crystal surface. Alonzo 
et al.32 have found that in the presence of HPMC, felodipine crystal growth shifted 
toward an integration-controlled mechanism from the diffusion-controlled mechanism. 
The visual findings from the simulations support the role of polymers in reducing surface 
integration rate. The observed rapid and strong adsorption of the PEG-b-PLA selectively 
to (001) provides physical blockage for other TLZ molecules to integrate into the (001) 
surface for extending the crystals in the (001) direction. This resulted in the TLZ 
morphology change (Figure 32). However, the polymer–crystal surface specific 
interaction does not inhibit crystallization because some surfaces are not inhibited and are 
still free to grow. The MD simulation is potentially a method to screen polymers for 
intended purposes. For example, if crystal habit modification is needed, the screening 
will look for specific crystal surface interaction with different polymers. If the objective 
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is to inhibit crystal growth at all or to obtain significantly reduced particle size, the 
screening can target the polymers with a universal inhibition across different crystal 
surfaces. Applying MD simulation for such an application may become a reality 
relatively sooner due to advances in MD simulation methodology and rapid increases in 
computational speed. 
Importance of VDW Forces in  
Polymer–Crystal Surface Interaction 
The MD simulations demonstrate the important role of VDW forces in TLZ–PEG-
b-PLA interactions. Most oxygen atoms (shown as red in Figure 39) in the polymer are 
oriented toward water, while the atoms on the hydrocarbon chain which are hydrophobic 
are tightly inserted into the layers of phenyl rings on the (001) face. Thus, the polymer 
forms hydrophilic and H-bond interactions with water molecules but hydrophobic and 
van der Waals interactions with the TLZ surface molecules. 
The visual observation in Figure 39 is quantitatively captured in Figure 38 where 
the interaction energy landscape between the polymer and TLZ molecules is presented. 
The electrostatic interaction energy (Figure 38b,d,f) is small compared to VDW 
interaction energy (Figure 38a,c,e). The electrostatic energy, including hydrogen 
bonding, only accounts for 7.0% of total interaction energies between PEG-b-PLA and 
(001) (2 out of 29 kJ/mole), 23% of that on (010) (4.8 out of 21.3 kJ/mole), and 15.6% of 
that on (001) at the (001/(100) edge (3.8 out of 24.0 kJ/mole). The small electrostatic 
interaction is mainly contributed by the PLA block and minimally by the PEG block. 
This conforms to the chemical structures of the PEG-b-PLA and TLZ. Only one 
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hydrogen atom at the PLA tail can be donated to form a hydrogen bond (Figure 33c). The 
rest of polymer has multiple hydrogen bond acceptors. The carbonyl oxygen in PLA is a 
stronger hydrogen acceptor than the ether oxygen in PEG because it is more 
electronegative. In the TLZ crystal, the methyl phenyl ring on (001) and (010) faces or 
the azepane on (100) face do not possess strong H-bond donors or acceptors. TLZ 
molecules in the crystal are dimerized by intermolecular NH–O hydrogen bonds165 which 
are not accessible from the surfaces. These data indicate that hydrophobic interactions 
rather than hydrophilic interactions are responsible for most polymer–TLZ intermolecular 
interactions. 
The above conclusion for TLZ can be applied to many other poorly water-soluble 
compounds for several reasons. Firstly, more than two third of the marketed poorly 
soluble drugs (219 out of 318 BCS Class II and IV compounds) surveyed in 2011 are 
highly hydrophobic (CLogP > 2.50), similar to or more hydrophobic than TLZ 
(LogP = 2.69).166 When placed in a polar environment (i.e. water), these non-polar 
molecules will have a tendency to group together with the non-polar motif of the polymer 
to minimize the surface area in contact with water. This is the nature of hydrophobic 
interactions. Therefore, for these crystal surfaces, formation of hydrophobic interaction 
with polymers would be much more energetically favorable. 
Another important factor to consider is the role of water. The interaction of a 
polymer with a drug in dry state (i.e. in amorphous solid dispersion where H-bonding 
with polymers is important for physical stability) changes when water is introduced. 
Formation of drug–polymer H-bonds in aqueous solutions should be less favorable due to 
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the strong competition from water. Since water is 55 M and an excellent H-bond donor 
and acceptor, it would dominate the H-bond sites on the crystal surface as well as on the 
polymers. An MD simulation study on adsorption of polyethylene glycol (PEG) on the 
surface of dicalcium silicate showed that the absorption energy decreased more than 10-
fold in the presence of water compared to under vacuum due to the added interaction of 
water with the PEG and dicalcium silicate.167 
Thirdly, the VDW interactions are not as weak as often perceived. Although 
hydrogen bonding (bond energy of 8–30 kJ/mole)168 is in general stronger than VDW 
forces (bond energy of 4–41 kJ/mole)168 on a per interaction basis, the total interaction 
energy from the VDW forces could overwhelm the contribution from hydrogen bonding 
due to the larger numbers of VDW interactions. The sum of many VDW interactions can 
be very strong as exemplified in the TLZ and PEG-b-PLA system where the VDW 
interaction energy with the (001) face is 27.1 kJ/mol/monomer (Figure 38a), reaching the 
level of a strong H-bond (O–H→O bonding energy is 25 kJ/mol).168 This explains how a 
ppm level of PEG-b-PLA was able to block the (001) surface growth.158 
The lack of experimental techniques to accurately measure the level of hydrophobic 
interactions between the polymer and the drug may have been why the hydrophobic 
interactions have not been emphasized in the past. Recently more work has recognized 
the role of hydrophobic interactions in crystallization inhibition. In 2013, IIevbare et 
al.169 reported a comprehensive study on the crystal growth rate of three structurally 
diverse hydrophobic drugs (celecoxib, efavirenz, and ritonavir) in the presence of 22 
different polymers in aqueous solution. Despite the different chemical properties and 
158 
 
 
structures of the model compounds, nonspecific hydrophobic drug−polymer interactions 
appeared to be important in determining the impact of a given polymer on crystal growth 
for of all three drugs. Among the 22 polymers, specific intermolecular interactions were 
only found between PVPVA [(poly(vinylpyrrolidone vinyl acetate)] and celecoxib and 
efavirenz. The same group reported again in 2013157 that the effectiveness of these 22 
polymers in inhibiting nucleation from aqueous solutions appeared to depend on the 
hydrophobicity of the polymer relative to that of the drugs (celecoxib, efavirenz and 
ritonavir). Powell et al.170 studied crystal growth in organic glasses (amorphous form) of 
three poorly soluble hydrophobic drugs (nifedipine, felodipine and indomethacin) in the 
presence of 1% polymers. Interestingly, among the seven polymers tested, the ability to 
inhibit crystal growth is not well ordered by the strength of host−polymer hydrogen 
bonds, but correlates extremely well with the neat polymer’s glass transition temperature 
(Tg), suggesting that the mobility of polymer chains is an important factor in inhibiting 
crystal growth in organic glasses. This study was focused on amorphous solids rather 
than crystal growth in aqueous solution. However, the outcome of the study indicated that 
H-bonds are not dominating stabilization factors and there may be other reasons why 
these polymers are so effective at merely 1%. 
Therefore, for poorly water-soluble and highly hydrophobic compounds, polymers 
capable of forming a hydrophobic interaction would be more important than those with 
hydrogen bonding capacities. The MD simulation is capable of providing both VDW and 
electrostatic interaction energies to clearly delineate this insight. With the positive results 
from this study, it is encouraging to conduct more MD simulation studies in the future 
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using different drug–polymer systems in order to assess the broad impact of VDW 
interactions in drug crystallization inhibitions. 
Conclusions 
We employed MD simulations to study the interaction of an amphiphilic diblock 
copolymer (PEG-b-PLA) with tolazamide (001), (010) and (100) crystal surfaces in 
water. The very different behaviors of the polymer on each surface can be explained by 
different TLZ molecular packing on the surface layer and the differences in polymer–
TLZ interaction energies. The results from the simulations demonstrated the polymer’s 
strong interaction with (001), weaker interaction with (010) and minimal to no interaction 
with (100), which matched remarkably well with the reported crystal habit alteration by 
the preferential interaction of PEG-b-PLA primarily with the (001) and partially with 
(010).158,164 The MD simulations suggest that for poorly water-soluble and hydrophobic 
drugs, such as tolazamide, the hydrophobic interaction is perhaps more important in 
establishing polymer-drug interaction in aqueous solutions. The implication of this 
conclusion is that during selection of polymers to inhibit crystallization and to maintain 
supersaturation during dissolution of enabling formulations, it is more important to look 
for polymers that can engage strong hydrophobic interactions rather than focusing solely 
on hydrogen binding capabilities. The consistency between the simulation and 
experimental results increased the confidence in further developing MD simulations as a 
tool to investigate polymer–drug interactions. 
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CHAPTER SIX 
GENERAL CONCLUSIONS 
This dissertation applied primarily molecular dynamics simulations to investigate 
fundamental processes involved in the pharmaceutical aqueous mass transfer phenomena 
which are important in drug product research and development. The three separate but 
cohesive studies addressed the following questions. First, how does a drug crystal 
dissolve into aqueous medium at the molecular level? Secondly, by what mechanism can 
one polymorph rapidly convert to another in some cases? Thirdly, how do polymers 
interact with a crystal surface to slow down the crystallization or polymorphic 
conversion? Interesting results were obtained in each of the three investigations. 
In the simulations of acetaminophen crystal Forms I and II dissolving into aqueous 
medium, we found that dissolution of the molecules from a crystal surface is not a 
random process. The order of the molecules entering the solution is strongly correlated 
with the drug–drug and drug–water interaction energies. The molecules at corners and 
edges quickly dissolved (corner and edge effect, shown in Figure 40) and those on 
different crystal faces dissolved at different rates (crystal face differentiated dissolution 
or morphology affected dissolution). Because of the corner and edge effect, there was no 
difference in the dissolution rate between the two acetaminophen polymorphs. In 
addition, these two nano-sized crystals exhibited much higher dissolution rate than 
regular size crystals which could not be accounted for by solubility and surface area 
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differences. The significance of these findings is two-fold; (1) the crystal morphology is 
expected to play a role in the initial dissolution rate, and (2) the existing dissolution 
equations based on surface area may not be able to estimate the dissolution rate of 
nanocrystals which have greater proportion of their molecules in corners and edges and 
countless defects created during milling. 
 
(a) (b) 
 
 
Figure 40. Corner and edge effect in drug crystal dissolution. Simulated from dissolution 
of ~4.5 nm acetaminophen single crystal in 0.15 M NaCl at 37 °C. Undissolved drug 
molecules are shown in line style and dissolved ones are in bulky VDW style. (a) Form I 
at 10 ns. (b) Form II at 10 ns. 
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In the second study, a series of MD simulations and experimental methods were 
utilized to identify which force (thermodynamic or kinetic) is responsible for the rapid 
polymorphic transformation of acetaminophen Form II to Form I in solutions. Using a 
new solubility method, we reported the first time an accurate measured thermodynamic 
solubility of Form II at 37°C. This allowed us to calculate the solubility ratio of Form II 
to Form I, which represents the thermodynamic driving force for the conversion. This 
value is only 1.27 ± 0.04 and was not high enough to create the supersaturation level to 
nucleate Form I. Finally, the molecular dynamics (MD) simulation suggested that large 
numbers of acetaminophen molecules were accumulating on the surface of Form II once 
in contact with water. This thick disordered molecular layer on Form II surface provides 
high local acetaminophen concentration for fast Form I crystallization. This was further 
supported by the rapid surface recrystallization of Form I from a Form II crystal in 
solution observed by polarized light microscopy and powder X-ray diffraction. The 
images from polarized light microscopy (Figure 29) showed no new crystals growing 
toward the solution phase, which is a truly surface crystallization phenomenon. 
Therefore, we identified a unique polymorphic transition mechanism, termed as SurFPT 
(surface facilitated phase transformation), as illustrated shown in Figure 41. This new 
mechanism promotes faster polymorphic transformation than the well-known mechanism 
of solution-mediated phase transformation (SMPT). 
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Figure 41. Schematic illustration of surface facilitated phase transformation (SurFPT). 
The metastable form hydrates at once when the water is introduced. The hydrated 
molecules quickly accumulate on the surface, approaching a high enough supersaturation 
level which leads to crystallization into the more stable solid form. 
 
The third study simulated tolazamide crystal surfaces in the presence of hydrated 
PEG-b-PLA, a diblock copolymer for 50 ns in a large water box. In this simulation the 
crystals were not allowed to dissolve so that the molecular interaction of the crystal 
surface with the polymer was visualized and the interaction energies were calculated. The 
results from the simulations demonstrated the polymer’s strong interaction with the (001) 
face, weaker interaction with the (010) face and minimal to no interaction with the (100) 
face, which matched remarkably well with the reported crystal habit alteration by the 
preferential interaction of PEG-b-PLA primarily with the (001) face and partially with the 
(010) face. Interestingly, van der Waals interactions were identified as the dominant 
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forces, accounting for 77–93% of total interaction energy and enabling strong drug–
polymer interactions on the (001) and (010) faces. These strong van der Waals 
interactions require a tight fit between the polymer and the crystal surface, as seen in 
Figure 42. These findings suggest that polymers capable of forming strong hydrophobic 
interactions are more effective in inhibiting crystallization of poorly water-soluble and 
hydrophobic drugs in aqueous media than those with hydrogen bonding capacities. Such 
in-depth analysis and understanding facilitate the rational selection of polymers in 
designing supersaturation-based enabling formulations. 
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Figure 42. PEG-b-PLA polymer–TLZ interaction at the (001) crystal –water interface at 
50 ns. The PLA part is located at the left side (color code of the atoms: oxygen is red, 
carbon is blue and hydrogen is white). The PEG part is at the right side (color code of the 
atoms: oxygen is red, carbon is beige and hydrogen is light pink). 
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CHAPTER SEVEN 
FUTURE RESEARCH 
Based on the recently available literature, we believe that the application of MD 
simulation in pharmaceutical research and development is still at an early phase. The 
results from this dissertation demonstrated that this new technique can significantly 
elevate our understanding in drug dissolution, polymorphic transformation and drug–
polymer interactions. Future studies should not only continue in these topics, but also 
expand into other topics. Several ideas for future studies are outlined below. 
Formulation Excipient Interaction with Drug Molecules 
Drug–Polymer Interaction  
at the Crystal Surface 
It is proposed to evaluate more polymer and drug systems. Structures and 
parameters for polymers frequently used in pharmaceutical formulations such as PVP, 
PVPVA, HPMC, HPMC-AS, HPC, etc. with or without H-bond capabilities can be 
populated as a database. Their interaction with various drug crystals with varied 
hydrophobicity can then be studied using our established MD simulation methodology. 
The purposes are (1) to evaluate the interaction forces (van der Waals or H-bonding or 
ionic) that are important (i.e. the broad impact of van der Waals interaction), and (2) to 
determine if the method is viable as a screening tool for rational selection of polymers.
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Drug–Polymer–Surfactant Interaction  
and Its Impact on Crystallization 
Surfactants are also frequently used in pharmaceutical formulation. Their role in 
crystallization of drug molecules in solution will be also very interesting. They can be 
studied using the same methodology in the presence or absence of polymers. 
Pharmaceutical Nanoparticle Systems 
Dissolution of Drug Nanoparticles 
We have found that the APAP nanocrystals dissolved very quickly. The fast rate of 
dissolution could not be explained by existing knowledge based on the surface area or 
solubility. Larger crystals in sizes more close to real nanoparticles (such as 50–100 nm) 
can be studied in water when computationally possible. This will help (1) to understand 
the dissolution rate with respect to different nano sizes (i.e. at what sizes the dissolution 
rate can be described by the equations established for macrosize crystals) and (2) whether 
or not the diffusion layer exists. Another interesting study will be to compare the 
dissolution behavior of nanocrystals that are water soluble and poorly water-soluble. 
The work presented in this dissertation demonstrates that all of these future 
studies are, or soon will be, possible. 
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APPENDIX A 
 
BUILDING CRYSTAL STRUCTURES 
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The following is a set of instructions on how to build a crystal surface using Mercury and 
VMD. 
Open Mercury software and load the drug single crystal structure file. Click 
“Packing” to show the unit cell. On the main menu, select Calculate - Packing/Slicing. 
Type in the numbers of unit cells to build to the right side of the column under “Pack”. 
Maximum of 10 unit cell can be entered. To build more than 10 unit cells, enter 10 on the 
right column, then enter minus number (i.e. -7) to the left side column. 17 unit cells will 
be built. 
Using the building of tolazamide (TLZ) 17x2x8 lattice (010) face as an example, 
in “a” direction, enter 10 on the right column, then enter a minus number (i.e. -7) to the 
left side column. In “b” direction, enter 2 on the right column. Finally, in the “c” 
direction, enter 8 on the right column. It will take a long time for Mercury to build this 
large lattice. To check if a correct crystal face is made, under Calculate\Planes\New 
Plane, type h=0, k=1 and l=0 (010 phase). It showed (010) is the large surface in 17x2x8 
lattice which is correct. Save it as a pdb file. 
The lattice file (.pdb) will be viewed as a single chain by VMD rather than as 
multiple TLZ molecules. Therefore the following procedure needs to be done to convert 
the original pdb to a useful pdb file. 
 Open the file via Word. Edit/Replace. Replace “UNK” with “TLZ” (the number 
spaces between UNK and next column, 1, should remain the same). Save it again 
using the original file name of “010_17x2x8.pdb”. Hit OK.  
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 Delete the rows that do not need to be changed (first few rows until HETATM, 
and rows after HETATM). There are hundreds of pages to delete after HETATM. 
To speed up, select the starting point to delete, hold down shif/ctrl and hit “End”. 
This will select all from the selected rows. Hit “delete”. Save the file as 
“010_17x2x8_deleted un-needed rows.pdb”. Hit OK. 
 Launch Excel program, File/Open “010_17x2x8_deleted un-needed 
rows.pdb”/Fixed Width. Click “Next”. Using the mouse to move the arrows that 
divide each columns to collapse the vertical lines before and after the column, 1, 
and leave only one line right before 1 (not 1.00). Be sure to collapse all vertical 
lines. 
 Click next to open in Excel and save it as “010_17x2x8_deleted un-needed rows 
_clapsed.xls”. 
 Insert 3 columns before the divided line (right before the number 1) 
 In the 1st new column, type in Space. Copy/paste to the rest of rows. 
 In the 3rd new column, type %. Copy/paste to the rest of rows. 
 In the 2nd column, type 1 to the first 42 row (because 42 atoms form one molecule 
of TLZ). In the 43st row type in 1+row1, then copy all the way down (Shift/Page 
down to move faster). There will be 408 molecules in total. Copy down together 
with the 1st and 3rd columns can save time. 
 Select the 2nd new column, go to Format Cell/Number/Custom, type in 00#, than 
hit OK. Now all of the numbers are in the format of 001, 002…., 099…, 408. 
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 Save it again as “010_17x2x8_deleted un-needed rows_clapsed.xls”. The next 
step is to Save it as file type CSV (select comma delimited, *.csv). 
010_17x2x8_deleted un-needed rows_clapsed.csv. Hit YES when the next 
dialogue shows up.  
 Open 010_17x2x8_deleted un-needed rows_clapsed.csv in Wordpad. 
 Replace “,Space,” with two spaces 
 Replace “,%,1” with no space 
 After done, there should be 2 spaces before the molecule number, and 6 spaces 
after the molecule number. 
 Save it as .txt file “010_17x2x8_ deleted un-needed rows.txt”. Close the file and 
open in Wordpad again. 
 Open the original pdb file, “010_17x2x8.pdb” also in Wordpad. Select the first a 
few rows before HETATM, copy and paste to the beginning of 010_17x2x8_ 
deleted un-needed rows.txt file. Then select all rows after HETATM 
(shift/ctrl/END), copy and paste to the end of above txt file. 
 Save the final text file as 010_17x2x8.pdb_finalized.pdb. This file can be opened 
from VMD shown as single chain for each TLZ molecule. 
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APPENDIX B 
 
CALCULATION OF INTERACTION ENERGIES 
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The following is a set of VMD instructions for making the PDB files needed to measure 
the interaction energies, and scripts to calculate interaction energies in the NAMD 
program. 
Interaction Energy between APAP and Surrounding APAPs 
Using APAP# 241 as an example, the first thing to do is to identify the APAP# 
surrounding the APAP#241. 
1. In VMP, load the psf and pdb files. 
2. Run the following in tk console. 
 
set sel [atomselect top "resname APAP and same resid as (resname APAP and within 4 of 
resid 241)"] 
$sel writepdb 241.pdb 
 
Open the 241.pdb file and 7 APAP# were shown: 242 50 49 33 177 114 178. The 
2nd step is to create the following. 
 
set basename apap1_40A 
[atomselect top all] set beta 0 
 [atomselect top "resname APAP and resid 242 50 49 33 177 114 178"] set beta 1 
 [atomselect top "resid 241"] set beta 2 
 [atomselect top all] writepdb $basename-interact_241.pdb 
 
The above interact_241.pdb file is used to calculate the interaction of APAP#241 
with surrounding APAPs within 4 A. 
Interaction Energy between APAP and Surrounding Water 
Similarly, use the following to create files for calculation.  
 
set basename apap1_40A_APAPwater 
[atomselect top all] set beta 0 
 [atomselect top "resname TIP3"] set beta 1 
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 [atomselect top "resname APAP and resname APAP and resid 4"] set beta 2 
 [atomselect top all] writepdb $basename-interact_4.pdb 
 
Interaction Energy between APAP and NaCl 
With Na+: 
set basename apap1_40A_APAP_Na 
[atomselect top all] set beta 0 
 [atomselect top "resname SOD"] set beta 1 
 [atomselect top "resname APAP and resid 61"] set beta 2 
 [atomselect top all] writepdb $basename-interact_61.pdb 
 
With Cl-: 
set basename apap1_40A_APAP_Cl 
[atomselect top all] set beta 0 
 [atomselect top "resname CLA"] set beta 1 
 [atomselect top "resname APAP and resid 61"] set beta 2 
 [atomselect top all] writepdb $basename-interact_61.pdb 
 
Interaction Energy between TLZ Crystal Surface  
and PEG-b-PLA Diblock Copolymer in Water 
The whole polymer was defined as segname O3. For (001) face, the selection of the PLA 
and PEG was defined by the following. 
PLA part: index 34290 to 34307 or index 34456 to 34510 
PEG part: index 34272 to 34289 or index 34308 to 34455 
set basename tlz_peg_interact_z 
[atomselect top all] set beta 0 
 [atomselect top "resname TLZ"] set beta 1 
 [atomselect top "segname O3"] set beta 2 
 [atomselect top all] writepdb $basename-all.pdb 
  
set basename tlz_peg_interact_z 
[atomselect top all] set beta 0 
 [atomselect top "resname TLZ"] set beta 1 
 [atomselect top "index 34290 to 34307 or index 34456 to 34510"] set beta 2 
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 [atomselect top all] writepdb $basename-pla.pdb 
 
The index numbers for (100) face are: PLA part index 16312 to 16366 or index 
16146 to 16163. PEG part index 16164 to 16311 or index 16128 to 16145. 
The index numbers for (001) face are: PLA part index 23032 to 23086 or index 
22866 to 22883. PEG part index 22884 to 23031 or index 22848 to 22865. 
 
MAMD Script to Calculate Interaction Energies 
An example script is shown below for the calculation of the PEG chain with the TLZ 
crystal (001) face. 
# initial config 
coordinates     tlz_peg_all_z_wb_autopsf.pdb 
temperature     0 
 
# output params 
outputname      tlz_peg-interact_z_peg 
binaryoutput    no 
 
# integrator params 
timestep        2.0 
 
# force field params 
structure      tlz_peg_all_z_wb_autopsf.psf  
paraTypeCharmm      on 
parameters      par_all27_prot_lipid_apap.inp  
parameters      Tolazamide.par  
parameters      Spartan_min1_pdb.par 
exclude         scaled1-4 
1-4scaling      1.0 
switching       on 
switchdist      10.0 
cutoff          12.0 
pairlistdist    13.5 
stepspercycle   40 
  
# Atoms in group 1 have a 1 in the B column; group 2 has a 2. 
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pairInteraction  on 
pairInteractionFile tlz_peg_interact_z-peg.pdb 
pairInteractionCol B 
pairInteractionGroup1 1 
pairInteractionGroup2 2 
 
# First frame saved was frame 1000. 
set ts 150 
 
coorfile open dcd tlz_peg_all_z_wb_prod_1-50_stride400.dcd 
 
# Read all frames until nonzero is returned. 
while { ![coorfile read] } { 
  # Set firstTimestep so our energy output has the correct TS. 
  firstTimestep $ts 
  # Compute energies and forces, but don't try to move the atoms. 
  run 0 
  incr ts 150 
} 
coorfile close 
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CALCULATIION OF NUMERS OF MOLECULES DISSOLVED WITH TIME 
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The following are steps to calculate the numbers of molecules dissolved from the crystals 
into water. 
 
Claculation of APAP Form I Dissolved with Time 
 
The first step is to identify the 4 APAP resid numbers (167, 218, 234 and 26) located in 
the center of the crysal. Then use the VMD to calculate the numbers of molecules 
dissolving by the following steps. 
• Load dcd file of APAP1_4x4x4_40A water (1-10 stride 100) and the PSF file. 
• Under Extension/Analysis/RMSD Trajectory tool, enter “resname APAP and 
resid 167 218 234 26”. Click “Align” to fix the molecule so that they do not move during 
calculation. 
• In Representation, create one with “resname APAP and not within X of (resname 
APAP and resid 167 218 234 26)”.  X is the radius of the crystal and was found to be 29 
for APAP1 in oder to inclue all of the molecules in the crystal at time 0. 
• Run the following sripit. 
 
#get the number of frames 
set mol top 
set num_steps [molinfo $mol get numframes] 
#open file for writing 
set fil [open number_apap_disolved.dat w] 
#loop over all frames in the trajectory 
for {set i 0} {$i < $num_steps} {incr i} { 
#select apaps and count 
 
set sel [atomselect top "type OH1 and resname APAP and not within 29 of (resname 
APAP and resid 167 218 234 26)"] 
$sel frame $i 
$sel update  
set num_apap [$sel num] 
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puts $fil "$i $num_apap" 
} 
close $fil 
 
Calculation of APAP Form II Dissolved with Time 
 
Similarly, the first step is to identify the 4 molecules located in the center of the Form II 
crystal. The script is listed in the following. 
 
#get the number of frames 
set mol top 
set num_steps [molinfo $mol get numframes] 
#open file for writing 
set fil [open number_apap_disolved.dat w] 
#loop over all frames in the trajectory 
for {set i 0} {$i < $num_steps} {incr i} { 
#select apaps and count 
set sel [atomselect top "type OH1 and resname APAP and not within 27 of (resname 
APAP and resid 19 126 162 271)"] 
$sel frame $i 
$sel update  
set num_apap [$sel num] 
puts $fil "$i $num_apap" 
} 
close $fil 
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APPENDIX D 
 
ANALYSIS OF THE LOG FILE FOR INTERACTION ENERGIES 
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Steps to plot the log file for interaction energy profile is described below using 
simulation file of APAP1_4x4x4_40 A water box as an exmple. 
• launch VMD. 
• Extensions/Analysis/NAMD plot. 
• Under File, select the log file for plot (e.g corner1.log, a txt file). 
• Click the energy to plot (Electric, VWD and total). 
• Go back to File/Plot selected data. 
• A plot will show up. In the plot, go to File/Export Xmgrace, then save it as 
corner1.arg file (click No and ignore the subsequent error message). Each log file will 
generate 3 arg files (elect, VDW and total). 
• The saved file can be opened in Excel. From Excel, File/Open .arg file, select 
delimited/next/Space/next until finish. 
• Plot elect, VDW and total as 3 groups. 
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APPENDIX E 
 
CALCULATION OF PAIR CORRELATION FUNCTION G(R)  
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Below are the steps to calculate g(r), pair correlation function as a function of frame 
number by the VMD program, using APAP1 as an example. 
1. VMD/Load the dcd file of APAP1 at stride 100 and the PSF file. 
2. Locate the center molecule (resid 167).  
3. Under Extention/Analysis/Trajectory tool, delete “protein”.  Enter “resname 
APAP and resid 167”. Click “Align” to fix the structure. 
4. Under Extention/Analysis/Radial Pair Distribution Function g(r), set up the 
following: Selection 1 = resname APAP and resid 167. Selection 2 = resname 
APAP. Frame number: from 0 to 0. Step = 1. Delta r = 0.1. Max = 50 (cover the 
diameter of the crystal). Click “use PBC”. Click “display g(r)”. Click “Save file” 
to save it under a designated folder. Finally, click “computer g(r)”.  
5. The file generated can be plotted using Excel. 
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APPENDIX F 
 
CALCULATION OF NUMBERS OF HYDROGEN BONDS  
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Below are steps to calculate the numbers of hydrogen bonds as a function of frame 
number by the VMD program, using APAP1 as an example. 
1. In VMD main menu, File/New molecule/Browse/Load the following files. 
APAP1_40A_autopsf_ion.psf 
APAP1_40A_autopsf_ion_prod_1to10_stride100.dcd  
2. Go to Main menu/Extensions/Analysis/Hbond 
a. Selection: resname APAP 
b. Frames: all 
c. Click to select “Update selection every frame?” 
d. Selection 1 is: both 
e. Donor/acceptor distance: 3.0 
f. Angle cut-off: 20 
g. Calculation detailed information for: unique hbond 
h. Output options 
i. Select “Plot the data to multiplot” 
ii. Directory is automatically selected 
iii. Frame/bond data: hbond.dat 
iv. Details output file: hbond_details.dat 
i. Click “Find hydrogen bonds” 
Note that it will take a long time (~15 min) to finish the calculation. Three files will be 
saved: gr0.dat, hbonds.dat and hbonds-details.dat. The hbond.dat file can be opened from 
the Excel and plotted. 
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